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PURIFICATION AND SUBSTRATE SPECIFICITY OF NEW C. ROSEUS ENZYMES
ABSTRACT
Terpene indole alkaloids (TIAs) are a class of natural products produced in plants. Many
TIAs have medicinal uses; for example, vinblastine has anti-cancer activity and ajmaline has
anti-arrhythmic activity. Many TIAs did not evolve to treat human disease, however, and thus
most likely do not have optimal pharmacological properties. If TIAs could be modified, the
novel TIAs produced could have improved bioactivities when compared with the unmodified
natural TIAs. Unfortunately, the immense structural complexity of TIAs makes cost-effective
industrial-scale synthesis of the majority of TIAs and TIA analogs unfeasible. Industrial-scale
production of TIAs would be improved if TIAs could be produced via reconstitution of the
enzymatic pathways in a heterologous organism such as yeast. However, many of the enzymes
involved in TIA biosynthesis are unknown, thereby precluding these efforts. If more TIA
biosynthetic enzymes were isolated, and the substrate specificity of the enzymes were known,
both natural and novel TIA analogs could be more readily produced on an industrial scale.
In this thesis I developed strategies to isolate new C. roseus enzymes and to make novel
analogs of the anti-hypertensive agent ajmalicine and the anti-neoplastic agent isositsirikine. The
NADPH-dependent reductases that produce ajmalicine and isositsirikine have not been isolated.
To produce ajmalicine and isositsirikine analogs in vitro, two aims must be accomplished: first,
the reductases forming ajmalicine and isositsirikine, ajmalicine synthase and isositsirikine
synthase, must be partially purified, and second, the substrate specificity of those reductases
must be determined. To satisfy the first of these aims, I developed a partial purification
procedure for ajmalicine synthase and isositsirikine synthase from Catharanthus roseus tissue.
My partial purification procedure involved acetone precipitation, ion exchange chromatography,
and gel filtration chromatography. Analysis by 2D SDS-PAGE shows that the proteins have been
significantly purified. I also performed crosslinking experiments with a substrate probe in
attempts to isolate ajmalicine synthase and isositsirikine synthase. In the crosslinking studies
four enzymes were isolated and cloned, and one has been found to have sinapyl alcohol
dehydrogenase activity.
I determined the substrate specificities of ajmalicine synthase and isositsirikine synthase'
as well as the enzyme that precedes both enzymes in the biosynthetic pathway, strictosidine-p-
glucosidase (SGD). I found that SGD, ajmalicine synthase, and isositsirikine synthase all have
broad substrate specificities, which is promising for the development of novel ajmalicine and
isositsirikine analogs with potentially improved therapeutic activities.
Thesis Supervisor: Sarah E. O'Connor
Title: Latham Family Career Development Associate Professor of Chemistry
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I. Structure and pharmacological uses of monoterpene indole alkaloids (TIAs)
Monoterpene indole alkaloids (TIAs) are a group of secondary metabolites produced by
plants that all derive from the same precursor, strictosidine 1 (Figure 1-1). There are over 2,000
TIAs, many of which have medicinal properties (Figure 1-1)1. For example, vinblastine 2 and
vincristine 3 have anti-cancer activity2, ajmalicine 4 has anti-hypertensive activity3, and
serpentine 5 has type II topoisomerase inhibition activity4 . Yohimbine 6 has a2 adrenoreceptor
antagonist activity , isositsirikine 7 has anti-neoplastic activity 6, quinine 8 has anti-malarial
activity , ajmaline 9 has anti-arrhythmic activity8 , and camptothecin 10 has anti-tumor activity'
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Vinblastine 2 and vincristine 3 (Figure 1-1), which are produced by the pantropical plant
Catharanthus roseus (Madagascar periwinkle), were discovered in the late 1950s by Dr. Robert
Noble and Dr. Charles Beer. Dr. Noble had been given 25 Madagascar periwinkle leaves by his
brother, who had received the leaves from a patient claiming that the leaves were popular in
Jamaica for treating diabetes. Noble tested the leaves for anti-diabetic activity by crushing the
dried leaves and brewing them as a tea. After having rats consume the tea, Noble tested their
blood and did not find any changes in sugar levels, but he noticed that that leaves reduced the
number of white blood cells. With the assistance of Beer, Noble was able to isolate the
compound responsible for the reduction of white blood cells, and named the compound
"vinblastine." Noble and Beer then began clinical tests with vinblastine 2 on patients with
lymphoid cancer. When vinblastine 2 was shown to have anti-cancer activity, Eli Lilly began to
2,10produce vinblastine 2 for clinical use . Vinblastine 2 has been produced under the names
Velban@, Velsar@, and vincaleukoblastine, and currently it is used in the treatment of breast
2,10
cancer, testicular cancer, non-Hodgkin lymphomas, and Hodgkin's disease' . Vinblastine 2 is
produced in the plant by the coupling of two TIAs, catharanthine and vindolinel (Figure 1-2).
Noble and Beer isolated an oxidized form of vinblastine 2, named vincristine 3, that also
had anti-cancer activity. Vincristine 3 differs from vinblastine 2 in that the methyl group on N-i
of vinblastine 2 is oxidized to an aldehyde (Figure 1-2). Vincristine 3 was introduced to the
clinic in 1963 and has been produced under the names leurocristine, Oncovin@, Vincasar PFS@,
2
and Vincrex2 . Vincristine 3 has proven effective against a slightly different spectrum of
cancers than vinblastine 2, and is used to treat acute leukemia, childhood leukemias,
neuroblastomas, rhabdoyosarcomas, Hodgkin's disease, and other lymphomas1 4.
The anti-neoplastic activity of vinblastine 2 and vincristine 3 comes from their propensity
to bind to tubulin, preventing the formation of microtubules. This disruption causes dissolution
of mitotic spindles, leading to metaphase arrest in dividing cells. Cells accumulate in metaphase,
and this accumulation triggers cell death2, 10. Vinblastine 2 and vincristine 3 are often used in
combination chemotherapy with DNA-alkylating drugs because action on the tubulin protein
does not interfere with the action of the DNA-alkylating drugs.
A number of semi-synthetic derivatives of vinblastine 2 and vincristine 3 have been
synthesized and developed as chemotherapy drugs. These include, for example, vinorelbine 11
(Navelbine@) (Figure 1-2) which was discovered in the mid-1990s by the Pierre Fabre Company
and is used as an anti-mitotic chemotherapy drug against breast cancers, testicular cancers,
2,10
epithelial ovarian cancers, and non-small-cell lung cancers' . Vinorelbine 11 differs in structure
from vinblastine 2 in that it contains only one methylene between the N-6' and C-9' of the
catharanthine moiety, has a double bond between C-3' and C-4', and lacks a hydroxyl group at
2,11C-4' (Figure 1-2). Vindesine 12 (Eldesine@, Fildesin@) is another example of a semi-
synthetic derivative that is currently used in chemotherapy treatments to treat lung cancer, breast
cancer, melanoma, lymphoma, and leukemia". Vindesine 12 differs in structure from vinblastine
2 by having an amide instead of a methyl ester at C-3, and by having a hydroxyl instead of an
acetyl group at C-4 (Figure 1-2) .
Vinflunine 13 (Figure 1-2) is a semi-synthetic derivative currently in late-stage clinical
trials in Europe. Vinflunine 13 is obtained from vinorelbine 11 by using superacid chemistry
(HF-SbF5) to reduce the double bond between C-3' and C-4' and to introduce two fluorine
atoms . In clinical trials vinflunine 13 has shown less cross-resistance in multidrug-resistant
tumor cell lines than vinblastine 2, vincristine 3, and vinorelbine 11 have. Other halogenated
derivatives have since been synthesized and are currently being tested2 ,1
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Figure 1-2: The structure and numbering system (in blue) of vinblastine 2, which is derived from
catharanthine and vindoline 2. The structures of vinorelbine 11, vindesine 12, and vinflunine 13
are also shown, with the moieties that differ from that of vinblastine 2 in red".
Ajmalicine 4 (Figure 1-1, Figure 1-3) is another TIA produced by C. roseus. Ajmalicine
4 was first used in 1957 for the treatment of hypertension. It has been marketed under the names
Hydroserpan@, Lamuran@, and raubasine. When used clinically, ajmalicine 4 is often combined
with a synthetic compound called almitrine 14 (Figure 1-3); this combination is called Duxil@.
Duxil@ is used clinically in France to treat age-related cerebral disorders and for functional
rehabilitation after stroke3'14- 6 . No ajmalicine 4 analogs have been reported or investigated as
potential therapeutics.
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Figure 1-3: Structures of ajmalicine 4 and almitrine 1414.
Serpentine 5, yohimbine 6, and isositsirikine 7 are also produced by C. roseus (Figure
1-4). Serpentine 5, which is hypothesized to be produced via a peroxidase-catalyzed oxidation of
14
ajmalicine 4, is a type II topoisomerase inhibitor'. Yohimbine 6 acts as an a2 adrenoreceptor
antagonist and has potential clinical applications in erectile dysfunction'' 5 ,17, and isositsirikine 7
has anti-neoplastic activity6 .
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Figure 1-4: Structures of serpentine 5, yohimbine 6, and isositsirikine 7.
Quinine 8 (Figure 1-1), isolated from the bark of the Cinchona tree, is most famous for its
anti-malarial activity. It is believed that quinine 8 acts as an anti-malarial agent by inhibiting
heme polymerase, which causes cytotoxic free heme to accumulate in the parasite. Quinine 8
also has anti-pyretic, anti-inflammatory, and analgesic activity, and is used to treat lupus and
arthritis. It was the most widely used drug to treat malaria until 1944, when it was replaced by
another drug, chloroquine. Quinine 8 is still used occasionally, however, because resistance has
developed to chloroquine .
Ajmaline 9 (Figure 1-1) is produced by the plant Rauvolfia serpentinal. Ajmaline 9 is an
anti-arrhythmic drug that has potent sodium channel-blocking properties. The short half life of
ajmaline 9 makes ajmaline 9 a useful drug for acute intravenous treatments. Ajmaline 9 has been
8
used to treat atrial fibrillation in patients with Wolff-Parkinson-White syndrome .
Camptothecin 10 (Figure 1-1) is a topoisomerase I inhibitor that is isolated from the bark
and stems of the Chinese "happy tree" Camptotheca acuminata, and is also produced by the
plant Ophiorrhiza pumilal. Although camptothecin 10 showed anti-cancer activity in clinical
trials in the late 1960s, its severe toxicity prevented camptothecin 10 from being prescribed.
Another drawback of camptothecin 10 is its poor water solubility, which makes drug delivery
difficult. Numerous derivatives of camptothecin 10 were developed to overcome these
drawbacks. Two clinically successful, water-soluble synthetic derivatives are topotecan 15 and
irinotecan 16 (Figure 1-5). Topotecan 15 is used to treat lung cancer and ovarian cancer, while
9
irinotecan 16 is primarily used to treat colon cancer .
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Figure 1-5: Structures of camptothecin 10, topotecan 15, and irinotecan 169.
II. Biosynthesis of TIMs
All TIAs are derived from a central intermediate called strictosidine 1. Strictosidine 1 is
formed by a stereoselective Pictet-Spengler condensation of the iridoid terpene secologanin 17
and tryptamine 18 catalyzed by the enzyme strictosidine synthase (Figure 1-6)1.
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Figure 1-6: Structures of tryptamine 18, secologanin 17, and strictosidine 1. Tryptamine 18 and
secologanin 17 condense in a reaction catalyzed by strictosidine synthase to form strictosidine 11.
The biosynthetic pathway for secologanin 17 has not been fully elucidated, and there are
numerous proposed intermediates that remain uncharacterized. The mechanisms of the
subcellular trafficking of biosynthetic intermediates in TIA biosynthesis also remain largely
unknown'. Secologanin 17 biosynthesis begins in the plastid'. The precursor for all terpenoids,
3-isopentenyl pyrophosphate 19 (IPP) can be produced by either the mevalonate pathway (Figure
1-7)18 or the non-mevalonate pathway, which is also called the triose phosphate/pyruvate
pathway1'8"9 (Figure 1-8). Feeding studies utilizing 13C glucose have shown that the triose
phosphate/pyruvate pathway is most likely the pathway utilized to produce IPP for secologanin
17 biosynthesis. Once produced, IPP is converted to dimethylallyl pyrophosphate 20
(DMAPP)' 9 .
In the mevalonate pathway (Figure 1-7), the primary hydroxyl of (R)-mevalonate is
phosphorylated twice, and the tertiary hydroxyl is also phosphorylated. Decarboxylation then
........ ...
occurs, expelling the phosphate on the tertiary hydroxyl. The simulataneous decarboxylation and
phosphate expulsion produces IPP 19, which is isomerized by isopentenyl pyrophosphate
isomerase to produce DMAPP 2018.
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Figure 1-7: In the mevalonate pathway, dimethylallyl
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pyrophosphate 20 (DMAPP) is formed
In the non-mevalonate pathway, or triose phosphate/pyruvate pathway (Figure 1-8), 1-
deoxy-D-xylulose-5-phosphate (DXP) first undergoes a rearrangement of the carbon skeleton of
the molecule. Next the carbonyl group is reduced to an alcohol by NADPH and DXP reductase,
forming 2-C-methylerythritol-4-phosphate (MEP). MEP then reacts with cytidine triphosphate
(CTP) to form 4-diphosphocytidyl-2-C-methylerythritol (CDP-ME). CDP-ME is then
phosphorylated to form 4-diphosphocytidyl-2-C-methylerythritol-2-phosphate (CDP-MEP). A
cyclization reaction then occurs, forming 2-C-methylerythritol-2,4-cyclopyrophosphate
(MEcPP). The intermediates and mechanisms involved in the conversion of MEcPP to 3-
isopentenyl pyrophosphate 19 (IPP) are largely unknown, though it is proposed that radical
reactions mediated by enzymes containing iron-sulfur clusters are involved. Once formed, IPP 19
is converted to dimethylallyl pyrophosphate 20 (DMAPP) by isopentenyl pyrophosphate
18isomerasel
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Figure 1-8: The non-mevalonate, or triose pyruvate/phosphate, pathway'19. "Fd" is an
abbreviation for ferredoxin.
One unit of DMAPP 20 and one unit of IPP 19 then condense to form geraniol
pyrophosphate 21 via a monoterpene synthase (Figure 1-9). Upon loss of the diphosphate,
geraniol 22 is formed, which is then exported to the cytosoll. The hydroxylation of geraniol 22
by the P450 vacuolar membrane-bound geraniol-lO-hydroxylase (GIH) is the first committed
step of iridoid terpene biosynthesis 20,21. The resulting 10-hydroxy geraniol 23 then undergoes a
series of oxidations and cyclizations by yet-unidentified enzymes in the vacuole to form iridotrial
1,2224 (Figure 1-10, Figure 1-15)
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Figure 1-9: Formation of geraniol pyrophosphate 21 from one unit of dimethylallyl
pyrophosphate 20 (DMAPP) and one unit of 3-isopentenyl pyrophosphate 19 (IPP) 1. Upon loss
of the diphosphate, geraniol 22 is formed.
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Figure 1-10: Proposed mechanism of formation of iridotrial 24 from geraniol 22.
Iridotrial 24 is then oxidized, glycosylated, and esterified to form deoxyloganin', which is
then hydroxylated to form loganin 25. In what some have proposed to be the rate-limiting step in
indole alkaloid biosynthesis, the endomembrane-associated P450 oxidase enzyme secologanin
synthase (SLS) converts loganin 25 to secologanin 17 (Figure 1-11, Figure 1-15).
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Figure 1-11: Formation of secologanin 17 from iridotrial 241.
Tryptamine 18, which reacts with secologanin 17 and strictosidine synthase to form the
central intermediate strictosidine 1, is derived from L-tryptophan 26, which is produced by the
shikimate pathway (Figure 1-12). Chorismate, the precursor of tryptophan, is converted to
anthranilate by anthranilate synthase. A series of four enzymes - anthranilate
phosphoribosyltransferase, N-(5'-phosphoribosyl) anthranilate isomerase, indole-3 -glycerol
phosphate synthase, and the a unit of tryptophan synthase - convert anthranilate to indole, which
is converted to L-tryptophan 26 by tryptophan synthase'.
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Figure 1-12: Biosynthesis of L-tryptophan 26 from chorismate23 ,24
L-tryptophan 26 is decarboxylated by the pyridoxal-dependent cytosolic enzyme
tryptophan decarboxylase (TDC) to form tryptamine 18, which is then transported into the
vacuole (Figure 1-15)1. Tryptamine 18 and secologanin 17 undergo a stereoselective Pictet-
Spengler condensation (Figure 1-13) catalyzed by the enzyme strictosidine synthase. The
resulting product, strictosidine 1, has S stereochemistry at the C-3 position (Figure 1-15)1.
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Figure 1-13: The proposed mechanism of strictosidine synthase. With strictosidine synthase,
tryptamine 18 and secologanin 17 undergo a stereoselective Pictet-Spengler condensation to
form strictosidine 11. The C-3 position of strictosidine 1 is shown in blue. "Glc" is an
abbreviation for p-glucose.
Strictosidine 1 is the central intermediate for biosynthesis of all TIAs. Strictosidine 1 is
exported out of the vacuole into the cytosol, where it is then deglycosylated by the enzyme
strictosidine-p-glucosidase (SGD) 2. SGD is a soluble enzyme associated with the endoplasmic
reticulum membrane but is still accessible from the cytosoll. Upon deglycosylation, strictosidine
1 is converted to a reactive hemiacetal intermediate (Figure 1-14, Figure 1-15). This hemiacetal
is then channeled into a number of biosynthetic pathway branches that lead to hundreds of
different TIAs. The reactive hemiacetal intermediate can rearrange in numerous ways, resulting
in a variety of alkaloid structures. These structural frameworks are further functionalized,
thereby leading to hundreds of different alkaloids (Figure 1-16). The majority of the enzymes
occurring downstream of strictosidine synthase and SGD are unknown, and the mechanisms that
control which alkaloids are produced at which levels are also unknown'.
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Figure 1-14: Upon deglycosylation by SGD, strictosidine 1 converts to a reactive hemiacetal that
interconverts between various isomers.
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Figure 1-15: In TIA biosynthesis, L-tryptophan 26 is decarboxylated by the cytosolic enzyme
tryptophan decarboxylase (TDC) to produce tryptamine 18, which then enters the vacuole.
Geraniol 22 is hydroxylated by the vacuolar membrane protein geraniol- 1 0-hydroxylase (G 1 OH)
to form 10-hydroxy geraniol 23, which undergoes a series of enzymatic steps to form
secologanin 17. Secologanin 17 and tryptamine 18 produce strictosidine 1 in a stereospecific
Pictet-Spengler condensation catalyzed by strictosidine synthase (STS). Strictosidine 1 is then
exported to the cytosol, where it is deglycosylated by SGD, which is associated with the
endoplasmic reticulum (ER). Deglycosylated strictosidine is then channeled into different
..........  .. 
biosynthetic pathways that lead to hundreds of different TIAs that are typically stored in the
vacuole.
The Apocynaceae, Loganiaceae, Nyssaceae, and Rubiaceae families of plants all produce
TIAs. Three different groups of TIAs produced by C. roseus - the corynanthe group, the
aspidosperma group, and the iboga group - each have representative members that are used
medicinally. Each of these structural classes is derived from strictosidine 1 (Figure 1-14, Figure
1-16). Corynanthe TIAs produced in C. roseus include ajmalicine 4, serpentine 5, yohimbine 6,
and isositsirikine 7. Aspidosperma alkaloids include tabersonine 27 and vindoline 28, and iboga
alkaloids include catharanthine 29. Via the action of a peroxidase, catharanthine 29 and
vindoline 28 dimerize to form the anti-cancer agent vinblastine 2 (Figure 1-16)1,25
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Figure 1-16: The three main branches in TIA biosynthesis in C. roseus. Ajmalicine 4, serpentine
5, yohimbine 6, and isositsirikine 7 from the corynanthe class are shown in blue, catharanthine
29 from the iboga class is shown in red, and tabersonine 27 and vindoline 28 from the
aspidosperma class are shown in green. Vinblastine 2 is produced by the dimerization of
catharanthine 29 and vindoline 281. All alkaloids shown derive from the strictosidine-p-
glucosidase (SGD)-catalyzed deglycosylation of strictosidine 1, the central intermediate in TIA
biosynthesis.
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III. TIAs in Catharanthus tissue
Catharanthus, which belongs to the family Apocynaceae, is a genus of eight species
(Table 1-1), seven of which are endemic to Madagascar. The eighth species, Catharanthus
pusillus, is native to the Indian subcontinent. Some species of Catharanthus are woody,
perennial shrubs that grow to heights of approximately 80 centimeters, but the more common
varieties are small, cultivated ornamental plants (Figure 1-17). The flowers can be many
different colors, such as red, dark red, peach, and white. Catharanthus roseus is also known as
Vinca rosea and Lochnera rosea, as well as the common names "Old maid," Vinca, and
periwinkle".
Members of Catharanthus genus Representative alkaloids
C. coriaceus none reported
C. lanceus apparicine, catharine26
C. longifolius cathafoline"
C. ovalis vindorosine, cathovaline2s
C. roseus vinblastine, ajmalicine'
C. scitulus none reported
C. trichophyllus vincaleukoblastine, periformyline29
C. pusillus leurosine, lochnerinine 0'3
Table 1-1: The eight species in the genus Catharanthus, and representative alkaloids from each
species, if applicable. All except for C. pusillus are endemic to Madagascar.
Figure 1-17: Pictures of the "rosy" (left) and "little bright eyes" (right) varieties of Catharanthus
32,33roseus
C. roseus has been widely studied in part because of the large number of medicinal
natural products it produces. Unfortunately, many of these products are produced at low levels in
the plant. To isolate one gram of vinblastine 2, for example, approximately 500 kilograms of
dried C. roseus leaves are needed 2. Also, because many different alkaloids are present in the
plant, the isolation and purification of a particular alkaloid can be prohibitively difficult and
expensive. The vast majority of the TIAs are structurally complex, containing numerous
stereocenters, thus making industrial-scale synthesis difficult and expensive.
Three types of C. roseus tissue commonly used to produce TIAs are plants (both
seedlings and mature plants), hairy root cultures, and cell suspension cultures (Figure 1-18).
Seedlings and plants produce a greater variety of TIAs than hairy root and cell suspension
cultures do, yet typically they grow more slowly and produce TIAs in lower quantities than hairy
root and cell suspension cultures2 34. Seedlings can also produce vindoline 28, the precursor to
the anti-cancer TIAs vinblastine 2 and vincristine 3, whereas hairy root cultures and cell
34suspension cultures cannot
seedlings hairy root culture cell suspension culture
Figure 1-18: C. roseus seedlings, hairy root culture, and cell suspension culture3 s,36
TIAs are also produced by hairy root cultures (Figure 1-18), a type of tissue that results
upon infection of C. roseus seedlings with Agrobacterium rhizogenes 3,37 . Hairy root tissues are
convenient to work with since the tissues can be continuously propagated, exhibit biochemical
and genetic stability, and produce a diverse array of TIAs. The major alkaloids produced by
hairy roots are ajmalicine 4, serpentine 5, catharanthine 29, and tabersonine 2734. Hairy roots
also grow relatively fast, with a doubling time of three to four days38 . It has been found that
specific yields for many natural products are higher in hairy root cultures than in the plant. One
misconception regarding hairy root cultures is that certain metabolites found in aerial parts of the
plant may not be produced in hairy roots. This is not always true, however, for in many cases the
site of accumulation of secondary metabolites in plants does not coincide with the site of
production. For example, a napthoquinone derivative called lawsone is found in the aerial parts
of the plant henna and not in the roots. Nevertheless, lawsone is produced in hairy root cultures
39in significant quantities
Plant cell suspension culture (Figure 1-18) was the subject of extensive development in
the 1980s, when it was discovered that these nondifferentiated plant cells could be grown in
bioreactors in liquid medium 39. TIAs can be produced by cell suspension cultures, which are
most commonly established from callns tissue. Callus tissues are nondifferentiated cells that are
grown on solid media; transfer of callus tissue to liquid media results in the formation of cell
14
suspension cultures . One advantage of cell suspension cultures is fast growth; cell suspension
cultures typically have a doubling time of one and a half to five days38. Fewer types of TIAs are
typically produced in cell suspension cultures than are produced in seedlings or hairy root
cultures. In the cell suspension cultures used in the research for this thesis, for example, few
alkaloids apart from ajmalicine 4, catharanthine 29, and tabersonine 27 are observed.
IV. Potential pharmacological properties of novel TIAs
The vast majority of TIAs are structurally complex and cannot be made synthetically on
an industrial scale. The current method for industrial-scale production of ajmalicine 4, for
example, is isolation from the plant2 . Plants, however, do not naturally produce TIA analogs,
such as C-Il chlorinated ajmalicine. If more TIA enzymes were cloned and the substrate
specificity for those enzymes are known, perhaps novel TIA analogs could be produced on the
scale required for industrial production. These novel TIAs could potentially have improved
activities. Though structure-activity relationship studies of ajmalicine 4 have not been
performed, a variety of other analogs of TIAs have been shown to have improved or altered
bioactivity. For example, the anti-cancer drugs irinotecan 16 and topotecan 15 are derived
synthetically from camptothecin 10, which is too toxic to be used clinically (Figure 1-19)40.
Vinblastine 2 analogs are also used clinically . Novel ajmalicine 4 analogs could potentially
have improved activities; for example, perhaps C-I1 chlorinated ajmalicine could be shown to
have better anti-hypertensive activity than naturally occurring ajmalicine 4.
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Figure 1-19: Topotecan 15 and irinotecan 16 are synthetically derived analogs of camptothecin
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Novel TIAs can be produced by incorporating substituents at various positions of the
structure. Substituents can alter the bioavailability, electron density, and conformational
properties of compounds 41. Solubility and bioavailability are major factors in determining
whether or not a drug candidate successfully passes clinical trials; approximately 40% of
compounds fail clinical trials because of poor oral bioavailability or short half-life in plasma42.
One limiting factor in oral bioavailability is low water solubility or high lipophilicity of a
compound. A compound that is too lipophilic has difficulty diffusing through the cytosol. A
sample must still be lipophilic enough, however, to traverse membranes and display appropriate
pharmacokinetics 42. According to Lipinski's Rule of Five 43, which are guidelines to assess
whether a compound will be orally active, the octanol-water partition coefficient log P of a
compound should be less than 5, where P = [drug]organic solvent / [drug]aqueous solvent.
Lipinski's Rule of Five also gives guidelines for the number of hydrogen bond donors
and acceptors in a potential drug43. To facilitate oral absorption and distribution, compounds
should not have more than five hydrogen bond donors (NH and OH groups) or more than ten
hydrogen bond acceptors (N and 0 atoms). Exceptions to this rule include cardiac glycosides,
vitamins, anti-fungals, and antibiotics, for they typically have active transporters that take them
42
across membranes
Halogens are frequently incorporated as substituents in drug candidates 44: indeed, one out
41
of every three drugs contains a halogen . Halogenation of a compound makes a compound more
lipophilic, improving the ability of the compound to traverse the membrane. One drawback of
44
halogenated compounds, however, is that they tend to accumulate in lipid tissue
Halogenation often improves the bioactivity of a compound. In the series of anti-
histaminic compounds shown in Figure 1-20, for example, the fluorinated (X = F) and
chlorinated (X = Cl) derivatives show three to four fold higher activity than the parent
nonhalogenated compound, tripelennamine 30 (X = H) (Figure 1-20)41. Similarly, with a
monoamine oxidase inhibitor 31 (Figure 1-2 1), the brominated (X = Br) and trifluoromethyl (X =
CF 3) derivatives show sixfold and twelvefold lower IC50 values than the parent compound
3141,45. In a third example, the antibiotic clorobiocin is reported to have eight fold higher activity
against Bacillus subtilis bacteria than its des chloro analog 46'47.
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Figure 1-20: The structure of the anti-histaminic compound tripelennamine 30 (X = H)41.
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41Figure 1-21: The structure of the monoamine oxidase inhibitor 31
Fluorine is the most widely used halogen in drug discovery efforts. It is the smallest
halogen and is isosteric to hydrogen (Table 1-2). Fluorine increases the lipophilicity of a
molecule; although fluorine is only slightly more lipophilic than hydrogen, trifluoromethyl is
significantly more lipophilic than methyl, and trifluoromethyl groups are often used as
replacement for methyl groups to improve the pharmacological activity of a compound.
Additionally, carbon-fluorine bonds are stronger than carbon-hydrogen bonds; fluorine thus
imparts oxidative stability to a compound. Fluoro derivatives are often more stable to metabolic
degradation. For example, CF 3 groups are generally biostable, whereas CH 3 groups are easily
oxi 
48
oidized by cytochrome P45Os present in the human liver
Interatomic Bond stren thAtomic radius (A) Bond distance (A) (kcal mol~)
hydrogen: 0.29 C-H 1.14 93
fluorine: 0.64 C-F 1.45 114
chlorine: 0.99 C-Cl 1.74 72
bromine: 1.14 C-Br 1.90 59
iodine: 1.33 C-I 2.12 45
Table 1-2: The atomic radius (A) of hydrogen and halogen atoms, and the bond, interatomic
distance, and bond strength of carbon-hydrogen and carbon-halogen bonds41.
After fluorine, chlorine is the second most frequently used halogen in drug discovery
efforts. Like fluorine, chlorine also increases the lipophilicity of a compound and can serve as a
metabolic obstruction4 1 . Bromine is used less frequently than fluorine or chlorine, and is most
often incorporated as a bromo aryl moiety. Iodine is the least-used halogen because of the
weakness of the carbon-iodine bond. The weak carbon-iodine bond allows iodide ions to be
formed easily, which can trigger unwanted reactions in the human body41.
Methylation also alters the properties of a potential drug by increasing the lipophilicity of
the compound. As with halogenated compounds, the increase in lipophilicity facilitates the
compound's traversing membranes but also impedes diffusion in the aqueous cytosol 44. Aryl
methyl groups can be oxidized in the body to carboxylic acids, which aids in the elimination of
the compound by improving its water solubility. Methylation can also prevent certain side effects
by obstructing reactions from occurring at a given position. For example, ortho-methyl
paracetamol 33 and ortho, ortho-dimethyl paracetamol 34 have lower hepatotoxicity than the
analgesic and anti-pyretic paracetamol 32 (acetaminophen) (Figure 1-22). It is believed that
methylation at the ortho positions to the phenolic hydroxy group of paracetamol 32 prevents
44
metabolic hydroxylation at those ortho positions
0 0
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Figure 1-22: The structures of paracetamol 32 (acetaminophen), o-methyl paracetamol 33, and
o,o-dimethyl paracetamol 3444.
Hydroxylation and methoxylation also alter the properties of a potential drug by,
conversely, increasing its water solubility. Hydroxylation also introduces potential new
44
hydrogen-bonding centers, which can influence the binding of the compound to its target
If a compound of interest contains a heterocycle, substitution of alternate, isosteric
heterocycles has been shown to alter the bioactivity of the compound. For example, an indole 35
moiety can be substituted with an aza-indole 36, a benzofuran 37, or a benzothiophene 38 moiety
(Figure 1-23)49. Intriguing biological properties have been reported for numerous compounds
containing aza-indole 36, benzofuran 37, and benzothiophene 38 moietiesso-s 7, and numerous
drugss8-60 contain such moieties. Aza compounds, for example, typically have high water
solubility and unique hydrogen-bonding properties61.
N
H H
indole aza-indole benzofuran benzothiophene
35 36 37 38
Figure 1-23: Structures of indole 35, aza-indole 36, benzofuran 37, and benzothiophene 38
moieties. In the aza-indole 36 moiety the nitrogen on the benzene ring can also be in other
positions on the benzene ring.
Different stereoisomers of a compound can have vastly different bioactivities62 . For
example, the S-(+)-isomer of the anti-histamine dexchloropheniramine 39 is approximately two
hundred times more powerful than the R-(-) isomer 40 (Figure 1-24)42. Altering the
stereochemistry at a chiral center is yet another way to potentially alter the bioactivity of a
compound.
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Figure 1-24: Structures of the S-(+) 39 and R-(-) 40 isomers of the anti-histamine
42dexchloropheniramine
V. Cloned TIA enzymes
A potentially useful way of making large amounts of TIAs and plant-derived natural
products in general is by heterologous reconstitution in yeast. Unfortunately, only a few of the
cDNA sequences encoding the enzymes of TIA biosynthesis in C. roseus have been cloned.
These enzymes include geraniol-lO-hydroxylase (G1OH), loganic acid methyltransferase
(LAMT), secologanin synthase (SLS), strictosidine synthase (STS), strictosidine-p-glucosidase
(SGD), and several enzymes that occur late in the biosynthesis of vindoline'.
Geraniol-lO-hydroxylase (G1OH) is a 56 kDa cytochrome P450 monooxygenase that
catalyzes the first committed step of iridoid terpene biosynthesis, the conversion of geraniol 22
to 10-hydroxy geraniol 23 (Figure 1-10). Geraniol-lO-hydroxylase has been heterologously
expressed in yeast and functionally characterized20 21 . Hydroxylation of geraniol 22 and its cis-
isomer nerol 41 were observed in a reconstituted system with geraniol-10-hydroxylase and
NADPH-cytochrome P450 reductase . Geraniol-lO-hydroxylase has a Km of 5.5 1iM for
22geraniol 22 and 11 IM for nerol 41 (Figure 1-25)
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Figure 1-25: The structures of geraniol 22 and its cis-isomer nerol 41.
The enzyme loganic acid methyltransferase (LAMT) methylates loganic acid 42,
converting it to loganin 25 (Figure 1-11). Loganic acid methyltransferase has been cloned and
expressed in E. coli 3 . Previous enzymatic studies with partially purified enzyme have shown
that loganic acid 42 is the substrate for the methylation reaction catalyzed by loganic acid 42
rmethyltransferase 22,64 . Loganic acid methyltransferase was reported to have an unusually high
Km of 14.76 + 1.7 mM for loganic acid 42 and 742.1 ± 37 pM for S-adenosyl-L-methionine, a
turnover of 19.6 min-], a pH optimum of 7.5, and a temperature optimum of 32 C63,64.
Secologanin synthase (SLS), the P450 oxidase that converts loganin 25 to secologanin 17
(Figure 1-11), has been cloned and expressed in E. coli as a translational fusion with the C.
roseus P450 reductases. Secologanin synthase was isolated from a cDNA library of a C. roseus
cell suspension culture66 68. Secologanin synthase was shown to accept only loganin 25 as a
substrate, and has a pH optimum of 7.5 and a temperature optimum of 30,C 68.
Strictosidine synthase (STS) catalyzes the formation of strictosidine 1 from secologanin
17 and tryptamine 18 (Figure 1-6, Figure 1-13). Strictosidine synthase is absolutely
stereoselective, forming only strictosidine 1 and not the C-3 R diastereomer vincoside 43.
Recombinant strictosidine synthase expressed in E. coli has been kinetically characterized: the
Km for tryptamine 18 and secologanin 17 are reported to be 6.2 pM and 39 jM, respectively, and
the kcat is 78.2 min-'. The optimal pH and temperature are reported to be 6.8 and 30'C,
respectively 9. Strictosidine synthase from Rauvolfia serpentina has been crystallized, and the
structure is a six-bladed p-propeller fold70. The only currently known enzymes that are
functionally related to strictosidine synthase are deacetylipecoside synthase, deacetylisoipecoside
synthase71, and norcoclaurine synthase 7 2. Deacetylipecoside synthase catalyzes the condensation
of secologanin 17 and dopamine 44 to produce deacetylipecoside 45, while deacetylisoipecoside
synthase catalyzes the condensation of secologanin 17 and dopamine 44 to produce
deacetylisoipecoside 46, leading to the family of monoterpenoid tetrahydroisoquinoline alkaloids
(Figure 1-26)71 . Norcoclaurine synthase catalyzes the condensation of 4-
hydroxyphenylacetaldehyde 47 and dopamine 44 to produce (S)-norcoclaurine 48, leading to the
family of benzylisoquinoline alkaloids (Figure 1-26)70,72. The amino acid sequence of
norcoclaurine synthase, which has been cloned, is not at all similar to that of strictosidine
synthase.
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Figure 1-26: Deacetylipecoside synthase and deacetylisoipecoside synthase catalyze the
condensation of dopamine 44 and secologanin 17 to produce deacetylipecoside 45 and
deacetylisoipecoside 46, respectively 1. Norcoclaurine synthase catalyzes the condensation of
dopamine 44 and 4-hydroxyphenylacetaldehyde 47 to produce (S)-norcoclaurine 487.
Strictosidine-p-glucosidase (SGD) catalyzes the deglycosylation of strictosidine 1, the
central TIA intermediate (Figure 1-14, Figure 1-27). SGD exists as a high molecular weight
complex formed from aggregates of 4, 8, or 12 monomers, with the monomer having a molecular
weight of 63 kDa. The main products of SGD deglycosylation of strictosidine 1 are cathenamine
49 and glucose 50, though other isomers of cathenamine 49 are also formed (Figure 1-27).7376
SGD from C. roseus has an optimum pH between 6 and 6.474, an optimum temperature of
30 C77, and reported Km values ranging from 18 to 200 iM77'7 8. SGD is discussed in further
detail in Chapter 2.
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Figure 1-27: Strictosidine 1 is deglycosylated by SGD to produce glucose 50, cathenamine 49,
and other isomers of cathenamine 49.
Tabersonine 27 is transformed to vindoline 28 in six reactions that have been studied
extensively by De Luca and coworkers (Figure 1-28)1. Many of the enzymes in the biosynthetic
pathway leading to vindoline 28 have been cloned. The first step is an aromatic hydroxylation of
tabersonine 27 at C-I1 by the microsomal cytochrome P450 monooxygenase tabersonine 16-
hydroxylase66. The hydroxyl group is then methylated by the cytosolic S-adenosyl-L-methionine
(SAM)-dependent 16-hydroxytabersonine O-methyltransferase (OMT) 79. The 2,16 double bond
is then hydrated by an unknown enzyme 2. A thylakoid-associated SAM-dependent 2,16-dihydro-
11 -hydroxytabersonine-N-methyltransferase (NMT) then methylates N-1, producing
desacetoxyvindoline 80. The C-17 of desacetoxyvindoline is then hydroxylated by the cytosolic
20-oxoglutarate-dependent dioxygenase (Dl7H)81. Vindoline is finally produced by 4-0-
acetylation by the cytosolic 17-0-deacetylvindoline-17-0-acetyltransferase82 (Figure 1-28). The
vindoline 28 produced is then coupled with catharanthine 29 by the known peroxidase 3',4'-
anhydrovinblastine synthase to produce a 5',6' iminium dimer83 . The 5',,6' iminium is then
reduced, producing a-3',4'-anhydrovinblastine 51. Hydroxylation of the 3',4' double bond yields
vinblastine 2, and further oxidation of the N-1-methyl group yields vincristine 3 (Figure 1-29).
The enzymes that act after the dimerization step, however, are uncharacterized'.
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Figure 1-28: Vindoline 28 biosynthesis from tabersonine 27 1,66,79-82, with the numbering system
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VI. Substrate specificity of TIA enzymes and precursor directed biosynthesis studies
Strictosidine 1, the central intermediate in TIA biosynthesis, is produced by a
stereoselective Pictet-Spengler condensation of secologanin 17 and tryptamine 1884. The
substrate specificity of strictosidine synthase was studied to determine which novel strictosidine
1 analogs can be produced enzymaticallyss,86 . Once formed, these strictosidine 1 analogs could
potentially be incorporated into various biosynthetic pathways to form novel TIAs with
improved or altered biological activities. Numerous secologanin 17 and tryptamine 18 analogs
were shown to be accepted by strictosidine synthase. In vitro studies have shown that
strictosidine synthase is able to accept ethyl-ester secologanin 52, allyl-ester secologanin 53, and
pentynyl-ester secologanin 54 (Figure 1-30)86.
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Figure 1-30: Secologanin 17 analogs accepted by strictosidine synthase include ethyl-ester
secologanin 52, allyl-ester secologanin 53, and pentynyl-ester secologanin 5469,86,87.
A variety of indole-substituted tryptamine 18 analogs are also accepted by strictosidine
synthase. The tryptamine 18 and strictosidine 1 numbering systems are shown below in Figure
1-31. The 4-, 5-, 6-, and 7- positions of tryptamine correspond to the 9-, 10-, 11-, and 12-
positions of strictosidine 1, respectively. Tryptamine 18 analogs that are accepted by strictosidine
synthase to form the corresponding strictosidine 1 analogs include 4-fluoro, 5-fluoro, 6-fluoro, 7-
fluoro, 4-methyl, 6-methyl, 7-methyl, 5-hydroxy, 6-methoxy, 5,6-dihydroxy tryptamine, and a-
methyl tryptamine 70' 86' 88. Tryptamine analogs tested that are not accepted by strictosidine
synthase include 5-methyl, 5-chloro, 5-bromo, 5,7-dihydroxy, 5-methoxy tryptamine, N-methyl
tryptamine, and N-o-methyl tryptamine86
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Figure 1-31: The numbering system for tryptamine 18 and strictosidine 1 indole substituents is
shown in blue. The 4-, 5-, 6- and 7- positions of tryptamine 18 correspond to the 9-, 10-, 11-, and
12-positions of strictosidine 1, respectively 86. The a-position and the N-1 nitrogen and N-
o nitrogen of tryptamine 18 are indicated in blue.
Different heterocyclic amines were also assayed with strictosidine synthase. N-methyl
tryptamine 58, 2-(1H-Pyrrol-3-yl)-ethylamine 59, and 2-(1H-Imidazol-4-yl)-ethylamine 60 are
not accepted by strictosidine synthase to form the corresponding strictosidine 1 analogs (Figure
1-32). However, 2-benzofuran-3-yl-ethylamine 61 and 2-benzo[b]thiophen-3-yl-ethylamine 62
form benzo strictosidine 1-a and thio strictosidine 1-b, respectively (Figure 1-33). The 2-
benzo[b]thiophen-3-yl-ethylamine 62 substrate was accepted so slowly by strictosidine synthase
that a quantitative enzymatic kinetic analysis was not possible. The 2-benzofuran-3-yl-
ethylamine 61 substrate had a Km value similar to that of tryptamine, but it had a much lower
kcat; we speculate that catalysis is slowed by the electron-deficient nature of the benzofuran
rings6
NH2
N-methyl
tryptamine 58
NH2  NH2
N N
H H
2-(1H-Pyrrol-3-yl) 2-(1H-Imidazol-4-yl)
-ethylamine 59 -ethylamine 60
Figure 1-32: The substrates N-methyl tryptamine 58, 2-(1H-Pyrrol-3-yl)-ethylamine 59, and 2-
(1H-Imidazol-4-yl)-ethylamine 60 are not accepted by strictosidine synthase to form the
86
corresponding strictosidine analogs
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Figure 1-33: The substrates 2-benzofuran-3-yl-ethylamine 61 and 2-benzo[b]thiophen-3-yl-
ethylamine 62 are accepted by strictosidine synthase to form benzo strictosidine 1-a and thio
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strictosidine 1-b, respectively
Precursor directed biosynthesis studies
To probe the capacity of the biosynthetic machinery to produce novel alkaloids,
tryptamine 18 analogs were also co-cultured with hairy root cultures in precursor directed
biosynthesis studies (Figure 1-34), and it was found that many of the enzymes in TIA
biosynthesis can accept alternative substrates34,36. The substrates 4-7-fluoro, 4-7-chloro, 4-7-
bromo, 4-7-methyl, and 4-7-methoxy tryptamine, as well as benzo strictosidine 1-a, were co-
cultured with hairy root cultures for two weeks. The cultures were then extracted with methanol
and the alkaloid content was analyzed. The corresponding ajmalicine 4, serpentine 5,
isositsirikine 7, akuammicine 63, catharanthine 29, tabersonine 27, and vindoline 28 analogs
were observed, indicating that numerous enzymes downstream of SGD are able to accept
36
alternative substrates
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Figure 1-34: The substrates 4-7-fluoro, 4-7-chloro, 4-7-bromo, 4-7-methyl, and 4-7-methoxy
tryptamine, as well as benzo strictosidine 1-a, were incorporated into hairy root cultures and
produced the corresponding ajmalicine 4, serpentine 5, isositsirikine 7, akuammicine 63,
catharanthine 29, tabersonine 27, and vindoline 28 analogs 4 .
VII. Thesis overview
Because of synthetic complexity of TIAs, cost-effective industrial-scale synthesis of
many TIAs is currently not feasible. A potential strategy to produce large amounts of TIAs is
heterologous reconstitution of the pathway in yeast". Unfortunately, only a few of the enzymes
found in TIA biosynthesis in C. roseus, strictosidine synthase, strictosidine-p-glucosidase
(SGD), and several enzymes that occur late in the biosynthesis of vindolinel have been cloned.
There are reports of natural product analogs that have proven to be more
pharmaceutically useful than the parent natural product; for example, the camptothecin 10
analogs topotecan 15 and irinotecan 16 (Figure 1-5) are used clinically, yet the natural product
camptothecin 10 is too toxic and water insoluble to be used as a drug9 . If the substrate specificity
of TIA enzymes were known, novel TIAs could be produced on an industrial scale once the
enzymes were isolated and cloned. A library of novel TIAs could be created, and assayed in a
variety of pharmaceutical screens.
In this thesis I discuss my work studying the enzymes strictosidine-p-glucosidase (SGD),
ajmalicine synthase, and isositsirikine synthase. As described, SGD deglycosylates strictosidine
1, the central intermediate of TIA biosynthesis. Ajmalicine synthase and isositsirikine synthase
are NADPH-dependent reductase enzymes that reduce the reactive hemiacetal moiety generated
by the action of SGD (Figure 1-35). Ajmalicine synthase produces ajmalicine 4, which is used to
treat hypertension 3, and isositsirikine synthase produces isositsirikine 7, which has anti-
6
neoplastic activity . In this thesis I developed strategies to make novel ajmalicine 4 and
isositsirikine 7 analogs in vitro. The NADPH-dependent reductase enzymes that produce the
anti-hypertensive agent ajmalicine 4 and the anti-neoplastic agent isositsirikine 7 have not been
isolated. I developed a partial purification procedure for ajmalicine synthase and isositsirikine
synthase from C. roseus hairy root and cell suspension cultures. I also performed crosslinking
experiments with a substrate probe in attempts to isolate ajmalicine synthase and isositsirikine
synthase. In my substrate specificity studies I found that ajmalicine synthase and isositsirikine
synthase have broad substrate specificity substrate specificity, which is promising for the
development of novel ajmalicine 4 and isositsirikine 7 analogs with potentially improved
therapeutic activities.
ajmalicine N H
N "H
synthase, H O
NH/ 0 OH + NADPH O0
' N "H OH SGD N "Hajmalicine 4
H OHO O H OH
00 /0H
"0 0H0 N "H .
strictosidine 10 isositsirikine H
+ other isomers synthase, O 5( OH
NADPH 0isositsirikine 7
Figure 1-35: Strictosidine 1 is deglycosylated by SGD. Ajmalicine synthase and isositsirikine
synthase are NADPH-dependent reductases that reduce deglycosylated strictosidine to ajmalicine
4 and isositsirikine 7, respectively.
Chapter 2 describes my work determining which strictosidine 1 analogs are accepted by
SGD. I assayed strictosidine 1 analogs containing modified indole, methyl ester, vinyl, and
glucose moieties, as well as the diastereomer of strictosidine 1, vincoside 43. I also discuss the
steady state kinetic analysis studies that I performed to obtain a quantitative assessment of the
substrate specificity of this enzyme. Chapter 3 discusses the partial purification procedure that I
developed for ajmalicine synthase and isositsirikine synthase. Efforts to clone these enzymes are
described. I also describe deglycosylated strictosidine 49 analogs that I found were accepted by
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ajmalicine synthase and isositsirikine synthase to produce new corynanthe type alkaloids.
Chapter 4 describes the enzymes that have been isolated and cloned by a crosslinking strategy.
One of these enzymes has been found to have sinapyl alcohol dehydrogenase activity. Finally,
chapter 5 discusses future directions of the project.
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I. Introduction
Strictosidine-3-glucosidase (SGD) is the enzyme that acts after strictosidine
synthase in monoterpene indole alkaloid (TIA) biosynthesis. SGD deglycosylates the
central TIA intermediate strictosidine 1, producing a reactive aglycone 49 that can
rearrange in numerous ways1 . This reactive aglycone 49 and its isomers then enter
multiple biosynthetic pathways, ultimately producing hundreds of different TIAs (Figure
732-1)
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Figure 2-1: Strictosidine 1 is deglycosylated by SGD to produce a reactive hemiacetal
intermediate that can rearrange in many ways. Different enzymes then act to produce
hundreds of different TIAs, such as vinblastine 2, ajmalicine 4, and yohimbine 61.
This reactive aglycone 49 forms a mixture of isomers in equilibrium, including
4,21-dehydrogeissoschizine 64 and cathenamine 49 (Figure 2). The compound 4,21-
dehydrogeissoschizine 64 is a proposed intermediate for other TIAs, including the anti-
cancer agents vinblastine 2 and vincristine 3. Cathenamine 49 is reported to be the major
product in vitro of strictosidine 1 deglycosylation by SGD (Figure 2-2) 1.
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Figure 2-2: Upon deglycosylation by SGD, strictosidine 1 forms an aglycone 49 that
rapidly interconverts between various isomers'.
In 2000, a SGD cDNA clone was isolated from a C. roseus cDNA library, and
then expressed in Saccharomyces cerevisiae. The recombinant SGD protein was shown
specifically to deglycosylate strictosidine 1; several other glucosides tested were not
deglycosylated73 75. SGD can also be heterologously expressed in E. coli. The optimum
pH of SGD from C. roseus was found to be between 6 and 6.44. It was also discovered
that SGD expression could be induced by the plant hormone methyl jasmonate, which is
known to increase alkaloid production when provided to C. roseus seedlings and cell
suspension cultures73
SGD has also been cloned from Rauvolfia serpentina. Unlike SGD from C.
roseus, SGD from R. serpentina lacks a C-terminal signal sequence predicted to direct it
to the endoplasmic reticulum (ER). The in vitro deglycosylation of SGD from R.
serpentina is believed to proceed through the same mechanism as in C. roseus. The
amino acid sequence of SGD from R. serpentina is 70% identical to that of the enzyme
from C. roseus7 4, though the optimum pH of SGD from R. serpentina was found to be
between 5 and 5.2, somewhat lower than the pH optimum observed for C. roseus.
Sequence alignment studies indicate that SGD is part of the glycosyl hydrolase family
76
SGD from R. serpentina has been recently crystallized (PDB: 2FJ6)76. The
crystal structure of SGD from R. serpentina shows that this enzyme has a (p/a)8 barrel
fold, 13 a-helices, and 13 p-strands. Eight parallel p-strands form a p-barrel that is the
core of the structure. The p-barrel is surrounded by eight helices, and the binding site for
strictosidine 1 is located in the barrel 76. At the base of the p-barrel there are several
charged, hydrophilic residues that appear to interact with the glucose moiety. At the
entrance of the pocket there are several hydrophobic residues - Phe-221, Trp-388, Gly-
386, Met-275, Thr-210, and Met-297 - that surround the indole moiety of strictosidine 1
(Figure 2-3)76.
The amino acid residues Glu-207 and Glu-416 are conserved in SGD and in all
other glucosidases of the glycosyl hydrolase family 1. In the proposed concerted
hydrolysis of strictosidine 1 deglycosylation by SGD, Glu-416 acts as a nucleophile,
attacking the C-i' position of the glucose moiety of strictosidine 1, and Glu-207 acts as a
proton donor (Figure 2-3A) 76. Barleben et al. report that a Glu207Gln mutant had no
detectable hydrolysis activity (Figure 2-3B), which suggests the importance of the Glu-
207 residue in catalysis76
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Figure 2-3: A: In the proposed concerted hydrolysis of strictosidine 1 deglycosylation by
SGD, Glu-416 acts as a nucleophile, attacking the C-1' position of the glucose moiety of
strictosidine 1, and Glu-207 acts as a proton donor 76. B: Figure of the active site of the
inactive SGD mutant Glu207Gln. This figure is taken from Barleben et al.76
Native PAGE of C. roseus SGD has shown three different protein bands at
approximately 250, 500, and 630 kDa. In contrast, under denaturing conditions, one
protein band of 63 kDa is observed, suggesting that SGD can form aggregates of 4, 8, or
7312 monomers . SGD has also been found to be glycosylated, though because
recombinant protein from E. coli is active, glycosylation does not appear to be essential
73for activity
SGD from C. roseus has a C-terminal KKXKX sequence that likely directs it to
the ER 73-75 . An in situ localization method and a sucrose gradient analysis have also
indicated that SGD is likely associated with the ER73. In the in situ localization method,
cells and protoplasts of C. roseus containing SGD activity were incubated with 2 mM
strictosidine 1 and analyzed by fluorescence microscopy. Strictosidine 1 deglycosylation
by SGD produces a yellow degradation product, 5,6-dihydroflavopereirine 66 (Figure
2-4), that has low solubility in water. The degradation product is derived from 4,21-
dehydrogeissoschizine 64, which is in equilibrium with cathenamine 492. After
strictosidine 1 and SGD were incubated for ten minutes with the protoplasts, a yellow-
colored degradation product, 5,6-dihydroflavopereirine 66, appeared. Longer incubation
times resulted in more intense coloration in the area where the ER is located and less
dense coloration throughout the cytosol. Samples taken from the incubation mixture
throughout the incubation period showed a disappearance of strictosidine 1 by HPLC,
indicating SGD activity2 . An additional study was performed in which the SGD inhibitor
D-gluconic acid 6-lactone 67 (Figure 2-4) was added. In protoplasts in which D-gluconic
acid 6-lactone 67 was present, no yellow coloration was observed73 . In a sucrose gradient
analysis of SGD in C. roseus lysate, SGD activity was found in the 47% sucrose fraction
along with an ER marker enzyme, also suggesting that SGD is possibly associated with
the ER 73 .
N HO 0 0
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Figure 2-4: The structures of 5,6-dihydroflavopereirine 66, a degradation product of 4,21-
dehydrogeissoschizine 64, and of D-gluconic acid 6-lactone 67, an inhibitor of SGD2
We have hypothesized that the enzymes acting downstream of SGD are also
located near the ER, because the deglycosylated strictosidine isomers are reactive and
have poor solubility, thus making transportation by diffusion to other sites difficult. It is
unknown whether there are specific carrier proteins for various TIA intermediates73
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It was found by Gerasimenko et al.74 that when SGD was incubated with N-p-
methyl strictosidine (dolichantoside 68), several products formed, including a product
called isocorreantine A 69 (Figure 2-5). The formation of isocorreantine A 69 and not a
cathenamine 49 analog led the researchers to believe that the dialdehyde intermediate
produced upon deglycosylation is released from SGD and further rearrangements occur
spontaneously. The researchers suggest that the divergence leading to the numerous TIA
biosynthetic pathways occurs at a later stage than strictosidine deglycosylation, after the
formation of 4,21 -dehydrogeissoschizine 64
N Me 0 .. 'OH
N'Me , OH \ / N
'N OH SGD HN N-Me CyCliZation NNHy.Ia1~ NH Me
OH O H 'HHO
/0 0 H H H O-
dolichantoside 68 HO 0 O
(N-p-methyl strictosidine) 0 isocorreantine A 69
dialdehyde intermediate
Figure 2-5: Dolichantoside 68 is N-p-methyl strictosidine; the methyl group that
differentiates dolichantoside 68 from strictosidine 1 is labeled in blue. Dolichantoside 68
is deglycosylated by SGD to form a dialdehyde intermediate. Upon deglycosylation, the
indole nitrogen attacks the aldehyde (green arrow) and then cyclizes to form
74isocorreantine A 69. Attack by the methylated nitrogen (red arrow) does not occur
Deglycosylation of strictosidine 1 by SGD may also play a role in C. roseus plant
cell defense. The aglycone 65 produced by strictosidine 1 deglycosylation by SGD has
been shown to have anti-microbial activity against a number of microorganisms76
Though its detailed ecological relevance is not clear, this is not an unprecedented finding:
.. ....... - - -
many glucosidases found in other plants also have defense-related functions.
Deglycosylation in a variety of other plants leads to the formation of toxic or bitter small
molecules that are known to be defensive, such as isothiocyanates 90, DIMBOA91 , or
cyanide92
Strictosidine 1 is a unique central intermediate. It is rare for a glucoside to act as a
precursor at the beginning of a biosynthetic pathway, and for the precursor to become
activated by deglycosylation. Glucosides more typically appear in natural product
biosyntheses at the end of biosynthetic pathways, acting as a means of converting end
products into water-soluble compounds. Once water-soluble, the end products can easily
be stored in plant vacuoles. SGD is thus a unique glucoside in that it has both defensive
76and synthetic importance
Besides SGD, there are only two other examples of biosynthetic pathways in
which a glucosidase has synthetic relevance. In isoquinoline alkaloid biosynthesis, the
central intermediate glucosides deacetylisoipecoside 45 and deacetylipecoside 46 are
deglycosylated (Figure 2-6)93 and then go on to form numerous isoquinoline alkaloids. In
lignin biosynthesis, the glucoside coniferin 70 (Figure 2-6) is deglycosylated to form
coniferyl alcohol94 , which is a precursor to lignin76
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Figure 2-6: The structures of glucosides deacetylipecoside 45, deacetylisoipecoside 46,
and coniferin 70.
Numerous tryptamine 18 and secologanin 17 analogs have been reported to be
accepted by strictosidine synthase to form strictosidine 1 analogs 36,86,87, and directed
biosynthesis studies have shown that the TIA pathway can produce a variety of novel
alkaloids by utilizing nonnatural substrate analogs. For novel alkaloids derived from
strictosidine 1 analogs to be produced, these analogs must be accepted by SGD. This
chapter discusses my work in determining which strictosidine 1 analogs are accepted by
SGD. I assayed a broad scope of strictosidine 1 analogs containing modified indole,
methyl ester, vinyl, and glucose moieties, as well as the diastereomer of strictosidine 1,
vincoside 43. I also performed steady state kinetic analysis on numerous substrates to
determine whether SGD acts as a bottleneck in the production of novel alkaloids.
II. Results
Strictosidine analogs
To determine whether SGD acts as a gatekeeper in the production of novel TIAs,
I synthesized a broad array of strictosidine 1 analogs in one step from tryptamine and
secologanin analogs (Figure 2-7 - Figure 2-9). To determine the substrate specificity of
SGD, I altered numerous moieties of strictosidine 1, including the indole ring, methyl
ester, and glucose moieties. I modified numerous positions, including the C-20 vinyl
position, the C-5 a position, and the C-3 position. Further details on the synthesis and
characterization of all strictosidine 1 analogs described herein are in the Materials and
Methods section.
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Figure 2-7: Structure of strictosidine 1, with the numbering system shown in blue. The 5
position is commonly referred to as the a position, and the 6 position is commonly
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referred to as the p position
The indole substituted strictosidine analogs synthesized included 9-fluoro 1-c, 10-
fluoro 1-d, 11-fluoro 1-e, 12-fluoro 1-f, 9-methyl 1-g, 10-methyl 1-h, 11-methyl 1-i, 12-
methyl 1-j, 9-chloro 1-k, 10-chloro 1-1, 12-chloro 1-m, 9-bromo 1-n, 10-bromo 1-o, 10-
hydroxy 1-p, 1 0-isopropyl 1-q, 1 0-methoxy 1-r, and 11 -methoxy 1-s (Figure 2-7, Figure
2-8).
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Figure 2-8: The structures of strictosidine 1 and indole substituted strictosidine analogs 1-
c through 1-s.
In addition to indole substituted strictosidine 1 analogs, I also synthesized
isotopically labeled d4 strictosidine 1-1, vincoside 43, d4 vincoside 43-1, pentynyl-ester
strictosidine 1-t, 10-fluoro-a-methyl strictosidine 1-u, a-dimethyl strictosidine 1-v, 9-aza
strictosidine 1-w, 12-aza strictosidine 1-x, benzo strictosidine 1-a, and thio strictosidine
1-b (Figure 2-9). I also chemically synthesized a diastereomeric mixture 45-1 of
deacetylipecoside and deacetylisoipecoside isomers from dopamine and secologanin.
Because the products could not be separated and thus completely characterized, despite
extensive efforts, it is possible that an alternate regioisomer is also present in this mixture
(Figure 2-9, 45-1). Hereafter, the mixture of all these various isomers will be called
"deacetylipecosides 45-1" (Figure 2-9). Dr. Peter Bernhardt generously provided des-
vinyl strictosidine isomers 1-y, as well as a diastereomerically pure des-vinyl strictosidine
isomer produced enzymatically with strictosidine synthase 1-z (Figure 2-9).
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Figure 2-9: The structures of d4 strictosidine 1-1, vincoside 43, d4 vincoside 43-1,
pentynyl-ester strictosidine 1-t, 10-fluoro-a-methyl strictosidine 1-u, a-dimethyl
strictosidine 1-v, 9-aza strictosidine 1-w, 12-aza strictosidine 1-x, benzo strictosidine 1-a,
thio strictosidine 1-b, deacetylipecosides 45-1, des-vinyl strictosidine isomers 1-y, and
des-vinyl strictosidine isomer produced with strictosidine synthase 1-z. The C-3 position
of vincoside 4395 and the 6', 7' and 8' positions of deacetylipecosides 45-1 96, are labeled
in blue.
SGD Assay
SGD from C. roseus was expressed in E. coli as an N-terminal maltose-binding
protein (MBP) or as a C-terminal hexa-His-tag fusion using a codon-optimized synthetic
gene. To assay SGD activity, strictosidine analogs 1-a through 1-z were incubated with
SGD in 0.15 M citrate phosphate buffer, pH 6. Three analytical methods were used to
detect SGD activity: LCMS, HPLC, and a colorimetric glucose-detection assay. With
both LCMS and HPLC, disappearance of strictosidine 1 analog and formation of
deglycosylated strictosidine 49 analog could be observed (Figure 2-10, Figure 2-11). A
glucose-detection assay with the Amplex@ Red Glucose/Glucose Oxidase Assay Kit
from Invitrogen was used as further verification of SGD activity; upon deglycosylation
the free glucose is oxidized by glucose oxidase. The H20 2 that results reacts with
Amplex@ Red and horseradish peroxidase to generate a fluorescent compound, resorufin.
deglycosylated 10-methyl
strictosidine 49-h
m/i 365
10-methyl strictosidine 1-h
m/z 545
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Figure 2-10: Representative assay using LCMS. Selected ion chromatograms of an assay
of 10-methyl strictosidine 1-h with SGD showing starting material and product.
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Figure 2-11: Representative assay using HPLC. HPLC chromatogram of an assay of 11-
fluoro strictosidine 1-e with SGD, with the absorbance at 238 nm measured.
A. Novel deglycosylated strictosidine analogs
LCMS analysis showed that SGD was able to deglycosylate all the indole
substituted strictosidine 1 analogs shown in Figure 2-8, as well as 10-fluoro-a-methyl
strictosidine 1-u and a-dimethyl strictosidine 1-v. This result contrasts with that of
strictosidine synthase, the enzyme acting before SGD, which does not accept 5-methyl
70,86,88
tryptamine 18-h, 5-methoxy tryptamine 18-s, or a-dimethyl tryptamine 18-v . SGD
is apparently more tolerant than strictosidine synthase for substitutions at the C-5 and C-
10 positions. That all indole substituted strictosidine 1 analogs are accepted by SGD is
exciting for the prospect of producing novel downstream TIAs with improved biological
activities. Fluorination, for example, is reported to improve metabolic stability by making
nearby moieties less susceptible to oxidation by cytochrome P450s 48. Fluorination,
chlorination, bromination, and methylation are all reported to increase the lipophilicity of
compounds, facilitating the penetration of membranes. Hydroxylation and methoxylation
can improve the water solubility of compounds, facilitating diffusion in the cytosol.
Pentynyl-ester strictosidine 1-t was also accepted, indicating that the SGD active
site can tolerate much larger groups than a methyl ester. I used pentynyl-ester
strictosidine 1-t in crosslinking studies, which are described in Chapter 4.
SGD could deglycosylate strictosidine analogs containing alternate heterocyclic
moieties: 9-aza strictosidine 1-w, 12-aza strictosidine 1-x, benzo strictosidine 1-a, and
thio strictosidine 1-b (Figure 2-12) were all accepted by SGD. I assayed 9-aza
strictosidine 1-w, 12-aza strictosidine 1-x, benzo strictosidine 1-a, and thio strictosidine
1-b in order to explore what effect, if any, the decreased electron density of the analogs
would have on deglycosylation. Numerous compounds containing aza, benzofuran, and
benzothiophene moieties have been reported to have intriguing biological
propertiess , including the drugs raloxifene58, zileuton 9, and sertaconazoleo. If the
aza 1-w and 1-x, benzo 1-a, and thio 1-b strictosidine analogs are accepted by SGD and
by enzymes farther downstream, perhaps novel TIAs with altered biological properties
could be produced. For example, aza compounds are reported to have high water
solubility and unique hydrogen-bonding properties61
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Figure 2-12: Structures of 9-aza strictosidine 1-w, 12-aza strictosidine 1-x, benzo
strictosidine 1-a, and thio strictosidine 1-b.
The mixture of isomers of deacetylipecosides 45-1 are also accepted by SGD;
LCMS analysis clearly showed the formation of deglycosylated deacetylipecoside
isomers, along with the disappearance of the starting material (Figure 2-13).
Deacetylipecosides 45-1 are produced enzymatically by deacetylipecoside synthase and
deacetylisoipecoside synthase7 1 , two of the few enzymes currently known to be
functionally related to strictosidine synthase 7 2. Deacetylipecoside synthase and
deacetylisoipecoside synthase catalyze the condensation of tryptamine 18 and dopamine
44, leading to the family of monoterpenoid tetrahydroisoquinoline alkaloids. I
investigated deacetylipecosides 45-1 as potential substrates for deglycosylation by SGD
because of the potential of using deglycosylated deacetylipecosides as substrates for later
TIA biosynthetic enzymes . Because SGD was able to deglycosylate various
deacetylipecoside isomers 45-1, perhaps later biosynthetic enzymes can produce novel
TIA analogs from these substrates.
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Figure 2-13: Structure of deacetylipecosides 45-1.
SGD from C. roseus also deglycosylates vincoside 43, the C-3 diastereomer of
strictosidine 1, and d4-vincoside 43-1 (Figure 2-14). This is intriguing, because vincoside
43 is not accepted by SGD from R. serpentina74 . To verify this surprising finding, a
glucose-detection assay was also used in addition to LCMS analysis. This finding is
encouraging because it suggests that downstream alkaloids containing alternate
stereochemistries can be produced. Different stereoisomers can have different
pharmacological profiles62, and perhaps downstream alkaloids containing R
stereochemistry at the C-3 position will have different pharmacological properties than
the natural alkaloids with S stereochemistry at the C-3 position.
",OH
vincoside 43 d4 vincoside 43-1
Figure 2-14: Structures of vincoside 43 and d4 vincoside 43-1.
I performed additional analysis of strictosidine 1 analogs with alternate
stereochemistry using a mixture of des-vinyl strictosidine isomers 1-y synthesized by Dr.
Peter Bernhardt (Figure 2-15)97. Using LCMS, this mixture was separated into six peaks.
A single diastereomer of des-vinyl strictosidine analog 1-z was also synthesized
enzymatically using strictosidine synthase. This enzymatically synthesized analog 1-z co-
elutes with peak 3 of the des-vinyl strictosidine mixture I-y (Figure 2-15 and Figure
2-16).
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Figure 2-15: Structure of des-vinyl strictosidine isomers 1-y and of the enzymatically
produced des-vinyl strictosidine isomer 1-z, with the C-15 and C-21 positions labeled in
blue.
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Figure 2-16: LCMS trace of the des-vinyl strictosidine mixture 1-y. Peak 3 (indicated
with an arrow) co-elutes with the des-vinyl strictosidine analog 1-z produced
enzymatically with strictosidine synthase.
When SGD was incubated with the des-vinyl strictosidine mixture 1-y, LCMS
analysis of the starting material showed a decrease in area of only two of the separable
six peaks, peaks I and 3 (Figure 2-16). Peak 3 co-elutes with the strictosidine synthase-
formed des-vinyl strictosidine analog 1-z, suggesting that the compound with natural
C15/21 trans stereochemistry is turned over by SGD. The observed deglycosylation of
various des-vinyl strictosidine isomers indicates that SGD does not require a vinyl moiety
on strictosidine 1 for turnover.
To fully explore the stereochemical promiscuity of downstream enzymatic
reactions, however, complete deglycosylation of the des-vinyl strictosidine mixture 1-y is
required. (Figure 2-16 and Figure 2-17). Because it has been previously shown that
strictosidine 1 can be deglycosylated by bacterial glucosidases** I89 examined whether two
commercially available glucosyl hydrolases, Bacillus stearothermophilus a-glucosidase
and almond p-glucosidase, display different deglycosylation patterns than SGD does.
Both an a-glucosidase and a p-glucosidase were chosen because the mixture of des-vinyl
-VON---
strictosidine isomers 1-y contains both a and P anomers, and complete deglycosylation of
the mixture was desired. B. stearothermophilus a-glucosidase is specific for terminal a-
1,4 bonds of maltosaccharides and a-glucans99 . Almond-p-glucosidase is a well-studied 00
retaining glucosidase that has a broad substrate specificity; it is often assayed with aryl-
glucosides 00' 10 1.
Almond- p-glucosidase was considerably more permissive than SGD, consuming
four out of the six peaks in the chromatogram, peaks 1, 3, 5, and 6 (Figure 2-17). B.
stearothermophilus a-glucosidase facilitated the consumption of two peaks that were not
converted by either p-glucosidase, peaks 2 and 4 (Figure 2-17). Based on these data, we
hypothesize that peak 1, peak 3, and peak 6 contain mainly p-anomers, while peaks 2 and
4 contain mainly a-anomers. Peak 5 appears to contain both a- and p-anomers. SGD
therefore appears to be more specific for its substrate strictosidine 1, while the two
commercially available glucosidases likely have active sites that allow a greater diversity
of substrates to be accepted. By using glucosidases from different metabolic pathways, it
is possible to bypass the native biosynthetic pathway to fully deglycosylate the des-vinyl
strictosidine mixture 1-y.
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Figure 2-17: Chromatogram 1: Des-vinyl strictosidine mixture 1-y subjected to
deglycosylation by B. stearothermophilus a-glucosidase (blue trace). Chromatogram 2:
Des-vinyl strictosidine mixture 1-y subjected to deglycosylation by almond p-glucosidase
(green trace). Chromatogram 3: Des-vinyl strictosidine mixture 1-y subjected to
deglycosylation by C. roseus SGD (red trace). Chromatogram 4: Des-vinyl strictosidine
mixture 1-y without glucosidase (black trace). Black downward arrows indicate peaks
that have decreased in area due to consumption by the glucosidase.
B. Steady state kinetic analysis
Not all substrate analogs are incorporated into the TIA pathway with equal
efficiency87. If substrate specificity of individual biosynthetic enzymes correlates with
rate-limiting steps in vivo, then enzymes having a low catalytic efficiency for a
nonnatural substrate could be reengineered to improve turnover of the analog. Therefore,
evaluation of enzyme substrate specificity is crucial for biosynthetic engineering efforts.
To determine quantitatively whether SGD acts as a bottleneck for the production of
various indole-substituted TIA analogs or TIA analogs with altered stereochemistry, I
performed steady state kinetic analysis studies with the indole substituted strictosidine
analogs 1-d, 1-e, 1-g, 1-h, 1-i, 1-j, 1-r, and 1-s, d4 strictosidine 1-1, and the C-3
diastereomer of d4 strictosidine 1-1, d4 vincoside 43-1. The indole substituted
strictosidine analogs were chosen as representative examples to determine the effects of
indole substituents on strictosidine deglycosylation by SGD.
To assess the catalytic efficiency of SGD, I incubated strictosidine 1 analogs with
SGD in 0.15 M citrate phosphate buffer, pH 6. I determined kinetic constants by
monitoring strictosidine 1 analog deglycosylation by HPLC or LCMS. Substrate
disappearance was measured instead of product formation because of the many rapidly
interconverting isomers that are produced by strictosidine 1 analogs upon
deglycosylation. These rapidly interconverting isomers prevented accurate quantification
of the product.
Since all steady state kinetic data (Table 2-1) appeared to fit a sigmoidal rather
than a Michaelis-Menten curve, kinetic constants (half-saturation value K05, maximum
velocity Vmax) were obtained from a sigmoidal fit to the data. SGD from C. roseus has
been reported to form aggregates consisting of 4-12 monomers; although a sigmoidal fit
has not been previously reported for C. roseus SGD, the oligomeric state of the enzyme is
compatible with the cooperative mechanism suggested by the sigmoidal curve. Hill
coefficients were also obtained for each analog; however, no correlation between the
substitution and the Hill coefficient was observed (Table 2-1).
With indole substituted strictosidine analogs 1-d, 1-e, 1-g, 1-h, 1-i, 1-j, 1-r, and 1-
s, the catalytic efficiencies (Vmax/Ko.5) varied by less than an order of magnitude from
naturally occurring strictosidine 1 (Table 2-1). Strictosidine analogs with methyl groups
in the 9, 10, 11, and 12 positions 1-g through 1-j demonstrated that steric effects did not
disrupt enzyme activity dramatically. Not surprisingly, replacement of methyl groups
with larger methoxy substituents 1-r and 1-s resulted in a small increase in the Ko.5
values. Electronic perturbations did not appear to impact the turnover profoundly; the
catalytic efficiencies of the fluorinated strictosidine analogs 1-d and 1-e (relative
Vmax/Ko.5 of 0.7 for both 1 0-fluoro strictosidine 1-d and 11 -fluoro strictosidine 1-e) did
not vary significantly from that of naturally occurring strictosidine 1.
Strictosidine Ko.5 (mM) Vmax (mM/min) Relative Hill
Substrate Vmax/Ko.) coefficient
strictosidine 1 0.22 + 0.009 0.078 + 0.002 1 1.8 + 0.1
9-methyl 1-g 0.22 +0.02 0.018 + 0.0003 0.2 3.3 0.9
10-methy1 1-h 0.071 + 0.002 0.016 + 0.0005 0.6 7.9 + 2.0
11-methyl 1-i 0.092 + 0.003 0.017 + 0.0001 0.5 3.3 +0.2
12-methyl 1-j 0.14 0.01 0.016 + 0.0007 0.3 2.0 0.4
10-methoxy 1-r 0.37 +0.03 0.035 + 0.001 0.3 4.3 1.5
11-methoxy 1-s 0.43 +0.05 0.037 + 0.003 0.2 2.3 0.7
10-fluoro 1-d 0.15 + 0.01 0.038 + 0.002 0.7 2.2 + 0.4
1I-fluoro 1-e 0.12 + 0.01 0.032 + 0.001 0.7 2.4 + 0.6
Table 2-1: Kinetic data and Hill coefficients of the indole substituted strictosidine 1
analogs deglycosylated by SGD.
d4 Strictosidine 1-1 had a catalytic efficiency (Vmax/Ko.5) 6-fold higher than that of
d4 vincoside 43-1 (Table 2-2). The crystal structure of SGD from R. serpentina shows
that the C-3 of strictosidine 1 is located near the surface of SGD . We speculate that the
orientation of the glucose 50 moiety, which is in the interior of SGD, remains unchanged
during turnover, while the binding pocket for more distal regions of the substrate, such as
the C-3 position, can accommodate vincoside 43.
Substrate 1.5 (mM) Vmax Hill(mM/min) coefficient
d4 vincoside 43-1 0.19 + 0.10 0.012 + 0.002 0.9 +0.3
Table 2-2: Kinetic data for d4 vincoside 43-1 deglycosylation by SGD.
III. Discussion
Substrate specificity studies:
I assayed numerous strictosidine 1 analogs with SGD (Figure 2-8, Figure 2-9),
and all were deglycosylated: this indicates that SGD is promiscuous in regard to substrate
turnover. The analogs tested included substitutions at the indole positions (C-9, C-10, C-
11, C-12), the a position (C-5), the C-3 position, the N-I position, the vinyl position (C-
20), the methyl ester, and the anomeric position (C-2 1).
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Figure 2-18: Strictosidine 1, with pink arrows indicating positions at which strictosidine 1
was modified and with the numbering system shown in blue95.
All C-9 through C-12 indole substituted strictosidine 1 analogs were accepted by
SGD. The recently reported crystal structure of SGD from R. serpentina indicates that
whereas the glucose 50 moiety of strictosidine 1 is buried within the enzyme active site,
,_-::::::: .... . .. ..... .
the indole portion of strictosidine 1 is located near the surface of the enzyme (Figure
2-19). Although the crystal structure of SGD is static, and does not show strictosidine 1
movement in the active site, the crystallographic data were consistent with the observed
turnover of all indole substituted strictosidine 1 analogs tested by SGD. The finding that
all indole substituted strictosidine 1 analogs are accepted by SGD agrees with the results
of a precursor directed biosynthesis study performed in which fluorinated, chlorinated,
brominated, methylated, and methoxylated indole substituted tryptamine 18 or
strictosidine 1 analogs were co-cultured with hairy root cultures36. In the study, alkaloids
downstream of SGD were observed for all analogs, indicating that each analog is
deglycosylated by SGD in vivo34 ,36
Figure 2-19: Structure of SGD (green) with strictosidine 1 (pink) bound in the active
1 6
site
Steady state kinetic analysis of indole substituted strictosidine 1 analogs revealed
that the methylated strictosidine analogs 1-g through 1-j each had relative catalytic
efficiencies (Vmax/Km) between 0.2 and 0.6 (with the catalytic efficiency of strictosidine 1
normalized to 1), with 10-methyl 1-h and 11-methyl 1-i strictosidine analogs having
catalytic efficiencies of 0.6 and 0.5, respectively. The 10-methoxy 1-r and 1 1-methoxy 1-
s strictosidine analogs had catalytic efficiencies of 0.3 and 0.2, respectively, and 10-
fluoro 1-d and 1 1-fluoro 1-e strictosidine analogs each had catalytic efficiencies of 0.7.
These results indicate that for C-10 and C-Il substituted strictosidine 1 analogs, the size
of the substituent at the C- 10 and C-11 positions was directly correlated to the catalytic
efficiency: the largest substituent, the methoxy moiety, was accepted less efficiently than
the methyl moiety, which was accepted less efficiently than the smallest substituent, the
fluorine moiety.
SGD could also deglycosylate strictosidine 1 analogs containing substitutions at
the C-5, or a, position. The finding that strictosidine 1 analogs containing substitutions at
the C-5 position can be accepted by SGD also agrees with the results of a previous
precursor directed biosynthesis study. Bernhardt et al.85 report that C. roseus hairy root
cultures co-cultured with (5R)-hydroxymethyl strictosidine 1-u-1 produced (5R)-
hydroxymethyl isositsirikine 7-u-1, which shows that (5R)-hydroxymethyl strictosidine
1-u-1 is deglycosylated by SGD in vivo.
SGD can also deglycosylate a strictosidine analog 1-t in which the methyl ester is
replaced by a pentynyl ester. The finding that pentynyl-ester strictosidine 1-t can be
deglycosylated by SGD in vitro agrees with an in vivo precursor directed biosynthesis
study in which pentynyl-ester secologanin 54 co-cultured with hairy root cultures
produced pentynyl-ester serpentine, which indicates that pentynyl-ester strictosidine 1-t is
deglycosylated by SGD in vivo87. In the precursor directed biosynthesis study, however, a
significant accumulation of pentynyl-ester strictosidine 1-t was observed87 . Strictosidine
1 is not normally a major product in hairy root cultures, and thus an accumulation of
pentynyl-ester strictosidine 1-t indicates that pentynyl-ester strictosidine 1-t is not being
deglycosylated by SGD at the usual rate. I confirmed this finding when I attempted a
steady state kinetic analysis of SGD with pentynyl-ester strictosidine 1-t. I did not
observe any turnover of pentynyl-ester strictosidine 1-t with the conditions used for the
steady state kinetic analysis of strictosidine analogs 1-d, 1-e, 1-g, 1-h, 1-i, 1-j, 1-r, and 1-
s, in which the SGD concentration was approximately 0.6 nM. I observed
deglycosylation only when the SGD concentration was increased from approximately 0.6
nM to 50 M, an increase of more than ten-thousand fold. This slow deglycosylation is
most likely caused by steric clashes of the pentynyl group with the surrounding enzyme
residues.
Benzo strictosidine 1-a and thio strictosidine 1-b were also accepted by SGD,
indicating that SGD is able to turn over substrates containing alternate heterocycles.
Examination of the crystal structure of SGD from R. serpentina76 reveals that the indole
nitrogen of strictosidine 1 is located approximately 6.5 A from Leu-475, 4.3 A from Tyr-
481, and 7 A from Tyr-345 (Figure 2-20). The van der Waals radii of oxygen and sulfur
are 1.50 A and 1.80 A, respectively' 03 ; thus there is sufficient space in the active site both
to accommodate the heteroatom oxygen, which has a slightly smaller van der Waals
radius than nitrogen, and also to accommodate the heteroatom sulfur, which has a van der
Waals radius that is approximately 15% larger than that of nitrogen. The closest residue
to the indole nitrogen is Tyr-481, and the 4.3 A distance between the Tyr-481 hydroxyl
and the indole nitrogen of strictosidine is sufficient to accommodate replacement of the
indole nitrogen with the larger sulfur heteroatom. The electronic perturbations of the
alternate heterocycles do not appear to affect deglycosylation. The turnover of these
analogs 1-a and 1-b also suggests that there is no hydrogen bonding interaction between
the enzyme and the indole nitrogen that is critical for substrate turnover. The compounds
9-aza strictosidine 1-w and 12-aza strictosidine 1-x were also accepted by SGD. Nitrogen
has a smaller van der Waals radius than carbon, and thus steric effects should not prevent
turnover of 9-aza strictosidine 1-w and 12-aza strictosidine 1-x by SGD. Although
alternate electronic properties could potentially prevent turnover, this was not observed:
both 9-aza strictosidine 1-w and 12-aza strictosidine 1-x were deglycosylated by SGD.
Although rates were not quantified for these particular substrates, the turnover of these
substrates agrees with precursor directed biosynthesis studies showing that 9-aza
strictosidine 1-w, 12-aza strictosidine 1-x, and benzo strictosidine 1-a are all
deglycosylated by SGD; in the precursor directed biosynthesis study, 12-aza strictosidine
1-x and benzo strictosidine 1-a were incorporated to form 12-aza isositsirikine 7-x and
36,104benzo isositsirikine 7-a
N
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Figure 2-20: The crystal structure of R. serpentina SGD76, with the indole nitrogen of
strictosidine 1 (dark blue) and the residues Leu-475, Tyr-481, and Tyr-345 labeled.
Distances (A) between the indole nitrogen and the various residues are shown in purple.
Strictosidine synthase is absolutely stereoselective. The vincoside 43 diastereomer
is not formed enzymatically in any known TIA pathway. Although SGD from R.
serpentina is not reported to turn over the vincoside 43 diastereomer 74, SGD from C.
roseus does in fact turn over the "nonnatural" vincoside 43, as evidenced by consumption
of starting material and detection of the glucose 50 product. Inspection of the SGD
sequence from R. serpentina did not reveal any obvious differences in the strictosidine 1
binding site, so the structural basis for the difference in diastereoselectivity between the
two enzymes remains to be determined76
In contrast to the relaxed substrate specificity observed for strictosidine analogs 1-
a through 1-x, strictosidine isomers containing an a glucose linkage were not accepted by
SGD; the P anomer was found to be absolutely required for turnover by SGD. When
SGD was incubated with the mixture of des-vinyl strictosidine isomers 1-y, LCMS
analysis of the starting material showed a decrease in area of only two of the separable
six peaks, peaks 1 and 3 (Figure 2-16). Peak 3 co-elutes with naturally occurring
strictosidine 1, suggesting that the compound with natural C15/21 trans stereochemistry
is turned over. SGD does not appear to be able to deglycosylate any a anomers of
strictosidine 1.
SGD could deglycosylate various isomers in the deacetylipecoside mixture 45-1;
several deglycosylated products were observed by LCMS. Detailed characterization of
the starting material and deglycosylated products was difficult, since despite extensive
efforts, the isomers of the deacetylipecoside mixture could not be separated.
Nevertheless, it was clear that deacetylipecoside isomers 45-1 were consumed by SGD
and thus the deglycosylation of various deacetylipecoside isomers 45-1 by SGD is further
evidence that the indole moiety of strictosidine 1 is not an important recognition element
for turnover by SGD. The finding that deacetylipecoside isomers 45-1 can be
deglycosylated by SGD is encouraging, for perhaps downstream TIAs can be produced
containing this altered structure. Downstream TIAs produced from deacetylipecoside
isomers 45-1 could potentially have excellent solubility and hydrogen bonding-
properties.
Conclusions
Strictosidine 1, the central intermediate of TIA biosynthesis, is deglycosylated by
SGD to produce a reactive hemiacetal intermediate that can enter numerous biosynthetic
pathways. For a novel TIA to be produced from a strictosidine 1 analog, the strictosidine
1 analog must be deglycosylated by SGD. My studies show that SGD does not appear to
be a bottleneck in the production of novel TIAs. SGD deglycosylated all indole
strictosidine 1 analogs assayed, as well as C-5 substituted analogs, 1 0-fluoro-a-methyl
strictosidine 1-u, and a-dimethyl strictosidine 1-v. SGD can also deglycosylate
strictosidine 1 analogs such as benzo strictosidine la and thio strictosidine lb that
contain alternate heterocycles such as benzofuran and benzothiophene moieties,
respectively. Atoms can be removed from the strictosidine structure, as in des-vinyl
strictosidine 1-y-z, or can be added, as in pentynyl-ester strictosidine 1-t. SGD is also not
selective for the natural stereoisomer; the C-3 diastereomer of strictosidine, vincoside 43,
is accepted by SGD. The primary recognition element appeared to be the 3 glucose
linkage. This broad substrate specificity is promising for the development of novel TIAs
with improved or altered biological properties. A number of serpentine 5, ajmalicine 4,
isositsirikine 7, and akuammicine 63 analogs produced from the TIA pathway are
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currently undergoing screening for cytotoxic activity (Usera, Lee, O'Connor,
unpublished).
IV. Materials and Methods
A. Synthesis of strictosidine analogs
Secologanin 17 was purified by procedures developed by the O'Connor
laboratory10 5 . Briefly, Lonicera tatarica leaves (100g, stored at -80'C) were ground in
methanol and filtered through cheesecloth. The filtrate was then pre-absorbed onto silica
gel and dried under vacuum overnight. Column chromatography was then performed
using a gradient of methanol and dichloromethane. Secologanin 17 elutes at a ratio of
approximately 10% methanol to 90% dichloromethane, and was concentrated in vacuo.
Secologanin 17 was then further purified by reverse-phase chromatography using a
methanol and water gradient. Secologanin 17 elutes at approximately 30% methanol:
70% water. Purified secologanin 17 was then frozen at -80'C and lyophilized. For every
100 g of leaves, approximately 1 g of secologanin 17 was obtained. Reverse-phase
chromatography is necessary in the secologanin 17 purification to separate secologanin
17 from the compound sweroside 71 (Figure 2-21). Sweroside 71 elutes closely to
secologaninio6
, COH 0 OH
o HO OHO
0 OH
sweroside 71
Figure 2-21: Structure of sweroside 71106
All tryptamine 18 analogs used for the synthesis of strictosidine analogs in the
substrate specificity study were obtained from Sigma, with the exception of 4-methyl, 7-
methyl, 4-fluoro, 7-fluoro, 4-chloro, 7-chloro, 4-bromo, and 5-isopropyl tryptamines,
which were provided by Dr. Elizabeth McCoy 36, and d4-tryptamine, which was obtained
from CDN Isotopes.
Indole substituted strictosidine 1 analogs were synthesized by incubating
secologanin 17 and tryptamine 18 in an enzymatic reaction with strictosidine synthase for
approximately 3 hours at 30'C in pH 6, 0.15 M citrate phosphate buffer (Figure 2-22). As
previously described85'86, strictosidine synthase was expressed in E. coli BL21(DE3) cells
with a C-terminal hexa-histidine tag and purified with cobalt-nickel resin. The resulting
strictosidine 1 analogs were purified by preparatory HPLC. A 15-minute method with a
10 to 40% gradient of acetonitrile in 0.1% formic acid was used, with detection at 238
nm. The strictosidine 1 analogs typically eluted at approximately 30% acetonitrile.
Enzymatic synthesis of strictosidine 1:
N HN
H strictosidine N .NH
tryptamine 18 synthase H H O, O
H pH 6, 0.15 M - O OH
OHcitrate phosphate 0 OH
o ,HO OH buffer strictosidine 1
0 OH
secologanin 17
Figure 2-22: Strictosidine 1 is produced enzymatically with strictosidine synthase by
incubating secologanin 17 and tryptamine 18 in 0.15 M citrate phosphate buffer, pH 6.
A chemical, nonenzymatic reaction was used for those tryptamine 18 substrates
that are known not be accepted by strictosidine synthase or that are turned over
slowlys,86 (Figure 2-23). Substrates made via the chemical reaction include vincoside 43,
d4-vincoside 43-1, and 10-methyl 1-h, 11-methyl 1-i, 10-fluoro 1-d, 11-fluoro 1-e, 9-
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chloro 1-k, 10-chloro 1-1, 12-chloro 1-m, 9-bromo 1-n, 10-bromo 1-o, 10-hydroxy 1-p,
10-isopropyl 1-q, 10-methoxy 1-r, 11-methoxy 1-s, 10-fluoro-a-methyl 1-u, and a-
dimethyl 1-v strictosidine. In the chemical reaction, secologanin 17 and the tryptamine 18
analog were incubated in pH 2, 0.1 M maleic acid at 30'C overnight. Both strictosidine 1
and its C-3 diastereomer vincoside 43 (Figure 2-23) are produced in the chemical
reaction. Strictosidine 1 has S stereochemistry at the C-3 position, and vincoside 43 has R
stereochemistry at the C-3 position. The resulting strictosidine 1 analogs could be
purified and separated from the vincoside 43 analogs by preparatory HPLC. A 15-minute
method with a 10 to 40% gradient of acetonitrile in 0.1% formic acid was used, with
detection at 238 nm. The strictosidine 1 analogs typically eluted at approximately 30%
acetonitrile. The vincoside 43 analogs typically eluted at approximately 35% acetonitrile.
Chemical synthesis of strictosidine 1:
- |
N 3 NH
N H2N H H' "
HO
tryptamine 18 pH 2, 0.3 M OHOH
H O maleic acid O OH
"0' O strictosidine 1
HO . OH N 3 NH '
Oa OHH0 OH H H ."0 0 *"' OH
secologanin 17 0  OHO OH
vincoside 43
Figure 2-23: In the chemical reaction to form strictosidine 1, tryptamine 18 and
secologanin 17 are incubated in 0.3 M maleic acid, pH 2. Strictosidine 1 and its C-3
diastereomer vincoside 43 are formed from the chemical reaction. Strictosidine 1 has S
stereochemistry at the C-3 position, and vincoside 43 has R stereochemistry at the C-3
position. The C-3 position of strictosidine 1 and vincoside 43 are labeled in blue.
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The resulting strictosidine 1 analogs were purified by preparatory HPLC. A 15-
minute method with a 10 to 40% gradient of acetonitrile in 0.1% formic acid was used,
with detection at 238 nm. The strictosidine 1 analogs typically eluted at approximately
30% acetonitrile.
Pentynyl-ester strictosidine 1-t was synthesized enzymatically by incubating
pentynyl-ester secologanin 54 and tryptamine 18 with strictosidine synthase. Pentynyl-
ester secologanin 54 was synthesized according to previously published procedures 7'105.
Pentynyl-ester strictosidine 1-t was purified by preparatory HPLC using the same method
as for indole strictosidine 1 analog purification.
The compounds 9-aza strictosidine 1-w, 12-aza strictosidine 1-x, benzo
strictosidine 1-a, and thio strictosidine 1-b were all made in an enzymatic reaction with
strictosidine synthase. The compounds 9-aza strictosidine 1-w and 12-aza strictosidine 1-
x were synthesized by Dr. Hyang-Yeol Lee by incubation of strictosidine synthase,
secologanin 17, and 4-aza tryptamine or 7-aza tryptamine, respectively 104. Benzo
strictosidine 1-a was synthesized enzymatically with strictosidine synthase, secologanin
17, and 2-benzofuran-3-yl-ethylamine 61 (Figure 2-24). Thio strictosidine 1-b was
synthesized enzymatically with strictosidine synthase, secologanin 17, and 2-
benzo[b]thiophen-3-yl-ethylamine 62 (Figure 2-24). The compound 2-benzofuran-3-yl-
ethylamine 61 was synthesized by reducing benzofuran-3-acetonitrile with LiAlH 4 in
THF86. The compound 2-benzo[b]thiophen-3-yl-ethylamine 62 was synthesized by
reducing benzo(B)thiophene-3-acetonitrile with LiAlH 4 in THF86. Benzo strictosidine 1-a
and thio strictosidine 1-b were purified by preparatory HPLC using the same method as
described for indole strictosidine 1 analog purification.
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N LiAlH 4  NH2  strictosidine
THF synthase,
reflux I secologanin17
o 0
benzofuran-3- 2-benzofuran
acetonitrile -3-yl-ethylamine 61
N LiAlH 4  NH2  strictosidine
THF synthase,
reflux secologanin 17K z"S
benzo(B)thiophene 2-benzo[b]-
-3-acetonitrile thiophen-3-yl-
ethylamine 62
NH /OGIc
o _0
0
/ 0
benzo strictosidine 1-a
N NH 4' OGIc
thio strictosidine 1-b
Figure 2-24: Benzofuran-3-acetonitrile and benzo(B)thiophene-3-acetonitrile are reduced
with LiAlH 4 in THF to produce 2-benzofuran-3-yl-ethylamine 61 and 2-benzo[b]-
thiophen-3-yl-ethylamine 62, respectively, which are incubated with secologanin 17 and
strictosidine synthase to form benzo strictosidine 1-a and thio strictosidine 1-b,
respectively86
Deacetylipecosides 45-1 were produced in a chemical reaction by incubating
dopamine 44 and secologanin 17 in pH 2, 0.1 M maleic acid. The mixture of isomers was
purified by preparatory HPLC using the same method as for indole strictosidine 1 analog
purification. The different isomers of the mixture could not be separated, and the
resulting mixture was referred to as "deacetylipecosides 45-1".
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HO NH
HO HO H
dopamine 44 0.15 M OH
0
0 H citrate HO OH
O OH
.O, O ,, OH phosphate deacetylipecosides
OOH buffer, pH 6 | NH 45-1
0 OH OH H O O ,"OH
secologanin 17 -0 C'-- HO OH
OH OH
Figure 2-25: Dopamine 44 and secologanin 17 condense in a nonenzymatic reaction to
form a mixture of deacetylipecoside isomers, called "deacetylipecosides 45-1."
The mixture of des-vinylated strictosidine analogs 1-y and the des-vinyl
strictosidine analog produced with strictosidine synthase 1-z (Figure 2-9) were both
synthesized and characterized by Dr. Peter Bernhardt97.
All strictosidine 1 analogs purified were characterized by high-resolution mass
spectrometry. Most were also previously characterized by 'H NMR, as previously
reported3 6' 85' 87' 104 and described below. Deglycosylated strictosidine 49 analogs were
characterized by high-resolution mass spectrometry; characterization by 1H NMR was
impeded because deglycosylated strictosidine 49 exists as a mixture of isomers that
interconvert rapidly and are difficult to separate.
B. LCMS analysis
Ultra-performance LC analysis was performed on an Acquity Ultra Performance
BEH C18 column with a 1.7 pm particle size, a 2.1 x 100 mm dimension, and a flow rate
of 0.5 mL min' in tandem with a Micromass LCT Premier TOF Mass Spectrometer with
an ESI Source (Waters Corporation). The capillary and sample cone voltages were
3000V and 30V, respectively. The desolvation and source temperatures were 300'C and
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100 0C, respectively. The cone and desolvation gas-flow rates were 60 1 hr-' and 8000 1
hr-1. Analysis was performed with MassLynx 4.1.
C. NMR characterization
Proton nuclear magnetic resonance (IH NMR) spectra were recorded on a Varian
300 MHz spectrometer. Chemical shifts (6) were referenced to residual protium in the
NMR solvent. 'H NMR data has been previously reported for strictosidine analogs 1-a
through 1-v36, 1-w and 1-x 4 , and 1-y and 1-z97.
D. High-resolution mass spectrometry data
High-resolution mass spectrometry data were obtained using either the O'Connor
lab LCMS or the MIT DCIF mass spectrometry equipment. Samples were diluted in
methanol and then ionized by ESI using a Micromass LCT Premier TOF Mass
Spectrometer. The LC was performed on an Acquity Ultra Performance BEH C18
column. MassLynx 4.1 was used for analysis, and accurate mass measurements were
obtained in W-mode, with reserpine as a reference. With the MIT DCIF mass
spectrometry equipment, the samples were diluted in methanol and then ionized by
ESI/FT-MS in the positive ion mode.
Secologanin analogs
pentynyl-ester secologanin 54: [M+H]* expected 441.1761, observed 441.1787
Strictosidine analogs
strictosidine 1: [M+H]* expected 531.2343, observed 531.2327
d4 strictosidine 1-1: [M+H]* expected 535.2588, observed 535.2569
105
benzo strictosidine 1-a: [M+H]* expected 532.2177, observed 532.2186
thio strictosidine 1-b: [M+H]* expected 548.1949, observed 548.1943
9-fluoro strictosidine 1-c: [M+H]* expected 549.2248, observed 549.2259
10-fluoro strictosidine 1-d: [M+H]+ expected 549.2248, observed 549.2220
11-fluoro strictosidine 1-e: [M+H]* expected 549.2248, observed 549.2240
12-fluoro strictosidine 1-f: [M+H]* expected 549.2248, observed 549.2232
9-methyl strictosidine 1-g: [M+H]* expected 545.2499, observed 545.2482
10-methyl strictosidine 1-h: [M+H]* expected 545.2499, observed 545.2474
1 1-methyl strictosidine 1-i: [M+H]* expected 545.2499, observed 545.2482
12-methyl strictosidine 1-j: [M+H]* expected 545.2499, observed 545.2498
9-chloro strictosidine 1-k: [M+H]* expected 565.1947, 565.1986
10-chloro strictosidine 1-1: [M+H]* expected 565.1947, observed 565.1918
12-chloro strictosidine 1-m: [M+H]* expected 565.1947, observed 565.1953
9-bromo strictosidine 1-n: [M+H]* expected 609.1442, 609.1458
10-bromo strictosidine 1-o: [M+H]* expected 609.1442, observed 609.1450
10-hydroxy strictosidine 1-p: [M+H]* expected 367.1652, observed 367.1648
10-isopropyl strictosidine 1-q: [M+H]+ expected 393.2173, observed 393.2181
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10-methoxy strictosidine 1-r: [M+H]* expected 561.2448, observed 561.2452
11-methoxy strictosidine 1-s: [M+H]* expected 561.2448, observed 561.2430
pentynyl-ester strictosidine 1-t: [M+H]* expected 583.2656, observed 583.2687
10-fluoro-a-methyl strictosidine 1-u: expected 563.2399, observed 563.2412
a-dimethyl strictosidine 1-v: expected 559.2650, observed 559.2637
enzymatically formed des-vinyl strictosidine 1-z: [M+H]* expected 505.2181, observed
505.2180
vincoside 43: [M+H]* expected 531.2343, observed 531.2356
deacetylipecosides 45-1: [M+H]* expected 524.2126, 524.2113
Deglycosylated strictosidine analogs
deglycosylated strictosidine 49: [M+H]f expected 351.1709, observed 351.1711
deglycosylated d4 strictosidine 49-1: [M+H]* expected 355.1954, observed 355.1939
deglycosylated benzo strictosidine 49-a: [M+H]* expected 352.1543, observed 352.1546
deglycosylated thio strictosidine 49-b: [M+H]* expected 368.1315, observed 368.1324
deglycosylated 9-fluoro strictosidine 49-c: [M+H]* expected 369.1614, observed
369.1612
deglycosylated 10-fluoro strictosidine 49-d: [M+H]* expected 369.1614,
369.1623
observed
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deglycosylated 11-fluoro strictosidine 49-e: [M+H]* expected 369.1614, observed
369.1623
deglycosylated 12-fluoro strictosidine 49-f: [M+H]* expected 369.1614, observed
369.1603
deglycosylated 9-methyl strictosidine 49-g: [M+H]* expected 365.1865, observed
365.1887
deglycosylated 10-methyl strictosidine 49-h: M+H]* expected 365.1865, observed
365.1887
deglycosylated 11-methyl strictosidine 49-i: [M+H]* expected 365.1865, observed
365.1863
deglycosylated 12-methyl strictosidine 49-j: [M+H]* expected 365.1865, observed
365.1885
deglycosylated 9-chloro strictosidine 49-k: [M+H]* expected 385.1313, observed
385.1346
deglycosylated 10-chloro strictosidine 49-1: [M+H]* expected 385.1313, observed
385.1300
deglycosylated 12-chloro strictosidine 49-m: [M+H]* expected 385.1313, observed
385.1325
deglycosylated 9-bromo strictosidine 49-n: [M+H]* expected 429.0808, observed
429.0795
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deglycosylated 10-bromo strictosidine 49-o: [M+H]* expected 429.0808, observed
429.0808
deglycosylated 10-hydroxy strictosidine 4 9 -p: [M+H]* expected 367.1652, observed
367.1648
deglycosylated 10-isopropyl strictosidine 49-q: [M+H]* expected 573.2807, observed
573.2822
deglycosylated 10-methoxy strictosidine 49-r: [M+H]* expected 381.1814, observed
381.1823
deglycosylated 11-methoxy strictosidine 49-s: [M+H]* expected 381.1814, observed
381.1802
deglycosylated pentynyl-ester strictosidine 49-t: [M+H]+ expected 403.2022, observed
403.2047
deglycosylated 10-fluoro-a-methyl strictosidine 49-u: expected 383.1765, observed
383.1750
deglycosylated a-dimethyl strictosidine 49-v: expected 379.2016, observed 379.2016
deglycosylated deacetylipecosides 49-45-1: [M+H]* expected 344.1492, observed
344.1496.
deglycosylated vincoside: [M+H]* expected 351.1709, observed 351.1722.
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E. Assay conditions
SGD was expressed in E. coli as an N-terminal maltose-binding protein (MBP) or
as a C-terminal hexa-His-tag fusion using a codon-optimized synthetic gene. The MBP
fusion was used for the determination of all kinetic constants. In assays to detect SGD
activity, strictosidine analogs were incubated at 30'C in pH 6, 0.15 M citrate phosphate
buffer for 5 to 10 minutes. Three methods of detection were used: LCMS, HPLC, and a
glucose 50 detection kit.
In the LCMS assay, aliquots from the enzymatic reaction were quenched with
methanol, centrifuged (13,000g, 1 min) to remove particulates, and then analyzed by
LCMS. The starting material and products were separated using a gradient of 10-40%
acetonitrile in water with 0.1% formic acid over a period of 5 minutes.
In the HPLC assay, cathenamine 49 formation and strictosidine 1 disappearance
were both observed. Aliquots from the assay were quenched with methanol, centrifuged
(1 3,000g, 1 min) to remove particulates, and then analyzed by HPLC. The starting
material and products were separated using a gradient of 10-90% acetonitrile in water
with 0.1% trifluoroacetic acid over a period of 15 minutes, with detection at 238 nm.
A glucose 50 detection assay was used as further verification that vincoside 43 is
deglycosylated by SGD. The glucose detection assay monitored the formation of glucose
50, one of the products of strictosidine deglycosylation by SGD. In the glucose detection
assay, the Amplex@ Red Glucose/Glucose Oxidase Assay Kit from Invitrogen was used
(Figure 2-26). Glucose formation was monitored at 560 nm using a reaction solution
made from glucose oxidase, horseradish peroxidase, and Amplex@ Red according to the
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manufacturer's instructions (Figure 2-26). Upon deglycosylation, glucose was released.
A coupled assay reaction with glucose oxidase and horseradish peroxidase converted
Amplex@ Red to a fluorescent compound, resorufin4 7.
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Figure 2-26: Representative UV-visible time courses at 560 nm of the glucose 50
detection assay. A: Vincoside 43 incubated with SGD and all components of the
Amplex@ Red assay. B: Vincoside 43 and all components of the enzyme assay without
SGD. C: Vincoside 43 and SGD without components of the Amplex@ Red assay
(Amplex@ Red, glucose oxidase, and horseradish peroxidase).
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F. Steady state kinetic analysis conditions
Steady state kinetic analysis conditions for indole substituted strictosidine
analogs 1, 1-d, 1-e, 1-g, 1-h, 1-i, 1-, 1-r, and 1-s
Quantitative steady state kinetic analysis assays for SGD with indole substituted
strictosidine analogs 1, 1-d, 1-e, 1-g, 1-h, 1-i, 1-j, 1-r, and 1-s were performed at pH 6,
the optimal pH of the enzyme 73,74, in 0.15 M citrate phosphate buffer. Assays were
conducted at 37'C in the presence of 0.61 nM SGD. Nine or more substrate
concentrations were used for each analog, and six time points were measured for each
substrate concentration. An HPLC assay was used to monitor strictosidine 1 consumption
at 238 nm with naphthalene acetic acid as an internal standard. The concentration of all
strictosidine 1 analogs was determined with a standard curve. A logistic curve using
OriginPro 7 (OriginLab, Northampton, MA) was used to fit the data, and R2 values
ranged from 0.979 to 0.999. A sigmoidal curve was observed for SGD expressed both as
an N-terminal maltose-binding protein fusion and as a C-terminal His-tag fusion,
indicating that a specific affinity tag does not significantly alter the kinetic parameters.
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Figure 2-27: Data fit for steady state kinetic analysis of SGD with indole substituted
strictosidine analogs 1, 1-d, 1-e, 1-g, 1-h, 1-i, 1-j, 1-r, and 1-s. The unit for the x-axis is
mM strictosidine analog, and the unit for the y-axis is mM strictosidine analog
deglycosylated per minute.
Steady state kinetic analysis conditions for d4 vincoside 43-1
Steady state kinetic analysis of d4 vincoside 43-1 was performed in 0.15 M citrate
phosphate buffer, pH 6, at 30*C in a 0.2 mL reaction volume with SGD concentrations
appropriate for measuring the initial rate of the reaction (0.005-0.2 gM). Aliquots (10 pL)
were quenched in 1 mL methanol, containing yohimbine 6 (500 nM) as an internal
9-methyl strictosidine 1-g
i
Il-methyl strictosidine 1-i
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standard, at appropriate time points. The samples were centrifuged (13,000g, 1 min) to
remove particulates and then analyzed by LCMS. The starting material and products were
separated using a 5-minute method with a gradient of 10-40% acetonitrile in 0.1% formic
acid. The disappearance of d4 vincoside 43-1 was monitored by peak integration and
normalized to the internal standard. Seven substrate concentrations were tested, and the
amount of d4 vincoside 43-1 remaining was correlated to peak area by standard curves.
Each concentration was assayed at least three times. The data were fitted (Figure 2-28)
with a logistic curve using OriginPro 7 (OriginLab, Northampton, MA). The unit for the
x-axis is mM d4 vincoside 43-1, and the unit for the y-axis is mM d4 vincoside 43-1
deglycosylated per minute.
tetradeuterated
vimcoside 43-1
mM
Figure 2-28: Data fit for steady state kinetic analysis of SGD with d4 vincoside 43-1. The
unit for the x-axis is mM d4 vincoside 43-1, and the unit for the y-axis is mM d4 vincoside
43-1 deglycosylated per minute.
Deglycosylation conditions for des-vinyl strictosidine isomers 1-y
Deglycosylation of the des-vinyl strictosidine isomers 1-y (0.24 mM final
concentration) was carried out in 0.15 M citrate phosphate buffer, pH 6, at 30*C in the
presence of SGD (20 gM), almond p-glucosidase (5 U), or B. stearothermophilus a-
...................
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glucosidase (15 U) in a 0.145 mL reaction volume. Aliquots (5 jIL) were quenched at
appropriate time points and treated as described above. Peaks corresponding to starting
material were integrated and normalized to the yohimbine 6 internal standard present in
the methanol quench solution.
115
V. Acknowledgments
I had helpful discussions with Dr. Elizabeth McCoy, Dr. Peter Bernhardt, Dr. Shi
Chen, Dr. Aimee Usera, and William Hillmann. Weslee Glenn provided assistance with
PyMol. Dr. Elizabeth McCoy showed me how to express and purify SGD and also
provided 4-methyl, 7-methyl, 4-fluoro, 7-fluoro, 4-chloro, 7-chloro, 4-bromo, and 5-
isopropyl tryptamine 18 analogs. Dr. Elizabeth McCoy and Dr. Carmen Galan performed
the precursor directed biosynthesis study in which pentynyl-ester strictosidine 1-t was fed
to hairy roots. Dr. Peter Bernhardt synthesized the des-vinyl strictosidine isomers 1-y and
1-z and assisted with 1H NMR analysis. An undergraduate student Jia Xin (Joann) Wu
assisted in the synthesis of various strictosidine 1 analogs. Dr. Hyang-Yeol Lee
synthesized 4-aza tryptamine and 7-aza tryptamine, which were used to make 9-aza
strictosidine 1-w and 12-aza strictosidine 1-x, respectively. Dr. L. Li of the MIT
Department of Chemistry Instrumentation Facility performed high-resolution mass
analysis.
116
VI. References
(1) O'Connor, S. E.; Maresh, J. J. Chemistry and biology of monoterpene
indole alkaloid biosynthesis. Natural Products Reports 2006, 23, 532-47.
(2) Geerlings, A.; Ibanez, M. M.; Memelink, J.; van Der Heijden, R.;
Verpoorte, R. Molecular cloning and analysis of strictosidine beta-D-glucosidase, an
enzyme in terpenoid indole alkaloid biosynthesis in Catharanthus roseus. The Journal of
Biological Chemistry 2000, 275, 3051-56.
(3) Gerasimenko, I.; Sheludko, Y.; Ma, X.; Stockigt, J. Heterologous
expression of a Rauvolfia cDNA encoding strictosidine glucosidase, a biosynthetic key to
over 2000 monoterpenoid indole alkaloids. European Journal of Biochemistry 2002, 269,
2204-13.
(4) Warzecha, H.; Gerasimenko, I.; Kutchan, T.M.; Stoeckigt, J. Molecular
cloning and functional bacterial expression of a plant glucosidase specifically involved in
alkaloid biosynthesis. Phytochemistry 2000, 657-66.
(5) Barleben, L.; Panjikar, S.; Ruppert, M.; Koepke, J.; Stockigt, J. Molecular
architecture of strictosidine glucosidase: the gateway to the biosynthesis of the
monoterpenoid indole alkaloid family. The Plant Cell 2007, 19, 2886-97.
(6) van der Heijden, R.; Jacobs, D. I.; Snoeijer, W.; Hallard, D.; Verpoorte, R.
The Catharanthus alkaloids: pharmacognosy and biotechnology. Current Medicinal
Chemistry 2004, 11, 607-28.
(7) Kjor, A.; Thomsen, H. Isothiocyanate-producing glucosides in species of
Capparidaceae. Phytochemistry 1963, 2, 29-32.
(8) Jonczyk, R.; Schmidt, H.; Osterrieder, A.; Fiesselmann, A.; Schullehner,
K.; Haslbeck, M.; Sicker, D.; Hofmann, D.; Yalpani, N.; Simmons, C.; Frey, M.; Gierl,
A. Elucidation of the final reactions of DIMBOA-glucoside biosynthesis in maize:
characterization of Bx6 and Bx7. Plant Physiology 2008, 146, 1053-63.
(9) Zagrobelny, M.; Bak, S.; Moller, B.L. Cyanogenesis in plants and
arthropods. Phytochemistry 2008, 69, 1457-68.
(10) Nomura, T.; Quesada, A. L.; Kutchan, T. M. The new beta-D-glucosidase
in terpenoid-isoquinoline alkaloid biosynthesis in Psychotria ipecacuanha. The Journal of
Biological Chemistry 2008, 283, 34650-59.
(11) Tsuji, Y.; Chen, F.; Yasuda, S.; Fukushima, K. Unexpected behavior of
coniferin in lignin biosynthesis of Ginkgo biloba L. Planta 2005, 222, 58-69.
(12) McCoy, E.; Galan, M.C.; O'Connor, S.E. Substrate specificity of
strictosidine synthase. Bioorganic and Medicinal Chemistry Letters 2006, 16, 2475-78.
(13) McCoy, E. Substrate analogs to investigate alkaloid biosynthesis in C.
roseus. Ph.D. dissertation, Massachusetts Institute of Technology, 2009.
(14) Galan, M.C., McCoy, E.; O'Connor, S.E. Chemoselective derivatization of
alkaloids in periwinkle. Chemical Communications 2007, 3249-51.
(15) McCoy, E., O'Connor, S.E. Directed biosynthesis of alkaloid analogs in
the medicinal plant Catharanthus roseus. Journal of the American Chemical Society 2006,
128, 14276-77.
(16) Szabo, L.F. Rigorous biogenetic network for a group of indole alkaloids
derived from strictosidine. Molecules 2008, 13, 1875-96.
117
(17) Helmuth, R.; Manske, F.; Holmes, H.L.; Ridrigo, R.G.A. The alkaloids:
chemistry andphysiology; Academic Press: New York, New York, 1981; Vol. 5.
(18) Ma, X.; Panjikar, S.; Koepke, J.; Loris, E.; Stockigt, J. The structure of
Rauvolfia serpentina strictosidine synthase is a novel six-bladed beta-propeller fold in
plant proteins. The Plant Cell 2006, 18, 907-20.
(19) Loris, E. A.; Panjikar, S.; Ruppert, M.; Barleben, L.; Unger, M.; Schubel,
H.; Stockigt, J. Structure-based engineering of strictosidine synthase: auxiliary for
alkaloid libraries. Chemistry and Biology 2007, 14, 979-85.
(20) Muller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking
beyond intuition. Science 2007, 317, 1881-86.
(21) Albaneze-Walker, J.; Rossen, K.; Reamer, R.A.; Volante, R.P.; Reider,
P.J. Synthesis of benzofuroquinolizine for alpha-2 adrenoceptor antagonist MK-912: an
O-analogue of the Pictet-Spengler reaction. Tetrahedron Letters 1999 40, 4917-20.
(22) Kawakubo, H.; Okazaki, K.; Nagatani, T.; Takao, K.; Hasimoto, S.;
Sugihara, T. Potent anticonflict activity and lessening of memory impairment with a
series of novel [1]benzothieno[2,3-C]pyridines and 1,2,3,4-tetrahydro[1]benzothieno[2,3-
C]pyridines. Journal of Medicinal Chemistry 1990 33, 3110-16.
(23) Perry, N.B.; Ettouati, L.; Litaudon, M.; Blunt, J.W.; Munro, M.H.H.
Alkaloids from the antarctic sponge kirkpatrickia-varialosa. 1. Variolin-b, a new
antitumor and antiviral compound. Tetrahedron 1994, 50, 3987-92.
(24) Schumacher, R.W.; Davidson, B.S. Didemnolines a-d, new N9-substituted
beta-carbolines from the marine ascidian Didemnum sp. Tetrahedron 1995, 51, 10125-
30.
(25) Trimurtulu, G.; Faulker, D.J.; Perry, N.B.; Ettouati, L.; Litaudon, M.;
Blunt, J.W.; Munro, M.H.G.; Jameson, G.B. Alkaloids from the antarctic sponge
Kirkpatrickia-varialosa. 2. variolin-a and N(3')-methyl tetrahydrovariolin-b. Tetrahedron
1994, 50, 3993-4000.
(26) Schafer, J.I.M.; Liu, H.; Tonetti, D.A.; Jordan, V.C. The interaction of
raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the
human estrogen reporter. Cancer Research 1999, 59, 4308-13.
(27) Lu, P.; Schrag, M.L.; Slaughter, D.E.; Raab, C.E.; Shou, M.; Rodrigues,
A.D. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by
zileuton, a 5-lipooxygenase inhibitor. Drug Metabolism and Disposition 2003, 31, 1352-
60.
(28) Croxtall, J.D.; Plosker, G.L. Sertaconazole: a review of its use in the
management of superficial mycoses in dermatology and gynaecology. Drugs 2009, 69,
339-59.
(29) Merour, J.Y.; Joseph, B. Synthesis and reactivity of 7-azaindoles (1H-
pyrrolo[2,3-b]pyridine). Current Organic Chemistry 2001, 5, 471-506.
(30) De-Eknamkul, W.; Suttipanta, N.; Kutchan, T.M. Purification and
characterization of deacetylipecoside synthase from Alangium lamarckii Thw.
Phytochemistry 2000, 55, 177-81.
(31) Samanani, N.; Facchini, P.J. Purification and characterization of
norcoclaurine synthase, the first committed enzyme in benzylisoquinoline alkaloid
biosynthesis in plants. The Journal of Biological Chemistry 2002, 277, 33878-83.
118
(32) De Camp, W.H. The FDA perspective on the development of
stereoisomers. Chirality 1989, 1, 2-6.
(33) Bernhardt, P.; Yerkes, N.; O'Connor, S. E. Bypassing stereoselectivity in
the early steps of alkaloid biosynthesis. Organic and Biomolecular Chemistry 2009, 7,
4166-68.
(34) Zhengwu, S.; Eisenreich, W.; Kutchan, T.M. Bacterial biotransformation
of 3-alpha-S-strictosidine to the monoterpene indole alkaloid vallesiachotamine.
Phytochemistry 1998, 48, 293-96.
(35) Takii, Y.; Takahashi, K.; Yamamoto, K.; Sogabe, Y.; Suzuki, Y. Bacillus
stearothermophilus ATCC12016 alpha-glucosidase specific for alpha-1,4 bonds of
maltosaccharides and alpha-glucans shows high amino acid sequence similarities to seven
alpha-D-glucohydrolases with different substrate specificity. Applied Microbiology and
Biotechnology 1996, 44, 629-34.
(36) He, S.; Withers, S.G. Assignment of sweet almond beta-glucosidase as a
family 1 glycosidase and identification of its active site nucleophile. The Journal of
Biological Chemistry 1997, 272, 24864-67.
(37) Golden, E.B.; Byers, L.D. Methyl glucoside hydrolysis catalyzed by beta-
glucosidase. Biochimica et Biophysica Acta 2009, 11, 1643-47.
(38) Niemeyer, H.; de la Luz Cirdenas, M.; Rabajille, E.; Ureta, T.; Clark-
Turri, L.; Pefiaranda J. Sigmoidal kinetics of glucokinase. Enzyme 1975, 20, 321-23.
(39) Bernhardt, P.; McCoy, E.; O'Connor, S. E. Rapid identification of enzyme
variants for reengineered alkaloid biosynthesis in periwinkle. Chemistry and Biology
2007, 14, 888-97.
(40) Anslyn, E.V.; Dougherty, D.A. Modern Physical Organic Chemistry;
University Science Books: Sausalito, California, 2006.
(41) Lee, H. Y.; Yerkes, N.; O'Connor, S. E. Aza-tryptamine substrates in
monoterpene indole alkaloid biosynthesis. Chemistry and Biology 2009, 16, 1225-29.
(42) Galan, M. C.; O'Connor, S.E. Semi-synthesis of secologanin analogues.
Tetrahedron Letters 2006, 47, 1563-65.
(43) Hamilton, R.G.; McLean, S. The conversion of sweroside to secologanin.
Canadian Journal of Chemistry 1981, 59, 215-16.
(44) Zhou, M.; Diwu, Z.; Panchuk-Voloshina, N.; Haugland, R. A stable
nonfluorescent derivative of resorufin for the fluorometric determination of trace
hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase
and other oxidases. Analytical Biochemistry 1997, 253, 162-68.
Chapter 3: Partial purification and substrate specificity of ajmalicine
synthase and isositsirikine synthase
I. Introduction
A. Previous reports
B. Plant enzyme purification techniques
II. Results
A. Assay development for detection of ajmalicine synthase and
isositsirikine synthase activity
B. Partial purification protocol for ajmalicine synthase and isositsirikine
synthase
C. Additional purification methods
i. Dye-ligand chromatography
ii. Ammonium sulfate precipitation
iii. Protein pulldown experiment with strictosidine-p-
glucosidase
D. Novel ajmalicine and isositsirikine analogs
i. Novel indole substituted, heterocyclic, and ester analogs
ii. Novel des-vinyl analogs
iii. Steady state kinetic analysis studies
Discussion
Materials and Methods
A. C. roseus hairy root cultures
B. C. roseus cell suspension cultures
III.
IV.
120
C. Preparation of strictosidine analogs
D. High-resolution mass spectrometry data
E. NMR characterization
F. Partial purification procedure
G. LCMS data
H. Steady state kinetic analysis conditions
I. Radioactive enzyme assay
J. Chemical reduction of deglycosylated strictosidine with NaCNBH 3
V. Acknowledgments
VI. References
The results in this chapter have been reported in the following publications:
" Peter Bernhardt*, Nancy Yerkes*, Sarah E. O'Connor. Bypassing
stereoselectivity in the early steps of alkaloid biosynthesis. Organic and
Biomolecular Chemistry 7 (2009) 4166-68. (*co-first authors)
" Hyang-Yeol Lee, Nancy Yerkes, Sarah E. O'Connor. Aza-tryptamine substrates
in natural product biosynthesis. Chemistry and Biology 16 (2009) 1225-29.
The results in this chapter will also be reported in a manuscript currently in
preparation:
0 Aimee R. Usera*; Nancy Yerkes*; Elizabeth McCoy*; David K. Liscombe;
Nathan E. Nims; Anne C. Friedrich; Sarah E. O'Connor. Crosslinking strategies
121
to isolate a new C. roseus enzyme. Manuscript in preparation, 2010. (* co-first
authors)
I. Introduction
Upon deglycosylation by strictosidine-p-glucosidase (SGD), strictosidine 1 is
converted into a reactive hemiacetal that rearranges into numerous isomers. These
isomers are channeled into various TIA pathway branches, resulting in the formation of
hundreds of different TIAs. Numerous pathways, such as the biosynthetic pathway to
vinblastine 2, involve many enzymes catalyzing diverse reactions such as oxidations,
reductions, hydroxylations, and methylations. Other pathways, such as the biosynthetic
pathways to the heteroyohimbine class alkaloids ajmalicine 4 and isositsirikine 7, are
proposed to be significantly shorter, involving only one or two reduction reactions'.
The reductases producing ajmalicine 4 and isositsirikine 7 isomers from
deglycosylated strictosidine 49 have never been isolated or cloned (Figure 3-1). Because
strictosidine synthase and SGD have previously been cloned, identification of these
reductases would complete the biosynthetic pathway from secologanin 17 and tryptamine
18 to ajmalicine 4 and isositsirikine 7. The reductases producing ajmalicine 4 and
isositsirikine 7 will herein be referred to as "ajmalicine synthase" and "isositsirikine
synthase."
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Figure 3-1: Ajmalicine synthase is proposed to produce ajmalicine 4 from deglycosylated
strictosidine 49 and NADPH (blue arrows). Isositsirikine synthase is proposed to produce
isositsirikine 7 from deglycosylated strictosidine 49 and NADPH (red arrows). "Glc" is
an abbreviation for the glucose moiety of strictosidine 1, and "SGD" is an abbreviation
for strictosidine-p-glucosidase.
Ajmalicine 4 is reported to be a major product in C. roseus cultures; one report
indicates that ajmalicine 4 constituted 13.5% of the total alkaloid content of a C. roseus
hairy root culture 8. In the proposed mechanism of ajmalicine 4 formation 109, an imine is
formed after strictosidine 1 deglycosylation, which is reduced by the pro-R hydride of
NADPH (Figure 3-1). Ajmalicine synthase has been shown to be able to accept
deglycosylated strictosidine analogs 49 in vivo. In one precursor directed biosynthesis
study, numerous indole substituted tryptamine analogs - 5-fluoro tryptamine 18-d, 6-
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fluoro tryptamine 18-e, 7-methyl tryptamine 18-j, and 5-hydroxy tryptamine 18-p - each
formed the corresponding ajmalicine 4 analogs when co-cultured with C. roseus hairy
34
root culture
In contrast to ajmalicine 4, isositsirikine 7 is produced in only small amounts in C.
roseus cultures. For a C. roseus culture in which ajmalicine 4 constituted 13.5% of the
total alkaloid content, isositsirikine 7 constituted only 0.75% 108. However, isositsirikine 7
analogs have been observed as major products in C. roseus precursor directed
biosynthesis studies. For example, in one precursor directed biosynthesis study, it was
found that C. roseus cell suspension cultures co-cultured with 12-aza-strictosidine I-x
(Figure 3-2) produced 16R, 19E isositsirikine 7-x as the major product (Figure 3-2)85. In
additional precursor directed biosynthesis studies, C. roseus cell suspension cultures co-
cultured with (5R)-hydroxymethyl strictosidine 1-u-1 and benzo strictosidine 1-a
produced (5R)-hydroxymethyl isositsirikine 7-u-1 and benzo isositsirikine 7-a,
respectively, as the major products (Figure 3-2)114,36. When co-cultured with benzo
strictosidine 1-a, C. roseus hairy roots produced benzo isositsirikine 7-a as approximately
58% of the total amount of furan-derived alkaloids produced, whereas benzo ajmalicine
4-a and benzo serpentine 5-a, which is formed via a peroxidase-catalyzed oxidation of
ajmalicine 41, constituted 0% and 10%, respectively, of the total amount of furan-derived
alkaloids produced (Figure 3-3)36. As will be addressed in this chapter, the reason for the
predominance of isositsirikine 7 analogs derived from these substrates is the substrate
specificity of isositsirikine synthase.
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Figure 3-2: A major product isolated from C. roseus cell suspension cultures incubated
with deglycosylated 7-aza strictosidine 1-x was 12-aza isositsirikine 7-x0. A (5R)-
hydroxymethyl isositsirikine analog 7-u-i was the major product of a C. roseus hairy root
culture incubated with (5R)-hydroxymethyl strictosidine 1-u-i 85. Benzo isositsirikine 7-a
was the major product of a C. roseus hairy root culture incubated with benzo strictosidine
361-a
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Figure 3-3: Results of a precursor directed biosynthesis study in which benzo
strictosidine 1-a was co-cultured with C. roseus hairy root cultures. Benzo ajmalicine 4-
a, benzo serpentine 5-a, and benzo isositsirikine 7-a constituted 0%, 10%, and 58%,
respectively, of the furan-derived alkaloids produced36
A. Previous reports of reductase activity
The two known ajmalicine 4 isomers produced by C. roseus are
tetrahydroalstonine 73 and 19-epi-ajmalicine 75 (Figure 3-5). Ajmalicine 4 has C-19 S,
C-20 R stereochemistry, tetrahydroalstonine 73 has C-19 S, C-20 S stereochemistry, and
19-epi-ajmalicine 75 has C-19 R, C-20 R stereochemistry. Gerasimenko et al.74 have
reported the chemical formation of tetrahydroalstonine 73, the C-20 S diastereomer of
ajmalicine 4, and two isositsirikine 7 isomers by reacting deglycosylated strictosidine 49
with sodium cyanoborohydride (NaCNBH 3). In their study, Gerasimenko et al.74 formed
tetrahydroalstonine 73 by incubating 225 nmol deglycosylated strictosidine 49 with 450
nmol NaCNBH 3 (Figure 3-4). When the NaCNBH 3 concentration was increased to a two-
thousand-fold excess over strictosidine 1, two isositsirikine 7 isomers were observed
(Figure 3-4)74.
. .. ...... . ..... te . . ... _ _
... .... ........ ..................
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Figure 3-4: Gerasimenko et al.74 reported that tetrahydroalstonine 73, the C-20 S
diastereomer of ajmalicine 4, formed when deglycosylated strictosidine 49 was incubated
1:2 with NaCNBH3. Two isositsirikine 7 isomers formed when deglycosylated
strictosidine 49 was incubated with a two-thousand-fold excess of NaCNBH 374. The C-20
position of tetrahydroalstonine 73 is indicated in blue.
There has been only one report in the literature of a partial purification of a
reductase leading to tetrahydroalstonine 73. In 1985, Hemscheidt et al.1 0 reported a 33-
fold partial purification of an 81 kDa NADPH-dependent reductase that converted
cathenamine 49 into tetrahydroalstonine 73; Hemscheidt also reported a second reductase
activity from a C. roseus cell culture with a different alkaloid profile that converted
cathenamine 49 into ajmalicine 4 and 19-epi-ajmalicine 75. However, minimal data is
reported about this reductase activity" 0 . No further studies on this enzyme have been
reported.
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Figure 3-5: Structures of ajmalicine 4, tetrahydroalstonine 73, and 19-epi-ajmalicine 75.
The numbering system is shown for ajmalicine 411 1.
In Hemscheidt's partial purification procedure1 0 , a C. roseus cell line that
produced tetrahydroalstonine 73 and no other heteroyohimbine alkaloids such as
ajmalicine 4 and 19-epi-ajmalicine 75 was cultured for seven days, filtered, frozen with
liquid nitrogen, and stored at -18'C. The cells were then thawed in 0.1 M borate buffer,
pH 7.6, containing 20 mM p-mercaptoethanol, and then centrifuged 20 minutes at
27,000g. An ammonium sulfate precipitation was next performed, with the enzymatic
activity retained in the 40-70% fraction. The protein precipitate was resuspended in 50
mM potassium phosphate buffer, pH 7, and then applied to a gel filtration column
followed by an ion exchange column. Overall, a mere 33-fold purification was attained.
The authors reported that gel filtration chromatography suggested that the molecular
weight of the native enzyme was 81 + 2.4 kDa. It was found that only NADPH, and not
NADH, could serve as a reducing cofactor in the reaction. No inhibition was observed in
2+ 2+ 2
the presence of EDTA, Mg , Mn , or Co 2+, though irreversible inhibition was observed
in the presence of 10 mM Fe2+, Cu2, Hg2+, and Zn2+. The optimum pH and temperature
were found to be 6.6 and 30'C, respectively. A 5.7 mM cathenamine 49 in DMSO
solution was used in the assays. DMSO was used because of the low solubility of
110cathenamine 49 in water'
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Hemscheidt also reported a partial enzyme purification from a cell line that
produced ajmalicine 4 and 19-epi-ajmalicine 75 in addition to tetrahydroalstonine 73. In
this purification, when an ammonium sulfate precipitation fraction was applied to a
DEAE-cellulose column after gel filtration chromatography, two additional enzyme
activities were observed, one forming ajmalicine 4 and one forming 19-epi-ajmalicine 75.
Collectively, these data suggest that there are three different reductases that produce
10
ajmalicine 4 isomers"
There are no literature reports demonstrating in vitro reductase activity that results
in formation of an isositsirikine 7 isomer. Because more than one isositsirikine 7 isomers
has been reported (Figure 3-6)1 2, it is possible that there are multiple reductases that
produce isositsirikine 7 isomers. Alternatively, a single nonspecific reductase could
produce all diastereomers. In a precursor directed biosynthesis study performed by Dr.
Elizabeth McCoy using C. roseus hairy root cultures, formation of multiple isositsirikine
7 analogs was observed for various indole substituted strictosidine 1 analogs 6 .
Isositsirikine 7 may form directly from deglycosylated strictosidine 49 or 4,21-
dehydrogeissoschizine 64 via a double reduction. Alternatively, one reductase may form
geissoschizine 64-1113 (Figure 3-6), which then goes on to form isositsirikine 7. A total
synthesis of geissoschizine 64-1 has recently been completed in the O'Connor laboratory
(Usera, O'Connor, unpublished) and will be used to further explore these questions.
129
6, 5
9 21 18 N N N
10 0 g3N
11 13 2 1415 17 N N H' N12 H 1H H H
0 H OH 0 H OH 0 H OH 0 H OH
/ 0 / 0 / O / 0
16R, 19Z 16S, 19Z 16R, 19E 16S, 19E
isositsirikine isositsirikine isositsirikine isositsirikine
7-i 7-i 7 7-iii
N
XN H
H -
0 OH
/ 0
geissoschizine 64-1
Figure 3-6: Structures of geissoschizine 64-1113 and the naturally occurring isositsirikine
1127 isomers, with the numbering system shown on 16R, 19Z isositsirikine 7-i
B. Plant enzyme purification techniques
Lysis
Plant tissues require harsh methods such as blending with stainless steel blades to
break the cellulose cell wall. The solution used for lysis needs to be adequately buffered,
since acidic plant cell vacuoles break during lysis, lowering the pH of the protein extract.
Proteolysis is another concern when purifying enzymes from the native organism, and
plant cells are no exception. Proteases are released upon cell lysis, so a variety of
protease inhibitors are included throughout the purification procedure.
Phenylmethanesulfonyl fluoride 76 (PMSF) (Figure 3-7), which inhibits serine proteases,
and ethylenediaminetetraacetic acid 77 (EDTA) (Figure 3-7), which deactivates metal-
dependent proteases by scavenging metal ions, are two commonly used proteolysis
114'115inhibitors'
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If oxygen is present during lysis, phenolic compounds present in plant cells are
converted to polymeric pigments by phenol oxidases, which can bind to and damage
proteins in the extract. To prevent formation of these polymeric pigments, a reducing
agent such as p-mercaptoethanol 78 (Figure 3-7) is added to inhibit the phenol oxidases.
Additionally, polymers such as polyvinylpyrrolidone 79 (PVP) (Figure 3-7) are added to
the mixture to adsorb phenolic polymers"4. PVP forms insoluble complexes with
phenolics via hydrogen bonding 6 . Borate buffer is frequently used for lysis because
borate buffer forms complexes with compounds that have cis hydroxyl groups, such as
115,116phenolics
0
O OH OH
O NN
HO 0 OHH
- F HO-,_SH
phenylmethane- ethylenediamine- p-mercapto- polyvinyl-
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Figure 3-7: Structures of phenylmethanesulfonyl fluoride 76 (PMSF),
ethylenediaminetetraacetic acid 77 (EDTA), -mercaptoethanol 78, and
polyvinylpyrrolidone 79 (PVP).
Protein Precipitation
Precipitation is a commonly used partial purification method for proteins. Protein
precipitation enables a protein to be simultaneously concentrated and purified from
contaminant proteins typically directly after lysis. Difficulties with protein precipitation
include irreversible denaturation and failure to re-solubilize the precipitated proteins" 4.
One commonly used method of precipitation for protein purification is ammonium sulfate
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precipitation,11 5 which is called "salting out" or "high salt precipitation." Protein
solubility is affected by the ionic strength of the solution. At high salt concentrations, the
solubility of proteins generally decreases with increasing salt concentration by disrupting
the solvation of the protein residues. At different salt concentrations, certain proteins will
aggregate more than others because of the presence of more hydrophobic surface residues
such as phenylalanine, valine, and leucine. Thus, some proteins precipitate at low salt
concentrations, and others precipitate only at high salt concentrations. Additionally,
114,115larger proteins typically precipitate earlier than smaller proteins' . One advantage of
ammonium sulfate precipitation is low heat of solubilization, which helps prevent
denaturation of proteins."4'"5
Acetone precipitation is another commonly used protein precipitation method.
Acetone, an organic solvent with a small dielectric constant, also causes protein
molecules to aggregate. Acetone is miscible with water, and when acetone is added to an
enzyme extract, the dielectric constant of the acetone-extract mixture is lowered. This
lower dielectric constant lowers protein solubility and induces protein precipitation"4'"5
Solvents with large dielectric constants, on the other hand, such as water and DMSO,
help stabilize the interaction between solvent and protein molecules, which favors the
dissolution of the protein molecules114,s115. Acetone has a lower tendency to denature
proteins than other organic solvents such as methanol or ethanol do because lower
concentrations of acetone are necessary to cause comparable amounts of precipitation.
Acetone is also more volatile than methanol or ethanol, enabling acetone to be removed
easily from resolubilized precipitates1 1 7 . As in ammonium sulfate precipitation, in
acetone precipitation, larger proteins typically precipitate earlier than smaller proteins" 7 .
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Ion exchange chromatography
Enzyme mixtures are often subjected to column chromatography after a crude
purification step such as protein precipitation. Ion exchange chromatography utilizes an
electrostatic interaction between oppositely charged adsorbent and protein. There are two
basic types of exchangers, positive (anion) and negative (cation). In anion exchange
chromatography, the immobilized functional group is positively charged, and the binding
ions are negative. Q-anion ("Q" for quaternary amine) and DEAE-anion ("DEAE" for
diethylaminoethane) are two commonly used anion exchange resins (Figure 3-8). In
cation exchange chromatography, the immobilized functional group is negatively
charged, and the binding ions are positive. S-cation ("S" for sulfate) and CM-cation
("CM" for carboxymethyl) are two commonly used cation exchange resins (Figure 3-8).
Resins are classified as either weak or strong exchangers. Weak exchangers, which
include DEAE-anion and CM-cation resins, have groups that titrate in the neutral pH
range at which enzymes are likely to function (Figure 3-8). Strong exchangers, which
include Q-anion and S-cation resins, stay fully charged throughout the pH range used in
the chromatography (Figure 3-8)"4'5.
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(strong exchanger) (weak exchanger)
-Y
anion exchange chromatography
0-
S-cation exchanger CM-cation exchanger
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cation exchange chromatography
Figure 3-8: Examples of resins used in anion exchange chromatography and cation
exchange chromatography. Q-anion and DEAE-anion are commonly used anion
exchange resins. S-cation and CM-cation are commonly used cation exchange resins.
DEAE-anion and CM-cation are weak exchangers, and Q-anion and S-cation are strong
114,115
exchangers
Ion exchange chromatography achieves protein separation because the amount of
salt needed to release proteins bound to the resin varies based on the pI of each
protein 4'"5. Ion exchange chromatography is a resolution-based technique, and
therefore works most effectively when used with fast performance liquid chromatography
(FPLC). Most ion exchange chromatography for protein purification is performed at a
slightly alkaline pH (8 to 8.5) using anion exchangers such as DEAE 4, since most
proteins are stable at those pH ranges.
Size exclusion chromatography
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Size exclusion, or gel filtration, chromatography uses bead particles with pores
that can be penetrated only by small proteins, while larger proteins are excluded from the
beads. Large proteins therefore pass through the column most rapidly, typically emerging
in a fraction about 25-35% of the column volume. Medium-sized molecules typically
elute in a fraction about 35-90% of the column volume, while the smallest proteins,
which enter the beads and thus take much longer to pass through the column, typically
elute in a fraction about 90-100% of the column volume. The separation achieved by gel
filtration chromatography is due to differences in size between proteins, or, more
precisely, on the Stokes radius, which is the radius of an equivalent spherical
molecule11 4'11 5. The formula for the Stokes radius, r, of a particle is r =f / (6ngr), wheref
23is the frictional coefficient of the particle, and rj is the viscosity of the solution
Affinity chromatography
Affinity chromatography utilizes specific interactions between a protein of
interest and an immobilized ligand for purification. A wide variety of ligands have been
successfully immobilized on a solid support to be employed in protein purification
efforts. Both proteins, such as an antibody, and small molecules can be used as
immobilized ligands. Unlike ion exchange chromatography, in which selectivity is
achieved through resolution, affinity chromatography achieves selectivity at the
14,115
adsorption stage"
The goal in affinity chromatography is for the target protein to selectively bind
the immobilized ligand. After an incubation period with crude protein and resin, the
adsorbent is washed to remove the undesired proteins that, theoretically, should not bind
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to the resin. Ideally, the protein of interest is then selectively eluted via a change in buffer
designed to disrupt the specific ligand-protein interaction. However, affinity
chromatography does not always work as well as expected. For instance, the lack of a
tight binding interaction between the ligand and the protein of interest, as well as
nonspecific interactions between contaminant proteins and the immobilized ligand, can
prevent successful affinity chromatography" 4'" 5.
Dye-ligand chromatography is a widely used type of affinity chromatography for
NADPH-binding enzymes, which are the focus of this chapter. Dye-ligand
chromatography was developed after the discovery that many textile dyes strongly bind
proteins, particularly enzymes that bind nucleotides 4. Since this initial discovery, many
dyes have been designed to bind biological materials such as cellulose and proteins. In
some cases this interaction occurs at the ligand binding site; alternatively, the interaction
may be nonspecific, with the dye binding at various sites on the protein surface. A range
of immobilized dyes have been reported to bind between 5 and 60% of proteins in crude
cell extracts. It is difficult to predict which dye will interact most effectively with a given
NADPH-binding protein, so typically many dyes are screened in the development of a
protein purification protocol. The dye used most in protein purification is Cibacron Blue
(Figure 3-11)118, which interacts with enzymes containing ATP- or NAD-binding sites,
and has been found to bind competitively with ATP- and NAD-nucleotides'18. A similar
dye, Reactive Red, has also been used for the isolation of NADP-dependent
dehydrogenases. Other commonly used dyes include Reactive Green, Reactive Brown,
and Reactive Yellow (Figure 3-9 - Figure 3-13)118. All of these dyes are available
immobilized to agarose.
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118Figure 3-9: Structure of Reactive Red Agarosel
Reactive Green Agarose
Agarose
Figure 3-10: Structure of Reactive Green Agarose 1 8 .
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Figure 3-11: Structure of Cibacron Blue Agarosel 18.
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Figure 3-12: Structure of Reactive Brown Agarose .
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Figure 3-13: Structure of Reactive Yellow Agarose 1 8.
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11. Results
A. Assay development for detection of ajmalicine synthase and
isositsirikine synthase activity
To successfully characterize and purify an enzyme, a robust assay for enzymatic
activity must be developed. In the assay to detect ajmalicine synthase and isositsirikine
synthase reductase activity, I incubated strictosidine 1 or strictosidine 1 analogs with
SGD, NADPH, and a partially purified enzyme fraction (Figure 3-14). A 200 pL reaction
volume was used, with 0.25 mM strictosidine 1 or strictosidine 1 analog, 750 nM SGD
(typically), 5 mM NADPH, and 180 gL partially purified reductase fraction (typically at a
concentration of 1 to 3 total mg protein mL-I). The reaction was incubated at 30'C, 5 pL
aliquots were quenched with methanol, and product formation was subjected to analysis
by LCMS. A description of the synthesis and characterization of the strictosidine 1
analogs used is provided in the Materials and Methods section. Strictosidine 1 analogs
were often used instead of strictosidine 1 in assays to ensure that no trace amounts of
ajmalicine 4 and isositsirikine 7 present in the partially purified enzyme fraction would
interfere with detection of reductase activity. Control experiments revealed that NADPH
was absolutely necessary for reduction to occur; no reduction was observed when NADH
was used as a cofactor.
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Figure 3-14: In the assay to detect ajmalicine synthase and isositsirikine synthase activity,
strictosidine 1 (or strictosidine 1 analogs) was incubated with SGD, NADPH, and a
partially purified enzyme fraction.
Co-elution studies with authentic standards demonstrated that ajmalicine 4 and
16R, 19E isositsirikine 7 are enzymatically produced in these assays. When d4
strictosidine 1-1 was incubated with SGD, NADPH, and a partially purified enzyme
fraction, a product with m/z 357 (353 + 4) eluted with the same LCMS retention time as
ajmalicine 4 (Figure 3-15). When benzo strictosidine 1-a was incubated with SGD,
NADPH, and a partially purified enzyme fraction, a product with m/z 356 eluted with the
same LCMS retention time as 16R, 19E benzo isositsirikine 7-a (m/z 356) (Figure 3-16).
Benzo isositsirikine 7-a was used as an authentic standard instead of natural isositsirikine
7 because no authentic standard of natural isositsirikine 7 was available for co-elution:
the quantities at which natural isositsirikine 7 are produced in C. roseus culture are too
small. The 16R, 19E benzo isositsirikine 7-a standard had been obtained from a precursor
directed biosynthesis study in which benzo strictosidine 1-a, which produces
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comparatively more of the isositsirikine 7 product, was co-cultured with C. roseus hairy
root cultures36
ajmaicine 4 standard
m z 353
tetradeuterated ajmalic
produced in assay
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0 o
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I 0
ajmalicine 4
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0
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Figure 3-15: In an enzymatic assay of ajmalicine synthase, the d4 ajmalicine 4-1
enzymatically produced (bottom chromatogram, m/z 357) has the same retention time on
LCMS as an ajmalicine 4 standard (top chromatogram, m/z 353). An LCMS gradient of
10-60% acetonitrile in water with 0.1% formic acid over a period of 5 minutes was used.
The x-axis is time in minutes and the y-axis is intensity.
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Figure 3-16: In an enzymatic assay of isositsirikine synthase, the benzo isositsirikine 7-a
enzymatically produced (bottom chromatogram, m/z 356) has the same retention time on
LCMS as a 16R, 19E benzo isositsirikine 7-a standard (top chromatogram, m/z 356). An
LCMS gradient of 10-60% acetonitrile in water with 0.1% formic acid over a period of 5
minutes was used. The x-axis is time in minutes and the y-axis is intensity.
A radioactivity assay utilizing R 3H-NADPH also confirmed ajmalicine synthase
activity by monitoring 3H-ajmalicine formation. R NADPH had been previously reported
in enzymatic production of ajmalicine 4109. In my assay, I incubated deglycosylated
strictosidine 49 with R 3H-NADPH and a partially purified enzyme fraction containing
ajmalicine synthase activity. Aliquots from the reaction mixture were spotted and run on
thin liquid chromatography (TLC) plates. The silica in the area of the plate with the same
Rf value as an ajmalicine 4 standard was removed with a scalpel, and suspended in
scintillation fluid, and the radioactivity was measured with a scintillation counter. One
drawback of this assay, however, was that it required synthesis of the labeled NADPH
cofactor; thus I did not routinely use this assay. Further details are available in the
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Materials and Methods section. A spectrophotometric assay that measured the change of
NADPH-NADP+ at 340 nm was also tested. However, the LCMS assay proved to be both
faster and more sensitive.
B. Partial purification protocol for ajmalicine synthase and
isositsirikine synthase
All active fractions contained both ajmalicine synthase activity and isositsirikine
synthase activity, and the two enzyme activities were never separated during the
purification procedure. Ajmalicine synthase activity was always approximately tenfold
higher than isositsirikine synthase activity. The purification procedure is described below,
and further details are provided in the Materials and Methods section.
In the partial purification procedure, hairy root or cell suspension cultures were
subcultured for two weeks, stored at -80'C or used fresh, and then lysed by blending in
borate buffer. After a brief centrifugation, an acetone precipitation was performed on the
supernatant, with three precipitation fractions collected. Each protein precipitate pellet
was resuspended in 50 mM sodium phosphate buffer, pH 7.5, containing 10% glycerol.
The first precipitate (25% v/v acetone) was discarded (Figure 3-17) because it did not
contain ajmalicine synthase or isositsirikine synthase activity. The second (40% v/v
acetone) and third (57% v/v acetone) precipitates contained ajmalicine synthase and
isositsirikine synthase activity; the specific activities of ajmalicine synthase and
isositsirikine synthase in gM min- per mg protein mL-1 for the two precipitates are
shown below. The third acetone precipitate was subjected to analysis by ID and 2D SDS-
PAGE (Figure 3-17, Figure 3-18).
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Acetone Ajmalicine synthase activity Isositsirikine synthase activity
fraction (ptM min-' / ig protein mL-1) (pM min~1 / mg protein m- 1)
fraction two
(40% v/v 0.068 0.003
acetone)
fraction three
(57% v/v 0.094 0.044
acetone)
Table 3-1: The specific activities of ajmalicine synthase and isositsirikine synthase in 1iM
min' per mg protein mL for acetone precipitation fractions two and three.
1 2 3 4 5 6 78
Figure 3-17: A ID SDS-PAGE of acetone precipitation fractions one, two, and three of a
typical partial purification procedure. Lanes 1 and 8: Protein ladder (Bio-Rad Precision
Plus Protein Prestained Standard, Dual Color), with weights marked in kDa. Lanes 2 and
3: Acetone precipitation fraction one. Lanes 4 and 5: Acetone precipitation fraction two.
Lanes 6 and 7: Acetone precipitation fraction three.
.......................................................................................................................................... .  .. ..   .. .  .... ...   ..  ... 
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Figure 3-18: A 2D SDS-PAGE of fraction three of an acetone precipitation of C. roseus
lysate.
The third fraction from the acetone precipitation was then applied to a DEAE
column on an FPLC system. A gradient of 400-800 mM NaCl in 50 mM sodium
phosphate buffer, pH 7.5, containing 10% glycerol with a flow rate of 5 mL min was
used, and the absorbance at 280 nm was monitored (Figure 3-19). Fractions were often
combined from two or three DEAE chromatographic steps, concentrated, and then
assayed for activity (Table 3-2). Fractions B8-9 (Figure 3-19) of the DEAE column were
consistently found to have the highest ajmalicine synthase specific activity and
isositsirikine synthase specific activity (Figure 3-20).
.......  
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Figure 3-19: Chromatogram of the third fraction of an acetone precipitation subjected to
ion exchange (DEAE) chromatography.
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Table 3-2: Ajmalicine synthase specific activity and isositsirikine synthase specific
activity of each DEAE fraction, in RM min- per mg protein mL-1. The DEAE fraction
numbers are shown in Figure 3-19. For each fraction, the approximate concentration of
mM NaCi at which the enzymes in the fraction eluted and the total number of mL buffer
used by the FPLC at that point are given.
Ajmalicine Isositsirikine
synthase synthase
DEAE fraction activity (pM activity
min-1 / mg (ptM min~1 / mg
rotein mL-1) protein mL-1)
A11-12
(490-510 mM NaCl, 0.120 0.004
100-120 mL buffer)
B10-12
(510-530 mM NaCl, 0.273 0.017
120-140 mL buffer)
B8-9
(530-550 mM NaCl, 0.333 0.019
140-160 mL buffer)
B6-7
(550-570 mM NaCl, 0.200 0.011
160-180 mL buffer)
B4-5
(570-590 mM NaCl, 0.146 0.009
180-200 mL buffer)
B2-3
(590-610 mM NaCl, 0.048 0.004
200-220 mL buffer)
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Figure 3-20: A 2D SDS-PAGE of DEAE fractions B8-9 (Figure 3-19) of a typical
purification procedure.
Fractions B8-9 from the DEAE column were then applied to a size 200 gel
filtration column on an FPLC system. For the size 200 gel filtration column, a 50 mM
sodium phosphate buffer, pH 7.5, containing 10% glycerol with a flow rate of 1 mL min
was used, and the absorbance at 280 nm was monitored (Figure 3-21, Figure 3-22).
Fractions were collected, concentrated, and assayed for activity. Fractions C9-12 and D9-
12 (Figure 3-21) of the size 200 gel filtration column consistently showed the best
ajmalicine synthase specific activities and isositsirikine synthase specific activities,
though unfortunately a decrease in specific activity occurred compared to the previous
purification step, which exemplified the lability of this enzyme activity. Nevertheless,
fractions C9-12 were subjected to separation by 2D SDS-PAGE, stained with SYPRO
Ruby protein gel stain (Sigma), and observed with a UV transilluminator (254 nm, Bio-
Rad). The major protein spots from this 2D SDS-PAGE (Figure 3-22) were excised and
sent to the Donald Danforth Plant Science Center (St. Louis, Missouri) for sequencing by
mass spectrometry. The peptide sequences obtained from spots 1 through 8 of the 2D
SDS-PAGE shown in Figure 3-22 were subjected to a BLAST (Basic Local Alignment
Search Tool) search against the available C. roseus expressed sequence tag (EST)
.......................... ..........
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database. ESTs are short sub-sequences of transcribed cDNA sequences that are used in
gene discovery efforts to identify gene transcripts 1 9. The ESTs that had the highest
sequence identity to spots (proteins) 1 through 8 are listed in Table 3-4.
Of the 8 proteins listed in Table 3-4, protein 3 appears to be the most promising in
terms of potential ajmalicine synthase and isositsirikine synthase activity, because it
exhibits 61% sequence identity to a cinnamyl alcohol dehydrogenase. Cinnamyl alcohol
dehydrogenases, which are discussed further in Chapter 4, are NADPH-dependent
enzymes that catalyze the reduction of p-hydroxycinnamyl aldehyde and p-
hydroxycinnamyl aldehyde analogs into the corresponding p-hydroxycinnamyl
alcohols 2 0 . Although 61% sequence identity to a cinnamyl alcohol dehydrogenase
suggests that the enzyme is likely to be an NADPH-dependent dehydrogenase, the
sequence identity is not so high as to suggest that the enzyme is definitively a cinnamyl
alcohol dehydrogenase. Notably, there is precedence for cinnamyl alcohol dehydrogenase
homologs that act on TIAs; for example, as will be further discussed in Chapter 4,
perakine reductase reduces the aldehyde moiety of the TIA perakine. Notably, perakine
reductase also reduces the aldehyde moiety of cinnamaldehyde, even though perakine and
cinnamaldehyde have vastly different structures 121 . Even if protein 3 exhibits cinnamyl
aldehyde dehydrogenase activity, it could potentially also reduce an imine to an amine, as
is required for ajmalicine 4 or isositsirikine 7 formation. Only the 3' fragment of this
gene is available in the public database, which impedes functional characterization.
Future efforts will involve the cloning and expression of the full length protein 3.
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Figure 3-21: Chromatogram of the DEAE B8-9 fractions subjected to size 200 gel
filtration chromatography.
Table 3-3: Ajmalicine synthase specific activity and isositsirikine synthase specific
activity of each size 200 gel filtration FPLC fraction, in jM min~4 per mg protein mL-1.
The size 200 gel filtration fraction numbers are shown in Figure 3-21. For each fraction
the total number of mL buffer used by the FPLC at that point are given.
Ajmalicine Isositsirikine
Size 200 gel synthase synthase
filtration fraction activity (ptM activity (pM
min / mg min / mg
protein mL-) protein mL)
C1-4
(48-56 mL buffer)
C5-8C5-80.014 0(56-64 mL buffer)
C9-12C9-120.033 0.003(64-72 mL buffer)
D9-12D9-120.031 0.010(72-80 mL buffer)
D5-8
(80-88 mL buffer)
D1-4
(88-96 mL buffer)
OEM . . .. ... .... ............
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Figure 3-22: A 2D SDS-PAGE of fractions C9-12 from a size 200 gel filtration column.
Major proteins ("spots") labeled 1 through 8 in green were excised and sequenced.
Spot EST accession number Enzyme type
RT00026RT3_026_B1 1_02JUNE2004_093_abi peroxidase
1 CR03015E07 peroxidase
1 SM-JB R1-F04 T3 F04 3100168_12 abI peroxidase
2 CR02028A05 malate dehydrogenaseCR02026D12 malate dehydrogenase
3 LB00039R T3_039 D07_21JUN2004 057 abl cinnamyl alcohol dehydrogenase
4 1 SM-JB Li1-H03_T3_H03_3100405 15 abl triosphosphate isomerase
5 no protein match no protein match
6 CR0101OCI1 succinyl-CoA ligase
7 CR01020F03 cysteine synthase
8 CR02002F08 S-adenosyl-L-homocysteine hydrolase
Table 3-4: Table of C. roseus ESTs that correspond to the peptide sequence data obtained
for each spot from the 2D SDS-PAGE shown in Figure 3-22. When more than one EST
accession number is listed, this indicates that the protein sequence matched equally well
to each of the listed ESTs.
. .. ............... .........  
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C. Additional purification methods
i. Dye-ligand chromatography
As Figure 3-22 shows, numerous proteins in addition to ajmalicine synthase and
isositsirikine synthase are present in the partially purified enzyme fraction even after the
third step in the purification protocol, the size 200 gel filtration FPLC step. The goal of
the protein purification procedure is to obtain ajmalicine synthase and/or isositsirikine
synthase in a fraction containing as few enzymes as possible. In an attempt to find other
purification methods, I used dye-ligand chromatography. Cibacron Blue Agarose,
Reactive Red Agarose, Reactive Brown Agarose, Reactive Green Agarose, and Reactive
Yellow Agarose (Figure 3-9-Figure 3-13) were all tested to see if they could be used as a
purification step. If a particular dye were able to partially purify ajmalicine synthase or
isositsirikine synthase, the dye could be incorporated into future purification procedures.
I obtained the most promising results by using Reactive Red Agarose. An acetone
precipitation fraction (1.5 mL, 1.9 mg protein mL-1) was added to 2.5 mL Reactive Red
Agarose (pre-packed column from Sigma Aldrich) pre-equilibrated with 10 mM Tris
buffer, pH 7.5, containing 0 M NaCl and 10% glycerol. The supernatant and wash were
collected, and 1500 mM NaCl was added to the Tris buffer for elution. The supernatant,
wash, and elution were assayed for ajmalicine synthase specific activity (Table 3-5).
Encouragingly, the highest ajmalicine synthase specific activity was seen in the elution
fraction. Similar results were obtained when I used a purer ajmalicine synthase fraction
(0.7 mg protein mL-1) obtained after purification from acetone precipitation, DEAE, and
size 200 gel filtration chromatography steps (Table 3-6); the best ajmalicine synthase
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specific activity was also seen in the elution fraction. The specific activity was modestly
improved by a factor of ten.
Ajmalicine synthase specific
Reactive Red Agarose activity
(pM min I mg protein mL-1)
Supernatant 0.010
Wash 0.051
Elution 0.158
Table 3-5: Ajmalicine synthase specific activity (pM min per mg protein mL ) for the
fractions from a Reactive Red Agarose column using an acetone precipitation fraction.
Ajmalicine synthase specific
Reactive Red Agarose activity
(IM min-1 / mg protein mL-1)
Supernatant 0
Wash 0.058
Elution 0.215
Table 3-6: Ajmalicine synthase specific activity (pM min- per mg protein mL-) for the
fractions from a Reactive Red Agarose column using a size 200 gel filtration fraction.
The procedure was then performed using Reactive Green Agarose and an acetone
precipitation fraction (1.2 mg protein mL). As with Reactive Red Agarose, ajmalicine
synthase specific activity correlated with increasing NaCl concentration used for elution
(Table 3-7).
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mM NaCl Ajmalicine synthase specific
activity (pM min' / mgfraction protein mL-1)
0 0.020
150 0.039
300 0.037
500 0.077
1500 0.090
Table 3-7: Ajmalicine synthase specific activity (pM min- per mg protein mL 1) for the
fractions from a Reactive Green Agarose column using an acetone precipitation fraction.
Reactive Brown Agarose, Cibacron Blue Agarose, and Reactive Yellow Agarose
were also assayed. An acetone precipitation fraction (1.6 mg protein mL-) was used.
Unlike Reactive Red and Reactive Green Agarose, however, decreasing ajmalicine
synthase specific activity was observed with increasing NaCl concentration (Table 3-8).
Reactive Brown Agarose, Cibacron Blue Agarose, and Reactive Yellow Agarose are thus
not suitable for purifying ajmalicine synthase.
Reactive Brown Cibacron Blue Reactive Yellow
mM NaCl fraction (IM min-1 / (IM min-' / (PM min-1 /
mg protein mL-1) mg protein mL-1) mg protein mL-1)
0 0.169 0.154 0.201
150 0.228 0.128 0.166
300 0.134 0.105 0.139
500 0.084 0.053 0.095
1500 0.055 0.033 0.083
Table 3-8: Ajmalicine synthase specific activity ( M min-1 per mg protein mL-1) for each
fraction using Reactive Brown Agarose, Cibacron Blue Agarose, and Reactive Yellow
Agarose.
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In future ajmalicine synthase purification procedures, Reactive Red Agarose or
Reactive Green Agarose could be used to supplement the purification procedure.
Ajmalicine synthase is eluted from both Reactive Red Agarose and Reactive Green
Agarose in fractions with high NaCl concentrations, which shows that ajmalicine
synthase is able to bind to Reactive Red Agarose and Reactive Green Agarose. The
specific activity was higher in the elution fractions, indicating that ajmalicine synthase is
partially purified by Reactive Red Agarose and Reactive Green Agarose. Additional
purification strategies such as the use of Reactive Red Agarose and Reactive Green
Agarose are necessary for the enrichment of ajmalicine synthase and isositsirikine
synthase, and efforts must also be made to ensure that no loss of specific activity occurs
during the additional purification steps.
ii. Ammonium sulfate precipitation
In my initial purification attempts I performed an ammonium sulfate precipitation
after the lysis step with borate buffer. I used ammonium sulfate precipitation because it is
much more commonly performed than acetone precipitation. I found that activity was
retained in the 40-70% ammonium sulfate fraction.
I switched to acetone precipitation because acetone precipitation can be done
much more quickly than ammonium sulfate precipitation, thus lowering the chance of
enzyme activity loss over time. A typical ammonium sulfate precipitation followed by
desalting and concentration lasted approximately four hours, whereas an acetone
precipitation followed by resuspension can be performed in approximately 15 minutes.
Importantly, protein obtained from acetone precipitation had higher specific activities for
ajmalicine synthase and isositsirikine synthase than did protein obtained with ammonium
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sulfate precipitation. Notably, isositsirikine synthase activity was observed only after
acetone precipitations, and not after ammonium sulfate precipitations. Perhaps
isositsirikine synthase loses its activity during the lengthy ammonium sulfate procedure,
or perhaps, for some unknown reason, isositsirikine synthase is able to tolerate acetone
precipitation better than ammonium sulfate precipitation.
iii. Protein pulldown experiment with strictosidine-p-
glucosidase
I performed a protein pulldown experiment (Figure 3-23) with strictosidine-p-
glucosidase (SGD). Because the intermediates produced by the action of SGD are
extremely reactive and have low solubility in water 76, it can be hypothesized that
ajmalicine synthase and isositsirikine synthase interact with SGD, which is believed to be
associated with the endoplasmic reticulum (ER)73. Protein complex, or "metabolon"
formation has been known to occur in Arabidopsis thaliana 122-12; much of
phenylpropanoid and flavonoid metabolism is hypothesized to occur in metabolons on
the cytosolic side of the ER 126. I performed a pulldown experiment (Figure 3-23) to
determine whether ajmalicine synthase and isositsirikine synthase associate with SGD. In
the pulldown experiment, a maltose binding protein (MBP) fusion of SGD was
immobilized onto an amylose resin. The resin with SGD was then incubated with extracts
from C. roseus seedlings. Proteins not interacting with SGD were eluted by washing the
resin with buffer. Finally, SGD, along with any potential interacting partners of SGD,
was eluted from the resin with maltose. Because of the large size of the MBP, an
alternative pulldown procedure was also performed. In the alternative procedure, the
MBP of SGD was first cleaved with thrombin. SGD was then crosslinked to an Affigel
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resin via the surface amines of SGD. Extracts from C. roseus seedlings were then added,
and non-interacting proteins were eluted by washing. After washing, proteins bound to
SGD were eluted by heat denaturation.
After elution, SDS-PAGE was used to analyze the wash and elution fractions.
Protein bands that appeared in the elution but not in the wash fractions were excised from
the gel and sequenced via nano-LCMS at the protein core facility of the University of
Arizona. Unfortunately, no proteins were found that had homology to known reductases;
many of the proteins sequenced had high sequence identity to methionine synthases.
Additionally, interacting proteins that were eluted with maltose were also found to have
no ajmalicine synthase activity.
Proteins from 0
Amylos . Wash, Amylose MBpSGDC. roseus extraAmylose
resin resin resinS-
Cah
Elute with0
- SDS PAGE maltose Amylose MBP SGDQ
resin
- Activity assay
Figure 3-23: Design of protein pulldown experiment with SGD.
These experiments do not exclude the possibility of SGD-ajmalicine synthase and
SGD-isositsirikine synthase metabolons, however. Most protein-protein interactions have
low affinities, and enzyme interactions in secondary metabolism are particularly difficult
to detect. Winkel-Shirley 26,127 speculates that enzyme interactions that occur in primary
metabolism, such as the metabolons involved in the tryptophan synthase, the pyruvate
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dehydrogenase, the citric acid and Calvin cycles, the proteasome, and the glycine
decarboxylase systems, may be relatively stable when compared to many interactions that
occur in secondary metabolism pathways. For example, whereas the primary metabolism
enzymes of the citric acid cycle can be co-purified, attempts to co-purify the secondary
metabolism enzymes of the phenylpropanoid pathway have failed 26 127
158
D. Novel ajmalicine and isositsirikine analogs
Novel ajmalicine 4 and isositsirikine 7 analogs can be produced if deglycosylated
strictosidine 49 analogs are accepted by ajmalicine synthase and isositsirikine synthase,
respectively. Previous work has explored the substrate specificity of strictosidine
synthase 36,85,86, and as described in Chapter 2, numerous strictosidine 1 analogs are
accepted by SGD. These strictosidine 1 analogs include indole substituted strictosidine
analogs 1-c through 1-s, strictosidine containing alternate heterocycles 1-a and 1-b and
esters 1-t, and des-vinyl strictosidine isomers 1-y and 1-z. If these unnatural biosynthetic
intermediates are accepted by downstream enzymes, novel alkaloids with potentially
improved biological properties can be made.
i. Novel indole substituted, heterocyclic, and ester analogs
Numerous strictosidine 1 analogs that were found to be deglycosylated by SGD in
vitro (Chapter 2) were assayed with a partially purified enzyme fraction containing
ajmalicine synthase and isositsirikine synthase activity (Figure 3-24 and Table 3-9). In
the assays, strictosidine 1 analogs were first incubated with SGD for 5 minutes, followed
by addition of NADPH and a partially purified enzyme fraction containing ajmalicine
synthase and isositsirikine synthase activity. After two hours, an aliquot was quenched
and subjected to LCMS analysis. Gratifyingly, all strictosidine 1 analogs tested (1-c, 1-g,
1-h, 1-k, 1-n, 1-o, and 1-p) (Table 3-9) except for a-dimethyl strictosidine 1-u were
found to form compounds with exact masses matching the corresponding ajmalicine 4
isomers. Co-elution with authentic standards in the LCMS assay further confirmed the
identity of some of the ajmalicine 4 and isositsirikine 7 analogs produced in the assays
(as shown in Figure 3-15 and in Figure 3-37 and Figure 3-38 in the Materials and
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Methods section) as well as the identity of the benzo isositsirikine compound 7-a (Figure
3-16). The standards were produced and characterized by Dr. Elizabeth McCoy 36 and Dr.
Hyang-Yeol Lee104. Enzymatic products were also characterized by high-resolution mass
spectrometry (Materials and Methods section). Indole substituted strictosidine analogs 1-
1 and 1-a, 1-b, 1-d, 1-e, 1-f, 1-i, 1-j, 1-m, 1-q, 1-r, 1-s, and 1-t (Table 3-9) were also
consumed by this enzyme preparation and were observed by LCMS to form the
corresponding ajmalicine 4 (Figure 3-39 in the Materials and Methods section) and
isositsirikine 7 analogs (Figure 3-40 in the Materials and Methods section), and d4
vincoside 43-1 appeared to form an isomer of ajmalicine, presumably the C-3 R
ajmalicine 85. However, because no standards are currently available for co-elution
studies, these enzymatic products were characterized only by high-resolution mass
spectrometry. Efforts to obtain the products from these partially purified enzyme assays
in sufficient quantities for more rigorous characterization by NMR unfortunately proved
unsuccessful. For a number of substrates, numerous products corresponding to the
isositsirikine 7 analog were observed, suggesting that this enzyme activity produced a
variety of isomers with identical molecular formulae upon reduction of certain substrate
analogs (Figure 3-40). In summary, for many of these analogs, rigorous structural
identification could not be performed. However, consumption of the starting material,
along with the formation of a product with an exact mass corresponding to the ajmalicine
4 and isositsirikine 7 analog strongly suggests that the substrate analogs are turned over.
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Figure 3-24: Indole substituted strictosidine analogs 1-1 and 1-a through 1-t were
accepted by ajmalicine synthase and isositsirikine synthase to form the corresponding
ajmalicine 4 and isositsirikine 7 analogs.
d4 strictosidine 1-1 9-chloro strictosidine 1-k
benzo strictosidine 1-a 10-chloro strictosidine 1-1
thio strictosidine 1-b 12-chloro strictosidine 1-m
9-fluoro strictosidine 1-c 9-bromo strictosidine 1-n
10-fluoro strictosidine 1-d 10-bromo strictosidine 1-o
11 -fluoro strictosidine 1-e 10-hydroxy strictosidine 1-p
12-fluoro strictosidine 1-f 10-isopropyl 1-q
9-methyl strictosidine 1-g 10-methoxy strictosidine 1-r
10-methyl strictosidine 1-h 11-methoxy strictosidine 1-s
11-methyl strictosidine 1-i pentynyl-ester strictosidine 1-t
12-methyl strictosidine 1-j
Table 3-9: Indole substituted strictosidine 1 analogs that were found to form the
corresponding ajmalicine 4 and isositsirikine 7 analogs.
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Figure 3-25: Representative LCMS chromatograms of enzymatically produced ajmalicine
4 and isositsirikine 7 analogs. The x-axis is time in minutes, and the y-axis is intensity.
ii. Novel des-vinyl analogs
In collaboration with Dr. Peter Bernhardt, 18,19-des-vinyl strictosidine 1-z was
enzymatically synthesized from tryptamine 18, des-vinyl secologanin, and strictosidine
synthase. This strictosidine analog was deglycosylated with SGD to produce 18,19-des-
vinyl strictosidine aglycone 49-z (as described in Chapter 2), which was then converted
by a partially purified ajmalicine synthase fraction into a compound with a 1H NMR
spectrum and mass (m/z 327) consistent with reduced 18,19-des-vinyl strictosidine
aglycone 4-z (Figure 3-26).
A mixture of 18,19-des-vinyl strictosidine isomers 1-y that were synthesized
chemically from tryptamine 18 and des-vinyl secologanin was completely deglycosylated
upon addition of a mixture of a- and P-glucosidases (SGD, P-glucosidase from almonds,
and a-glucosidase from B. stearothermophilus) to form 18,19-des-vinyl strictosidine
aglycone isomers 49-y (Figure 3-26 and chromatogram 1 of Figure 3-27). When NADPH
and a partially purified enzyme fraction were added to 18,19-des-vinyl strictosidine
.. ............. ... . . .........
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aglycone isomers 49-y, two separable reduced isomers formed (4-y); one product co-
eluted with the reduced product of 18,19-des-vinyl strictosidine aglycone 4-z (Figure
3-28). The reduced products 4-y contain two stereogenic centers, C-3 and C-15, and only
two sets of diastereomers are expected to separate under the chromatographic conditions.
Because all 18,19-des-vinyl strictosidine aglycone isomers 49-y were completely
consumed upon addition of the reductase activity, we conclude that the reductase(s)
present in the partially purified enzyme fraction turn(s) over all secologanin dihydropyran
configurations. The reductase(s) that generate heteroyohimbine alkaloids appear(s) to be
capable of acting upon a wide variety of substrates. This suggests that this reductase(s)
will have broad applications in chemoenzymatic synthesis after efforts to clone the
enzyme are successful. Synthetic installation of the vinyl group at the C-20 position will
allow access to an even broader range of alkaloid structures.
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Figure 3-26: 18,19-des-vinyl strictosidine aglycone 49-z is reduced by NADPH and a
partially purified enzyme fraction to produce a compound with a 1H NMR spectrum and
mass consistent with reduced 18,19-des-vinyl strictosidine aglycone 4-z (m/z 327). The
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mixture of 18,19-des-vinyl strictosidine aglycone isomers 49-y is reduced to two different
diastereomers 4-y (m/z 327) upon addition of NADPH and a partially purified enzyme
fraction.
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Figure 3-27: 18,19-des-vinyl strictosidine aglycone isomers 49-y (m/z 325)
(chromatogram 1) are completely converted by the reductase activity to reduced 18,19-
des-vinyl strictosidine aglycone isomers 4-y (m/z 327) (chromatogram 2). The two peaks
with m/z 325 observed in chromatogram 3 correspond to the isotope peaks of m/z 327; all
18,19-des-vinyl strictosidine aglycone isomers 49-y have been consumed by reductase(s)
present in the partially purified enzyme fraction. Chromatogram 1 shows the product 49-
y of incubation of 18,19-des-vinyl strictosidine 1-y with B. stearothermophilus a-
glucosidase, almond p-glucosidase, and C. roseus strictosidine-p-glucosidase, without
reductase. Chromatograms 2 and 3 are extracted masses from the same reaction, where
reductase has been added. The x-axis is time in minutes, and the y-axis is intensity.
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Figure 3-28: Chromatogram 1: Reduction of 18,19-des-vinyl strictosidine aglycone
isomers 49-y yields two separable isomers 4-y with m/z 327. Chromatogram 2: Reduction
of 18,19-des-vinyl strictosidine aglycone 49-z yields a single product 4-z with m/z 327.
The x-axis is time in minutes, and the y-axis is intensity.
iii. Steady state kinetic analysis studies
Steady state kinetic analysis studies on the reduction of representative
deglycosylated strictosidine 49 analogs by ajmalicine synthase and isositsirikine synthase
were performed to quantify the effects of substrate specificity. However, since despite
extensive efforts, neither ajmalicine synthase nor isositsirikine synthase has been purified
to homogeneity, we cannot rigorously exclude the involvement of additional reductases
in the turnover of the deglycosylated strictosidine 49 analogs described herein.
The steady state kinetic analysis for the reduction catalyzed by ajmalicine
synthase of deglycosylated d4 strictosidine 49-1 to d4 ajmalicine 4-1 (Figure 3-29) was
performed (Table 3-10). Partially purified ajmalicine synthase formed d4 ajmalicine 4-1
with a catalytic efficiency (Vmax/Km) of 1.61 x 10-2 min-1 The deuterium atoms of d4
. ..... ..... .... ..  ......
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strictosidine 1-1 are not expected to interfere with the catalytic efficiency of ajmalicine
synthase. d4 strictosidine 1-1 was used instead of natural strictosidine 1 to ensure that no
trace amounts of ajmalicine 4 present in the partially purified enzyme fraction would
interfere with detection of reductase activity.
HO O NADPH, D
D D O D D DD partially D
3NH ,0fOH SGD\ 3 NH OH purified \ 3N
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N OHO OH N H ajmalicine H -
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d4 strictosidine 1-1 deglycosylated d4  d4 ajmalicine 4-1
strictosidine 49-1
Figure 3-29: d4 Strictosidine 1-1 is deglycosylated by SGD to form deglycosylated d4
strictosidine 49-1, which is then reduced by NADPH and partially purified ajmalicine
synthase to d4 ajmalicine 4-1.
Strictosidine analog Vmax (tM/min) Km (piM) Vmax/Km (min-')
d4 strictosidine 1-1 1.09 0.06 67.9 11.5 1.61 x 10-2
Table 3-10: The steady state kinetic data of partially purified ajmalicine synthase. d4
Strictosidine 1-1 is deglycosylated by SGD and then reduced by partially purified
ajmalicine synthase to d4 ajmalicine 4-1.
To explore the effects of steric substitution on the indole ring, steady state kinetic
analysis was performed on 9-methyl 1-g, 10-methyl 1-h, 11-methyl 1-i, and 12-methyl 1-
j strictosidine (Table 3-11). The catalytic efficiency of ajmalicine synthase does not
appear to be significantly altered by indole substitution: Vmax/Km values for the four
methyl strictosidine analogs 1-g through 1-j did not differ by more than an order of
magnitude. Similarly, in a precursor directed biosynthesis study36 with 9-methyl 1-g, 10-
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methyl 1-h, 11-methyl 1-i, and 12-methyl 1-j strictosidine, the percentages of methylated
ajmalicine 4 analogs and methylated serpentine 5 analogs, which are formed via a
peroxidase-catalyzed oxidation of ajmalicine 41, did not vary significantly. Specifically,
the percentages of methylated ajmalicine 4 analogs and methylated serpentine 5 analogs
produced as part of the total amounts of alkaloids produced were 21%, 34%, 22%, and
6% for 9-methyl 1-g, 10-methyl 1-h, 11-methyl 1-i, and 12-methyl 1-j strictosidine,
respectively.
Strictosidine Vmax Vmax / Km Relative p in
analog (piM/mm) Km (FiM) (mm 1) Vmax / Km precursor
__________study
9-methyl 1-g 0.49+0.01 69.2+5.3 7.08 x 10- 0.61 21
10-methyl 1-h 0.46 0.01 70.6 5.7 6.52 x 10-3 0.56 34
Sl-methyl1-i 0.69±0.02 58.9±6.6 1.17 x 10-2 1 22
12-methyl 1-j 0.67 + 0.02 95.5 + 10.6 7.01 x 10-- 0.6 6
Table 3-11: Steady state kinetic data of partially purified ajmalicine synthase. Methylated
strictosidine analogs 1-g through 1-j were deglycosylated by SGD and then reduced by
partially purified ajmalicine synthase to form methylated ajmalicine analogs 4-g through
4-j, respectively. The relative Vmax/Km values are listed, with the Vmax/Km value for 11-
methyl strictosidine 1-i normalized to 1. The percentages of methylated ajmalicine 4
analogs and methylated serpentine 5 analogs formed as part of the total amounts of
methylated alkaloids produced in a previous precursor directed biosynthesis study36 are
also listed.
To quantitatively measure the capacity of this reductase for alternate
stereoisomers, the steady state kinetics for ajmalicine synthase with deglycosylated d4
vincoside 84 were also determined (Table 3-12 and Figure 3-43). Partially purified
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ajmalicine synthase formed a compound with an exact mass corresponding to an isomer
of ajmalicine, presumably d4 C-3 R ajmalicine 85. Partially purified ajmalicine synthase
reduced deglycosylated d4 vincoside 84 with a catalytic efficiency (Vmax/Km) of 1.13 x
10-4 min-. The preference for deglycosylated d4 strictosidine 49-1 compared to
deglycosylated d4 vincoside 84 suggests that the reductase activity derives from the
monoterpene indole alkaloid pathway; vincoside 43, the C-3 R diastereomer of
strictosidine 1, is not produced by strictosidine synthase, and no alkaloids downstream of
strictosidine 1 are naturally observed with C-3 R stereochemistry. Ajmalicine synthase,
which has evolved to catalytically prefer its natural substrate, can nevertheless reduce the
nonnatural stereoisomer.
HO NADPH
D D D D D D D D
D 0 D partially D
3NH 0' OH SGD 3NH H purified , s N H
N H OHO OH / N H _ ajmalicine H NH H 
S0 ~0 synthase O/ O / O /0
d4 vincoside 43-1 deglycosylated d4  d4 C-3 R ajmalicine
vincoside 84 85 isomer
Figure 3-30: d4 vincoside 43-1 is deglycosylated by SGD to form deglycosylated d4
vincoside 84, which is then reduced by NADPH and partially purified ajmalicine
synthase to form a compound with an exact mass corresponding to an ajmalicine isomer,
presumably d4 C-3 R ajmalicine 85. The C-3 position is indicated in blue.
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Strictosidine analog Vmax (pM/min) Km (pM) Vmax/Km (min-)
d4 vincoside 43-1 0.079 + 0.004 701.5 +91.7 1.13 x 10-4
Table 3-12: Steady state kinetic data of partially purified ajmalicine synthase. d4
vincoside 43-1 is deglycosylated by SGD and then reduced by partially purified
ajmalicine synthase.
In all of the substrate specificity assays using indole substituted strictosidine
analogs 1-c through 1-s, the ajmalicine 4 analog was the major product and the
isositsirikine 7 analog was a minor product. For benzo strictosidine 1-a and thio
strictosidine 1-b, however, the ratio of ajmalicine 4 analog to isositsirikine 7 analog was
reversed. Moreover, more than one product corresponding to the ajmalicine 4 product
analog was formed for benzo strictosidine 1-a and thio strictosidine 1-b; all other
strictosidine 1 analogs only produced a single ajmalicine 4 isomer product. Again, the
difficulties of obtaining milligram quantities of enzymatic product from these enzymatic
preparations unfortunately precluded more detailed analysis of these products.
Nevertheless, intrigued by this finding, I determined the steady state kinetics for the
reduction of deglycosylated d4 strictosidine 49-1, deglycosylated benzo strictosidine 49-
a, and deglycosylated thio strictosidine 49-b by partially purified isositsirikine synthase
(Table 3-13). Isositsirikine synthase showed a 25-fold catalytic preference (Vmax/Km) for
deglycosylated benzo strictosidine 49-a over deglycosylated d4 strictosidine 49-1, and a
37-fold catalytic preference for deglycosylated thio strictosidine 49-b over
deglycosylated d4 strictosidine 49-134.
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Strictosidine analog Vmax (pM/min) Km (pm) Vmax/Km (min-)
d4 1-1 0.16 +0.02 98.9+ 36.4 1.63 x 1-J
benzo 1-a 1.23 + 0.09 36.6 + 9.5 3.36 x 10-2
thio 1-b 1.04+0.04 17.2+2.1 6.03 x 10
Table 3-13: Steady state kinetic data of partially purified isositsirikine synthase. d4
Strictosidine 1-1, benzo strictosidine 1-a, and thio strictosidine 1-b were deglycosylated
by SGD and then reduced by partially purified isositsirikine synthase to form d4
isositsirikine 7-1, benzo isositsirikine 7-a, and thio isositsirikine 7-b, respectively.
We wanted to investigate whether the inherent electronic difference in the indole
35, benzofuran 37, and benzothiophene 38 moieties may have affected the product ratio
of ajmalicine 4 to isositsirikine 7. A chemical reduction of deglycosylated d4 strictosidine
49-1, deglycosylated benzo strictosidine 49-a, and deglycosylated thio strictosidine 49-b
with NaCNBH 3 was performed for comparison with the enzymatic reaction (Figure 3-31).
A 400- or 6,000-fold excess of NaCNBH 3 was added to deglycosylated d4 strictosidine
49-1, deglycosylated benzo strictosidine 49-a, or deglycosylated thio strictosidine 49-b in
50 mM sodium phosphate buffer, pH 7.5, and the reaction mixture was incubated at
30'C. Aliquots were quenched in methanol, and the starting materials and products were
analyzed via LCMS using a five minute, 10-90% acetonitrile in 0.1% formic acid
gradient. With this LCMS method, d4 ajmalicine 4-1 and d4 isositsirikine 7-1 are typically
observed at 2.0 and 1.8 minutes, respectively; benzo ajmalicine 4-a and isositsirikine 7-a
are typically observed at 2.3 and 1.7 minutes, respectively; and thio ajmalicine 4-b and
isositsirikine 7-b are typically observed at 2.3 and 1.8 minutes, respectively. For all time
points, from 1 minute to 2 hours, the ajmalicine 4 isomers were the major product
observed by LCMS; virtually no isositsirikine 7 products were observed (Figure 3-32).
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We therefore conclude that the faster reduction of deglycosylated benzo 49-a and
deglycosylated thio 49-b strictosidine to the corresponding isositsirikine 7 analogs in the
assay with partially purified isositsirikine synthase is the result of enzymatic, and not
chemical, effects.
Intriguingly, an additional reduced product 80 (Figure 3-32 and Figure 3-33) with
the same mass as isositsirikine 7 was produced for all three strictosidine 1 analogs in this
chemical reaction. This product 80 has the same retention time as ajmalicine 4, and we
hypothesize that this product results from reduction of the double bond of the a, P
unsaturated ester of the ajmalicine 4 isomer (Figure 3-33). This product is not formed in
the enzymatic reaction, it is not found in C. roseus hairy root or cell suspension culture,
and we do not believe it to be an isositsirikine 7 isomer its LCMS retention time is
significantly later than that of isositsirikine 7. Efforts to isolate and characterize the
product by 1H NMR proved unsuccessful.
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Figure 3-31: The d4 1-1, benzo 1-a, and thio 1-b strictosidine analogs were
deglycosylated and then incubated with sodium cyanoborohydride (NaCNBH 3). The
ajmalicine 4 isomer was the major product produced for all three analogs; virtually no
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detectable isositsirikine 7 isomer product was observed. X means NH for d4 strictosidine
1-1 and d4 ajmalicine isomers 4-1 (and two deuteriums at each of the C-5 and C-6
positions, which are labeled in blue), X means 0 for benzo strictosidine 1-a and benzo
ajmalicine 4-a isomers, and X means S for thio strictosidine 1-b and thio ajmalicine 4-b
isomers.
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Figure 3-32: LCMS chromatograms of NaCNBH 3 reaction with strictosidine analogs 1-1,
1-a, and 1-b. The chemical structure of each peak is shown. A gradient of 10-90%
acetonitrile in water with 0.1% formic acid over 5 minutes was used. Chromatogram 1: d4
ajmalicine isomer 81 elutes at 1.95 minutes. Chromatogram 2: No d4 isositsirikine isomer
is observed at 1.8 minutes. The peak at 2 minutes is the d4 reduction product 80-1 that we
hypothesize is produced via reduction of the double bond of the a, p unsaturated ester of
the ajmalicine isomer. Chromatogram 3: Benzo ajmalicine isomer 82 elutes at 2.3
............. ........... 
. . ............................
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minutes. Chromatogram 4: No benzo isositsirikine isomer is observed at 1.7 minutes.
The peak at 2.05 minutes is the benzo reduction product 80-a. Chromatogram 5: Thio
ajmalicine isomer 83 elutes at 2.3 minutes. Chromatogram 6: No thio isositsirikine
isomer is observed at 1.8 minutes. The peak at 2.15 minutes is the thio reduction product
80-b. The x-axis is time in minutes, and the y-axis is intensity.
5 6 5 6
\ N H excess N H
X ''H -' NaCNBH 3  x 'H
-0 0
0 0
0 0
ajmalicine 4 isomer reduction product 80
Figure 3-33: Proposed structure of the additional reduction product 80 observed in the
reaction of strictosidine analogs 1-1, 1-a, and 1-b with NaCNBH 3. X means NH for d4
reduction product 80-1 (and two deuterium atoms at each of the C-5 and C-6 positions,
which are labeled in blue), X means 0 for reduction product 80-a, and X means S for thio
reduction product 80-b.
III. Discussion
Partial purification procedure
In the partial purification procedure that I developed for ajmalicine synthase and
isositsirikine synthase, C. roseus hairy root and cell suspension cultures sub-cultured for
two weeks are first lysed by being ground in a blender with borate buffer at 40C. After
lysis, an acetone precipitation is performed as a first purification step. As the 1D SDS-
PAGE in Figure 3-17 shows, numerous proteins are present in the first (25% v/v acetone)
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and second (40% v/v acetone) acetone precipitations. The third acetone precipitation
(57% v/v acetone) contains the majority of the ajmalicine synthase activity; ajmalicine
synthase specific activities of 0, 0.068, and 0.094 1iM min- per mg protein mL- are
observed for the first, second, and third acetone precipitations, respectively. The third
acetone precipitation contains virtually all of the isositsirikine synthase activity;
isositsirikine synthase specific activities of 0, 0.003, and 0.044 ptM min per mg protein
mL' are observed for the first, second, and third acetone precipitations, respectively
(Table 3-1). The switch from ammonium sulfate precipitation, which I performed in my
early purification attempts, to acetone precipitation resulted in the discovery of
isositsirikine synthase activity; isositsirikine synthase activity had never been detected
from preparations using ammonium sulfate precipitation. There are no reports to date in
the literature for isositsirikine synthase; thus the switch from ammonium sulfate to
acetone precipitation was particularly fortuitous.
After the acetone precipitation step, I performed an anion exchange FPLC step
using a DEAE matrix. As Figure 3-19 and Table 3-2 show, the two groups of fractions
with the highest ajmalicine synthase specific activity and isositsirikine synthase specific
activity, B8-9 and B1O-12, have lower UV 280 absorbencies and thus lower protein
concentrations than fractions such as B6-7 and B4-5. Fractions B6-7 and B4-5 have
higher UV 280 absorbencies yet lower ajmalicine synthase specific activity and
isositsirikine synthase specific activity than fractions B8-9 and B1O-12. Thus, DEAE
FPLC chromatography successfully enriched the specific activity of ajmalicine synthase
and isositsirikine synthase.
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The size 200 gel filtration FPLC step following DEAE FPLC was partially
successful in purification (Figure 3-21). Unfortunately, however, low specific activities
are observed after this step, and ajmalicine synthase and isositsirikine synthase are spread
out over many fractions. The extreme lability of these reductases was an extraordinarily
challenging aspect of this purification. It is possible that ajmalicine synthase and
isositsirikine synthase exist as multimeric enzymes, and the decrease in activity could
perhaps be explained by separation of the subunits during the size 200 gel filtration FPLC
step. A 2D SDS-PAGE of fractions from the size 200 gel filtration step shows numerous
proteins (Figure 3-21). Additional purification strategies are necessary for enrichment of
ajmalicine synthase and isositsirikine synthase, but these efforts are complicated by the
loss in specific activity throughout the purification process.
Reactive Red Agarose, a dye affinity chromatography strategy, was shown to
elute ajmalicine synthase in high salt fractions while eluting the majority of the proteins
in wash fractions (Table 3-5). A purification step using Reactive Red Agarose could
potentially be performed after the DEAE FPLC step. However, 2D gel analysis did not
show significant purification of a fraction from size exclusion chromatography after
elution from Reactive Red Agarose, indicating that many more chromatography steps are
still required.
Nevertheless, protein sequences of the eight major proteins present after acetone
precipitation, DEAE, and size exclusion chromatography were subjected to protein
sequencing for identification after separation by 2D SDS-PAGE. One of the eight
proteins in Table 3-4, protein 3 exhibits 61% sequence identity to a cinnamyl alcohol
dehydrogenase, an enzyme that reduces an aldehyde to an alcohol. One cinnamyl
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alcohol dehydrogenase homolog, perakine reductase, has also been reported to reduce the
aldehyde moiety of the TIA perakine. It is possible, based on the sequence homology,
that protein 3 could reduce an imine to an amine, such as in the reduction of the iminium
moiety of cathenamine 49 to ajmalicine 4 (Figure 3-34). Only a partial sequence of
protein 3 is known and deposited in a C. roseus EST database (747 nucleotides). Because
cloning full length cDNA is difficult and time consuming, we defer further
characterization of this protein until a transcriptome sequencing project now underway is
completed: the completion is scheduled for July 2010.
N N \H N N
H H' H H H' H
0 0
cathenamine 49 ajmalicine 4
(iminium form)
Figure 3-34: An enzyme like cinnamyl alcohol dehydrogenase could potentially reduce
the iminium of cathenamine 49 to form the amine in ajmalicine 4.
Preliminary expression data obtained from the Illumina sequencing of C. roseus
seedling cDNA currently shows that the transcript for the EST for protein 3 in Table 3-4
is up-regulated in elicited seedlings along with all other alkaloid biosynthetic genes.
Elicitation of C. roseus seedlings by the plant hormone methyl jasmonate has been
reported to increase both alkaloid production and expression of TIA biosynthetic
genes128. Although the up-regulation observed in the preliminary expression data from
the transcriptome sequencing is modest (1.5-fold), it is similar to the levels of elicitation
observed in known vindoline 28 biosynthetic enzymes (1.5-1.9-fold) (R. Buell, Michigan
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State University, unpublished). Therefore, the levels of up-regulation of this gene are
consistent with those of an enzyme involved in alkaloid biosynthesis.
Substrate specificity and steady state kinetic studies
Ajmalicine synthase and isositsirikine synthase were shown to have broad
substrate specificity, reducing deglycosylated strictosidine 49 analogs containing altered
indole, ester, and heterocyclic moieties. This finding qualitatively agreed with previous
precursor directed biosynthesis studies 34,36. All deglycosylated indole substituted
strictosidine analogs, which included fluoro (49-c through 49-f), chloro (49-k through 49-
m), bromo (49-n and 49-o), and methyl (49-g through 49-j) substitutions, were accepted
by ajmalicine synthase and isositsirikine synthase to form products with exact masses
corresponding to ajmalicine 4 and isositsirikine 7 analogs, indicating that the active sites
of both enzymes are able to tolerate substitutions on the indole moiety. Deglycosylated
pentynyl-ester strictosidine 49-t was also reduced by both enzymes to form products with
exact masses corresponding to pentynyl-ester ajmalicine 4-t and pentynyl-ester
isositsirikine 7-t, indicating that a large alkyl ester chain does not prevent turnover.
Deglycosylated benzo strictosidine 49-a and deglycosylated thio strictosidine 49-b are
turned over as well, indicating that ajmalicine and isositsirikine synthase are able to
tolerate strictosidine 1 analogs with altered electron densities. Additionally,
deglycosylated d4 vincoside 84 was reduced by ajmalicine synthase to form an isomer of
ajmalicine, presumably d4 C-3 R ajmalicine 85, thus indicating that ajmalicine synthase
does not require a specific stereoisomer for turnover. The reduction of 18,19-des-vinyl
strictosidine aglycone isomers 49-y (Figure 1-35) further demonstrates that altered
stereochemical configurations are tolerated.
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The broad substrate specificity observed is promising for the development of
novel analogs with improved therapeutic activities. Ajmalicine 4 is used clinically as an
anti-hypertensive agent, and isositsirikine 7 has been reported to have anti-neoplastic
activities. The introduction of halogens as indole substitutions could increase the
lipophilicity of the ajmalicine 4 and isositsirikine 7 analogs, improving their ability to
traverse membranes. The introduction of a hydroxy moiety at the C-10 position could
improve the water solubility of ajmalicine 4 and isositsirikine 7 analogs, improving their
ability to diffuse through the cytosol. The introduction of altered stereochemical
configurations could drastically alter the biological properties of ajmalicine 4 and
isositsirikine 7 analogs.
Steady state kinetic studies also showed that 9-methyl 1-g, 10-methyl 1-h, 11-
methyl 1-i, and 12-methyl 1-j strictosidine all had catalytic efficiencies within an order of
magnitude. This finding indicates that ajmalicine synthase is able to tolerate substituents
at each indole position approximately equally. In a precursor directed biosynthesis study
performed by Dr. Elizabeth McCoy36, 9-methyl 1-g, 10-methyl 1-h, 11-methyl 1-i, and
12-methyl 1-j strictosidine were each incorporated to form methylated analogs of
ajmalicine 4 and serpentine 5, the downstream product of ajmalicine 4. The percentages
of ajmalicine 4 and serpentine 5, which is formed via a peroxidase-catalyzed oxidation of
ajmalicine 41, in the methylated alkaloid profiles varied from 6 to 34%36. Thus both in the
steady state kinetic analysis study of methylated strictosidine analogs and in the precursor
directed biosynthesis study, the presence of a methyl moiety at a given indole position of
strictosidine 1 did not have drastic effects either on the turnover by ajmalicine synthase or
on the partitioning of a given strictosidine 1 analog into the different biosynthetic
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pathways. The differences were more pronounced in vivo, suggesting that factors in
addition to enzyme substrate specificity direct the product partitioning.
methylated methylated
ajmalicine p serpentine
4 analogs 5 analogs
methylatedm
taberpentine
2 anlogs 7 Z methylated strictosidine methylated
analogs 1-g, 1-h, 1-i, 1-j isositsirikine7 analogs
methylated methylated
catharanthine akuammicine
29 analogs 63 analogs
Figure 3-35: In a precursor directed biosynthesis study performed by Dr. Elizabeth
McCoy 36, 9-methyl 1-g, 10-methyl 1-h, 11-methyl 1-i, and 12-methyl 1-j strictosidine
analogs were co-cultured with C. roseus hairy root cultures for two weeks, and the
resulting methylated alkaloid profile was measured. The percentages of methylated
ajmalicine 4 and methylated serpentine 5 analogs (blue) produced from the 9-methyl 1-g,
10-methyl 1-h, 11-methyl 1-i, and 12-methyl 1-j strictosidine analogs varied from 6 to
34% of the total amount of methylated alkaloids produced36
In steady state kinetic studies with partially purified ajmalicine synthase, the
slower rate of reduction of deglycosylated d4 vincoside 84 compared to reduction of
deglycosylated d4 strictosidine 49-1 suggests that the reductase activity derives from the
monoterpene indole alkaloid pathway. Vincoside 43, the C-3 R diastereomer of
strictosidine 1, is not produced by strictosidine synthase, and no downstream TIAs with
C-3 R stereochemistry are observed. Thus it is perhaps not unexpected that ajmalicine
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synthase reduces d4 deglycosylated strictosidine 49-1, its natural substrate, more
efficiently than it does the unnatural substrate, deglycosylated d4 vincoside 84.
Steady state kinetic analysis of isositsirikine synthase with deglycosylated d4
strictosidine 49-1, deglycosylated benzo strictosidine 49-a, and deglycosylated thio
strictosidine 49-b showed that isositsirikine synthase reduces deglycosylated benzo
strictosidine 49-a and deglycosylated thio strictosidine 49-b approximately 25- and 37-
fold faster, respectively, than it does deglycosylated d4 strictosidine 49-1. The reason for
this is currently unclear, though one hypothesis is that isositsirikine synthase is better able
to tolerate substituents with altered electron densities than ajmalicine synthase.
Chemical reduction of deglycosylated strictosidine analogs 49-1, 49-a, and 49-b
with NaCNBH 3 demonstrated that ajmalicine 4 isomers were the major product, with
virtually no isositsirikine 7 products formed. The mechanism of reduction by
isositsirikine synthase is also unknown; unlike ajmalicine 4 formation, in which one
NADPH-dependent reductions is required, two NADPH-dependent reduction steps are
required for the formation of isositsirikine 7 from deglycosylated strictosidine 49. It is
unknown whether one or two reductases catalyze these reactions (Figure 3-1). Further
studies are required to determine the mechanism of isositsirikine synthase. The
availability of the potential reaction intermediate geissoschizine 64-1 will allow us to
further explore these questions.
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IV. Materials and Methods
A. C. roseus hairy root cultures
Catharanthus roseus hairy root cultures (Figure 3-36) were obtained from
Professor Carolyn Lee Parsons of Northeastern University, Boston, MA. The hairy root
cultures were grown in the dark at 125 rotations per minute (rpm) at 26*C in 100 mL of
Gamborg's B5 media (half strength basal salts, full strength vitamins, 30 g sucrose L-1,
pH 5.7) and recultured every two weeks.
Figure 3-36: C. roseus hairy root cultures.
B. C. roseus cell suspension cultures
Catharanthus roseus PC510 cell suspension cultures were obtained from
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in
Germany. The cell suspension cultures were grown at 125 rpm at room temperature
(25'C) on a 12-hour light, 12-hour dark cycle. In each flask, 100 mL AMIB media
(PhytoTechnology Laboratories, Shawnee Mission, Kansas) was used, and the cultures
were recultured every two weeks.
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C. Preparation of strictosidine analogs
Strictosidine 1 analogs were synthesized both chemically and enzymatically as
described in the Materials and Methods section of Chapter 2.
D. High-resolution mass spectrometry data
All compounds were diluted in methanol to approximately 1 nM concentration
and then ionized by ESI/FT-MS in the positive ion mode.
Ajmalicine analogs
d4 ajmalicine 4-1: [M+H]* Expected: 357.2111. Observed: 357.2116
benzo ajmalicine 4-a: [M+H]* Expected: 354.1700. Observed: 354.1704
thio ajmalicine 4-b: [M+H]* Expected: 370.1471. Observed: 370.1463
9-fluoro ajmalicine 4-c: [M+H]* Expected: 371.1765. Observed: 371.1751
10-fluoro ajmalicine 4-d: [M+H]* Expected: 371.1765. Observed: 371.1771
1i-fluoro ajmalicine 4-e: [M+H]* Expected: 371.1765. Observed: 371.1750
12-fluoro ajmalicine 4-f: [M+H]* Expected: 371.1765. Observed: 371.1756
9-methyl ajmalicine 4-g: [M+H]* Expected: 367.2016. Observed: 367.2014
10-methyl ajmalicine 4-h: [M+H]* Expected: 367.2016 Observed: 367.2006
11 -methyl ajmalicine 4-i: [M+H]+ Expected: 367.2016. Observed: 367.2001
12-methyl ajmalicine 4-j: [M+H]* Expected: 367.2016. Observed: 367.2025
182
9-chloro ajmalicine 4-k: [M+H]* Expected: 387.1470. Observed: 387.1485
10-chloro ajmalicine 4-1: [M+H]* Expected: 387.1470. Observed: 387.1456
12-chloro ajmalicine 4-m: [M+H]* Expected: 387.1470. Observed: 387.1479
9-bromo ajmalicine 4-n: [M+H]* Expected: 431.0965. Observed: 431.0967
10-bromo ajmalicine 4-o: [M+H]* Expected: 431.0965. Observed: 431.0968
10-hydroxy ajmalicine 4-p: [M+H]* Expected: 369.1809. Observed: 369.1802
10-isopropyl ajmalicine 4-q: [M+H]* Expected: 395.2329. Observed: 395.2328
10-methoxy ajmalicine 4-r: [M+H]f Expected: 383.1965. Observed: 383.1952
1 1-methoxy ajmalicine 4-s: [M+H]* Expected: 383.1965. Observed: 383.1963
pentynyl-ester ajmalicine 4-t: [M+H]* Expected: 405.2173. Observed: 405.2159
Isositsirikine analogs
d4 isositsirikine 7-1: [M+H]+ Expected: 359.2267. Observed: 359.2276
benzo isositsirikine 7-a: [M+H]* Expected: 356.1856. Observed: 356.1861
thio isositsirikine 7-b: [M+H]* Expected: 372.1628. Observed: 372.1620
9-fluoro isositsirikine 7-c: [M+H]* Expected: 373.1922. Observed: 373.1923
10-fluoro isositsirikine 7-d: [M+H]* Expected: 373.1922. Observed: 373.1932
1 1-fluoro isositsirikine 7-e: [M+H]* Expected: 373.1922. Observed: 373.1921
12-fluoro isositsirikine 7-f: [M+H]* Expected: 373.1922. Observed: 373.1925
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9-methyl isositsirikine 7-g: [M+H]* Expected: 369.2173. Observed: 369.2188
10-methyl isositsirikine 7-h: [M+H]* Expected: 369.2173. Observed: 369.2173
11-methyl isositsirikine 7-i: [M+H]* Expected: 369.2173. Observed: 369.2191
12-methyl isositsirikine 7-j: [M+H]+ Expected: 369.2173. Observed: 369.2211
9-chloro isositsirikine 7-k: [M+H]* Expected: 389.1626. Observed: 389.1454
10-chloro isositsirikine 7-1: [M+H]* Expected: 389.1626. Observed: 389.1624
12-chloro isositsirikine 7-m: [M+H]* Expected: 389.1626. Observed: 389.1444
9-bromo isositsirikine 7-n: [M+H]* Expected: 433.1122. Observed: 433.0929
10-bromo isositsirikine 7-o: [M+H]* Expected: 433.1122. Observed: 433.0946
10-hydroxy isositsirikine 7 -p: [M+H]* Expected: 371.1965. Observed: 371.1961
10-isopropyl isositsirikine 7-q: [M+H]* Expected: 397.2486. Observed: 397.2129
10-methoxy isositsirikine 7-r: [M+H]* Expected: 385.2122. Observed: 385.2112
11-methoxy isositsirikine 7-s: [M+H]* Expected: 385.2122. Observed: 385.2127
pentynyl-ester isositsirikine 7-t: [M+H]+ Expected: 407.2329. Observed: 407.2325
E. NMR characterization
1H NMR data for reduced 18,19-des-vinyl strictosidine aglycone 4-z are described
by Bernhardt et al.97 1H-NMR data for authentic standards of strictosidine 1 and selected
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ajmalicine 4 and isositsirikine 7 analogs are described by Dr. Elizabeth McCoy 36 and Dr.
Hyang-Yeol Lee'0 .
F. Partial purification procedure
Hairy root or cell suspension cultures were subcultured for two weeks, and then
lysed by blending in borate buffer. Hairy roots (75 g) or filtered cell suspension cultures
(300 g) were blended in 200 mL of 0.1 M borate buffer, pH 7.5, containing 20 mM p-
mercaptoethanol, 0.1% PVP, 1 mM EDTA, and 10% glycerol. The hairy root or cell
suspension cultures were lysed in a blender at 4'C for 5 minutes. The mixture was then
centrifuged at 3,000g. The precipitate was discarded because it did not contain ajmalicine
synthase or isositsirikine synthase activity.
I then performed acetone precipitation on the supernatant. For the first
precipitation, 100 mL acetone was added to a total of 400 mL supernatant. The mixture
was stirred at 80 rpm at 4'C for 5 minutes, and then centrifuged at 4,000g for 3 minutes.
This first precipitate was discarded because it did not contain ajmalicine synthase or
isositsirikine synthase activity. An additional 100 mL acetone was then added to the
supernatant, and the mixture was stirred at 80 rpm at 4'C for 5 minutes, and then
centrifuged at 4,000g for 3 minutes. The second precipitate was resuspended in 50 mM
sodium phosphate buffer, pH 7.5, containing 10% glycerol (7 mL). A third precipitation
was then performed by adding 200 mL acetone to the supernatant, stirring at 80 rpm at
4'C for 5 minutes, and centrifuging at 4,000g for 3 minutes. The third precipitate was
also resuspended in 50 mM sodium phosphate buffer, pH 7.5, containing 10% glycerol (7
mL). I performed enzyme activity assays with resolubilized precipitate to assess
ajmalicine synthase or isositsirikine synthase activity.
185
I applied the third acetone precipitation fraction to a DEAE column (DEAE
Sepharose Fast Flow, GE Healthcare) on FPLC (GE Healthcare). Approximately 2 mg of
protein was eluted with a gradient of 400-800 mM NaCl in 50 mM sodium phosphate
buffer, pH 7.5, containing 10% glycerol. The flow rate was 5 mL min , and the
absorbance at 280 nm was monitored. Fractions were concentrated using Amicon Ultra
15 tubes (Millipore) with a 10 kDa membrane, and were then assayed for activity.
Fractions B8-9 (Figure 3-19), which eluted at approximately 530-550 mM NaCl,
consistently had the best ajmalicine synthase and isositsirikine synthase activity.
I then applied fractions B8-9 to a size 200 gel filtration column (HiLoad 16/60
Superdex 200 prep grade, GE Biosciences) on FPLC (GE Biosciences) using 50 mM
sodium phosphate buffer, pH 7.5, containing 10% glycerol. The flow rate was 1 mL
min-1, and the absorbance at 280 nm was monitored. Fractions were collected and
concentrated using Amicon Ultra 15 tubes (Millipore) with a 10 kDa membrane, and
were then assayed for activity. Fractions C9-12 and D9-12 (Figure 3-21), which eluted at
64-72 mL and 72-80 mL, respectively, consistently had the best ajmalicine synthase and
isositsirikine synthase activity.
To measure specific activity, I incubated strictosidine 1 or strictosidine 1 analogs
with SGD, NADPH, and a partially purified enzyme fraction. A 200 pL reaction volume
was used, with 0.25 mM strictosidine 1 or strictosidine 1 analog, 750 nM SGD
(typically), 5 mM NADPH, and 180 RL partially purified reductase fraction (typically at a
concentration of 1-3 total mg protein mL-). The reaction was incubated at 30'C, and 5
pL aliquots were quenched with 950 pL MeOH containing 500 nM yohimbine 6 as an
internal standard. The samples were centrifuged (13,000g, 1 min) to remove particulates
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and then analyzed by LCMS. The starting material and products were separated using a
gradient of 10-90% acetonitrile in water with 0.1% formic acid over a period of 5
minutes. The increase in the area of the product peak was used to obtain the initial rates
of the reduction reaction. The formation of ajmalicine 4 isomers was monitored by peak
integration, normalized to an internal standard (yohimbine 6), and correlated to peak area
using a standard curve of ajmalicine 4. The rate of ajmalicine 4 formation was divided by
the protein concentration to obtain the specific activity in units of gM min-' / mg protein
mL .
G. LCMS data
In Figure 3-37 and Figure 3-38 below, LCMS chromatograms for ajmalicine
analogs 4-c, 4-g, 4-h, 4-k, 4-n, 4-o, and 4-p and isositsirikine analog 7-c are shown, with
the top chromatograms showing the products of enzymatic assays, and the bottom
chromatograms showing the standards provided by Dr. Elizabeth McCoy36
Ajmalicine analogs 4-c, 4-k, 4-n, 4-o
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A: B: C: D:
4-c 4-k 4-n 4-o
(assay) (assay) (assay) (assay)
S371 mz 387 m/z 431 zfl 431
4-c 4-k 4-a 4-o
(standard) (standard) (standard) (standard)
vz 37 1 z 387 1z 43
Figure 3-37: A: 9-fluoro ajmalicine 4-c produced in assay (top chromatogram) and 9-
fluoro ajmalicine 4-c standard (bottom chromatogram). B: 9-chloro ajmalicine 4-k
produced in assay (top chromatogram) and 9-chloro ajmalicine 4-k standard (bottom
chromatogram). C: 9-bromo ajmalicine 4-n produced in assay (top chromatogram) and 9-
bromo ajmalicine 4-n standard (bottom chromatogram). D: 10-bromo ajmalicine 4-o
produced in assay (top chromatogram) and 10-bromo ajmalicine 4-o standard (bottom
chromatogram). All standards are provided by Dr. Elizabeth McCoy 36. The x-axis is time
in minutes, and the y-axis is intensity.
Ajmalicine analogs 4-g, 4-h, 4-p, 4-t and isositsirikine analog 7-c
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E: F: G: H:
4-g 4-h 4 7-c(assay) (assay) (assay) (sa
=6 mz 367 mz=369 m=mz=3
4-g 4-h 4 7-c(standard) (standard) (standrd) (standard)
Mz='367 mz=367 mz-369 mz= 33
Figure 3-38: E: 9-methyl ajmalicine 4-g produced in assay (top chromatogram) and 9-
methyl ajmalicine 4-g standard (bottom chromatogram). F: 10-methyl ajmalicine 4-h
produced in assay (top chromatogram) and 10-methyl ajmalicine 4-h standard (bottom
chromatogram). G: 10-hydroxy ajmalicine 4-p produced in assay (top chromatogram)
and 10-hydroxy ajmalicine 4-p standard (bottom chromatogram). H: 9-fluoro
isositsirikine 7-c produced in assay (top chromatogram) and 9-fluoro isositsirikine 7-c
standard (bottom chromatogram). All standards are provided by Dr. Elizabeth McCoy36
The x-axis is time in minutes, and the y-axis is intensity.
The LCMS retention times in minutes of standards of isositsirikine 7 analogs and
isositsirikine 7 analogs produced in assays are listed below. All standards are provided by
36Dr. Elizabeth McCoy
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9-methyl isositsirikine 7-g: 1.83 (standard), 1.83 (assay)
9-chloro isositsirikine 7-k: 2.03 (standard), 2.02 (assay)
9-bromo isositsirikine 7-n: 2.03 (standard), 2.04 (assay)
10-bromo isositsirikine 7-o: 2.04 (standard), 2.04 (assay)
1 0-hydroxy isositsirikine 7-p: 1.18 (standard), 1.17 (assay)
pentynyl-ester isositsirikine 7-t: 2.12 (standard), 2.12 (assay)
Figure 3-39 and Figure 3-40 below show LCMS chromatograms of all ajmalicine
analogs 4-1 and 4-a through 4-t and isositsirikine analogs 7-1 and 7-a through 7-t
produced in assays.
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Ajmalicine analogs 4-1 and 4-a through 4-t produced in assays
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Figure 3-39: LCMS chromatograms of ajmalicine analogs 4-1 and 4-a through 4-t
produced in assays. The x-axis is time in minutes, and the y-axis is intensity.
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Figure 3-40: LCMS chromatograms of isositsirikine analogs 7-1 and 7-a through 7-t
produced in assays. The x-axis is time in minutes, and the y-axis is intensity.
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H. Steady state kinetic analysis conditions
I performed steady state kinetic analysis of ajmalicine synthase to determine
substrate specificity with either a 40-70% ammonium sulfate fraction or, in later studies,
an acetone precipitation fraction. In the steady state kinetic study with d4 strictosidine 1-
1, d4 strictosidine 1-1 (10-400 ptM) was first incubated with 5 gM SGD. Under these
conditions, the reactions with the highest concentrations of d4 strictosidine 1-1 are
completely deglycosylated after 5 minutes at 30'C. After this time, deglycosylated d4
strictosidine 49-1 was added to a solution of NADPH (5 mM), partially purified enzyme
fraction from an acetone precipitation (0.9 mg protein mL-1), and 50 mM sodium
phosphate buffer, pH 7.5, containing 400 mM sodium chloride and 10% glycerol, for a
total reaction volume of 200 jiL. The reaction mixture was incubated at 30'C, and each
concentration was assayed at least twice. The aliquots were quenched with 950 gL
MeOH containing 500 nM yohimbine 6 as an internal standard. The samples were
centrifuged (13,000g, 1 min) to remove particulates and then analyzed by LCMS. The
starting material and products were separated using a gradient of 10-40% acetonitrile in
water with 0.1% formic acid over a period of 5 minutes. The increase in the area under
the product peak was used to obtain the initial rates of the reduction reaction. The
formation of ajmalicine 4 isomers was monitored by peak integration, normalized to an
internal standard (yohimbine 6), and correlated to peak area using a standard curve of
ajmalicine 4. The data were fitted by the same method as described for SGD kinetics with
d4 strictosidine 1-1 and d4 vincoside 43-1 (Chapter 2, Materials and Methods).
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tetradeuterated strictosidine
.1-1
Figure 3-41: Data fit for the steady state kinetic analysis of ajmalicine synthase with d4
strictosidine 1-1, with the x-axis in pM d4 strictosidine 1-1, and the y-axis in RM d4
ajmalicine 4-1 formed per minute.
For the steady state kinetic analysis of ajmalicine synthase with 9-methyl 1-g, 10-
methyl 1-h, 11-methyl 1-i, and 12-methyl 1-j strictosidine, a 75 RL reaction was
performed involving NADPH (4 mM), SGD (5 RM), a partially purified enzyme fraction
from an ammonium sulfate precipitation (3.4 mg mL- protein), and 9-methyl 1-g, 10-
methyl 1-h, 11-methyl 1-i, and 12-methyl 1-j strictosidine (0.005-1.4 mM). The reaction
was incubated at 37'C, and 10 jiL aliquots were taken every minute. Each concentration
was assayed at least three times. The LCMS conditions and data fitting methods
described above for the steady state kinetic analysis of d4 strictosidine 1-1 were used.
......  ......  . . . .......................................
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E E
9-methyl strictosidine 1-g 10-methyl strictosidine I-h
9 a
Figure 3-42: Data fit for the steady state kinetic analysis of ajmalicine synthase with 9-
methyl 1-g, 1I 1-methyl 1-Ithylin, and 12-methyl 1-j strictosidine, with the x-axis
in gM 9-methyl 1-g, 10-methyl 1-h, I11-methyl 1-i, or 12-methyl 1-j strictosidine, and the
y-axis in gM 9-methyl 4-g, 10-methyl 4-h, ll-methyl 4-i, or 12-methyl 4-j ajmalicine
formed per minute.
For the steady state kinetic analysis of ajmalicine synthase with d4 vincoside 43-1,
d4 vincoside 43-1 (38-2885 pM) was diluted in 0.15 M citrate phosphate buffer (pH 6,
0.05 mL final volume), and SGD (7.3 gM final concentration) was added. Under these
conditions, the reactions with the highest concentrations of d4 vincoside 43-1 are
completely deglycosylated after 30 minutes at 30*C. After this time deglycosylated d4
vincoside 84 was added to a solution containing NADPH (2.4 mM) and a partially
purified enzyme fraction from an ammonium sulfate precipitation (3.3 mg protein mL-).
.,::: ............... ........................ - - . ......
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The reaction mixture was incubated at 30'C, and 5 RL aliquots were quenched at
appropriate time points. Each concentration was assayed at least three times. The LCMS
conditions and data fitting methods described above for the steady state kinetic analysis
of d4 strictosidine 1-1 were used.
tetradeuterated
vincoside 43-1
pm
Figure 3-43: Data fit for the steady state kinetic analysis of ajmalicine synthase with d4
vincoside 43-1, with the x-axis in pM d4 vincoside 43-1, and the y-axis in PM ajmalicine
isomer, presumably d4 C-3 R ajmalicine 85, formed per minute.
For the steady state kinetic analysis of isositsirikine synthase with d4 strictosidine
1-1, benzo strictosidine 1-a, and thio strictosidine 1-b, the three strictosidine analogs (10-
400 RM) were first incubated with 5 M SGD. Under these conditions, the reactions with
the highest concentrations of d4 strictosidine 1-1, benzo strictosidine 1-a, or thio
strictosidine 1-b are completely deglycosylated after 5 minutes at 30'C. After this time,
deglycosylated d4 strictosidine 49-1, deglycosylated benzo strictosidine 49-a, or
deglycosylated thio strictosidine 49-b was added to a solution of NADPH (5 mM),
partially purified enzyme fraction from an acetone precipitation (0.9 mg protein mL),
and 50 mM sodium phosphate buffer, pH 7.5, containing 400 mM sodium chloride and
10% glycerol, for a total reaction volume of 200 pL. The reaction mixture was incubated
- - - ------- 
........... . .......  .......... . ........ -
197
at 304C. Each concentration was assayed at least two times. The LCMS conditions and
data fitting methods described above for the steady state kinetic analysis of d4
strictosidine 1-1 were used. The formation of isositsirikine 7 was monitored by peak
integration and normalized to the internal standard.
E *
- tetradeuterated benzo strictosidine 1-a
. stdetosidine 1-1
thio strictosidine 1-b
uM
Figure 3-44: Data fit for the steady state kinetic analysis of isositsirikine synthase with d4
strictosidine 1-1, benzo strictosidine 1-a, and thio strictosidine 1-b, with the x-axis in pM
d4 strictosidine 1-1, benzo strictosidine 1-a, or thio strictosidine 1-b, and the y-axis in pM
d4 isositsirikine 7-1, benzo isositsirikine 7-a, or thio isositsirikine 7-b formed per minute.
I. Radioactive enzyme assay
I synthesized tritiated R NADPH according to a previously published
procedure 129; R NADPH had been previously reported in enzymatic production of
ajmalicine1 09. All reagents were obtained from Sigma Aldrich. Tritiated R NADPH was
................. .... .... . ... ...........
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made from tritiated S NADPH (Figure 3-45). To synthesize tritiated S NADPH, 100 mM
potassium phosphate buffer, pH 8, with 1 mM EDTA (300 jiL) was added to 10 mM
NADP+ (300 pL) and 0.2 mCi [1- 3H]D-glucose (10 nmol). Glucose dehydrogenase
(GDH) (40 tL) was then added, and the reaction was incubated at 37'C for 15 minutes.
Afterwards, 10 mM [1- 1H]D-glucose (3 RL, 30 nmol) was added to the reaction solution
and the reaction proceeded for another 5 minutes; then 10 mM [1- IH]D-glucose (3 jiL, 30
nmol) was added. The reaction was then incubated for an additional 10 minutes. The
specific radioactivity of the final product obtained was estimated to be 2.7 Ci/mmol.
To the solution of S 3H-NADPH, acetone (20 tL) and tbADH (alcohol
dehydrogenase from Thermoanaerobium brockii) (100 [iL) were added, and the mixture
was incubated at 37'C for 12 minutes. The solution was then filtered through an Amicon
Ultra 15 tube with a 30 kDa filter and centrifuged at 4,500g at 4'C for 10 minutes. After
10 minutes, 'H-glucose (300 ptL) and GDH (40 [tL) were added, and the reaction was
incubated at 37'C for 15 minutes to yield R 3H-NADPH. The crude R 3H-NADPH was
used immediately in assays.
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Figure 3-45: Synthesis of R 3H-NADPH129
The relative activities of a series of gel filtration fractions was further confirmed
using an enzyme assay that utilized R 3H-NADPH (Figure 3-46, Table 3-14). In this
assay, deglycosylated strictosidine 49 was incubated with R 3H-NADPH and gel filtration
fractions containing ajmalicine synthase activity. At various time points, aliquots from
the reaction mixture were spotted on thin liquid chromatography (TLC) plates, vacuum
dried, and run in 15% methanol to 85% dichloromethane. The silica in the area of the
plate with the same Rf value as an ajmalicine 4 standard was then removed with a scalpel
and suspended in scintillation fluid, and the radioactivity was measured with a
scintillation counter. The results confirmed previous experiments: the fractions with the
highest ajmalicine synthase activity (C7-8) as measured by LCMS also had the highest
activity as measured by the scintillation counter. Fractions Dll -12 had a slightly higher
slope than fractions D2-3. Assays with no extract or no NADPH had the lowest slopes as
measured by the scintillation counter.
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scintillation counts
Figure 3-46: Rates of tritiated
strictosidine 1-1, SGD, and R
scintillation counts.
time (minutes)
ajmalicine formation using various gel filtration fractions,
3H-NADPH. The x-axis is in minutes, and the y-axis is in
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Graph symbol Fraction Equation R2
color
Most active gel
Pink (m) filtration fractions y = 29.5x + 1002.2 0.98
(C7-8)
Moderately active
Yellow ( ) gel filtration y = 11.3x + 896.6 0.82
fractions (D3-4)
Moderately active
Dark blue (+) gel filtration y = 6.7x + 1232.9 0.72
fractions (DII -12)
Purple (*) No extract control y = 2.5x + 1097.2 0.41
Cyan (*) No NADPH control y =0.04x + 32.3 0.28
Table 3-14: Tritiated NADPH assay using various gel filtration fractions.
J. Chemical reduction of deglycosylated strictosidine with NaCNBH
To chemically reduce deglycosylated d4 strictosidine 49-1, deglycosylated benzo
strictosidine 49-a, and deglycosylated thio strictosidine 49-b with NaCNBH 3, d4
strictosidine 1-1, benzo strictosidine 1-a, and thio strictosidine 1-b (0.2 pmol each) were
first deglycosylated with SGD in 0.15 M citrate phosphate buffer, pH 6. Upon
deglycosylation, the pH of the buffer was raised to 7.5, and 80 or 1200 Amol NaCNBH 3
was added. The reaction mixture was incubated at 30'C, and aliquots (5 RL) were
quenched at appropriate time points in 950 pL methanol. The starting materials and
products were separated using a gradient of 10-90% acetonitrile in water with 0.1%
formic acid over a period of 5 minutes.
.... ..........
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I. Introduction
A. Enzyme isolation via crosslinking
In addition to the traditional, chromatography-based strategies described in
Chapter 3, unknown enzymes can be isolated by crosslinking, or photoaffinity labeling.
In crosslinking, a substrate or inhibitor of an enzyme is modified with a photo-reactive
group. Upon photo-activation, the modified substrate, which is presumably bound to the
enzyme active site, is able to covalently modify the active site of the enzyme of interest.
Aryl azides 86, diazirines 87, and benzophenones 88 are all commonly employed photo-
reactive groups to modify enzymes (Figure 4-1)130. When aryl azides 86 are photo-
activated, a reactive nitrene 89 (Figure 4-1) is generated, whereas when diazirines 87 or
benzophenones 88 are photo-activated, a reactive carbene 90 (Figure 4-1) is generated.
Nitrenes 89 and carbenes 90 are highly reactive, and once formed they will covalently
modify nearby active site residues of the enzyme. One advantage of aryl azides 86 and
diazirines 87 over benzophenones 88 is that the azide 86 and diazirine 87 moieties are
significantly smaller than the benzophenone 88 moiety, making the presence of these
groups less likely to disrupt the ligand-protein interaction. One disadvantage of aryl
209
azides 86 is that the reactive nitrene 89 species can be generated only by using short
wavelength light, which can damage the enzyme of interest. Another disadvantage is that
the N-X bonds formed by nitrenes 89 are not always as stable as the C-X linkages formed
by carbenes 90130.
N=N= (250-380
aryl azide 86 m53 nitrene 89
N-N hv enzyme R
. R, R2 R, R2(330-370 R,*: I2 77Qdiazirine 87 carbene 90
(330-370
benzophenone 88 nm) carbene 90
Figure 4-1: Commonly used photo-reactive groups in crosslinking studies include aryl
azides 86, diazirines 87, and benzophenones 88. A nitrene 89 is a reactive species
generated by photo-activation of an aryl azide 86131; a carbene 90 is a reactive species
generated by photo-activation of a diazirine 87 or benzophenone 8810,32. Nitrenes 89
and carbenes 90 can react with active site residues of an enzyme.
In affinity based protein profiling (ABPP), multifunctional probes that contain a
bio-orthogonal handle and an electrophilic or photo-active group are used to isolate an
enzyme of interest. The electrophilic or photo-active group is used to modify the enzyme,
and the bio-orthogonal handle is used for detection1 33 . The bio-orthogonal handle is in
many cases an alkyne which can be functionalized via Huisgen 1,3 -dipolar cycloaddition,
or "click chemistry." In "click chemistry" a terminal alkyne and an alkyl-azide react to
form a triazole 91 (Figure 4-2). Rhodamine azides 92 or biotin azides 93 are often used to
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facilitate detection of the proteins by fluorescence spectroscopy or streptavidin binding,
respectively (Figure 4-3)134
bio-orthogonal
group
bio-orthogonal
group
me
ligand 30
reactive group
enzyme
2 nm
reactive group
R. 
- "click R.N-NR-N3'=N= chemistry" KNclick chemistry 
-R' O R'
P triazole 91
enzyme
reactive group
Figure 4-2: In affinity based protein profiling, a ligand is modified with both a reactive
electrophilic or photo-active group (green) and a bio-orthogonal handle (blue). Upon
irradiation, the photo-active group covalently modifies the enzyme. "Click chemistry"
using an alkyl azide (R-N3), typically either rhodamine azide 92 or biotin azide 93, is
then used for detection.
O +0
NN0l H
N .- / rhodamine azide 92
/ O -
N 0
N HNN
H NH
H H
S N O O-' N,
H O Nbiotin aZide 93
Figure 4-3: The structures of rhodamine azide 92 and biotin azide 93.
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B. Cinnamyl / sinapyl alcohol dehydrogenases, malate / mannitol
dehydrogenases, and 1 0-hydroxy geraniol oxidoreductase
For the experiments described in this chapter, partially purified C. roseus lysate
containing ajmalicine and isositsirikine synthase activity were subjected to crosslinking.
After crosslinking, proteins were separated on 2D SDS-PAGE and labeled proteins were
then identified by mass spectrometry. The peptide fragments obtained from the mass
spectrometry analysis were used to search a protein sequence database consisting of
expressed sequence tags (ESTs) of C. roseus to identify potential ajmalicine synthase and
isositsirikine synthase candidates. Dr. David Liscombe and Dr. Nathan Ezekiel Nims
(O'Connor group) then used a cDNA library to clone and express in E. coli four
candidates that displayed sequence identity to a variety of known NADPH-binding
enzymes. The four candidates, which were named Cr-2141, Cr- 12, Cr-318, and Cr-611,
had high sequence identity to cinnamyl / sinapyl alcohol dehydrogenases, malate /
mannitol dehydrogenases, and 1 0-hydroxy geraniol oxidoreductase 135 . A brief description
of each type of enzyme is provided below.
Cinnamyl / sinapyl alcohol dehydrogenases
Cinnamyl alcohol dehydrogenases are NADPH-dependent enzymes that catalyze
reduction of p-hydroxycinnamyl aldehyde and p-hydroxycinnamyl aldehyde analogs 94
into the corresponding p-hydroxycinnamyl alcohols 95 (Figure 4-4)120. Sinapyl alcohol
dehydrogenase is a type of cinnamyl alcohol dehydrogenase that reduces sinapyl
aldehyde, or sinapaldehyde 96, to sinapyl alcohol 97 (Figure 4-4). The alcohols serve as
precursors for both lignin and lignan. Lignin is a structural, heterogeneous biopolymer
found in all vascular plants 136. Lignans are a class of phytoestrogens derived from
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phenylalanine that are formed via dimerization of substituted cinnamyl alcohols. Lignans
have important roles in both human health and plant defensem. One medicinal lignan is
the anti-viral agent podophyllotoxin 98, which is used in the semi-synthesis of the anti-
cancer compounds etoposide 99 (Eposin@, Vepesid@, VP-16@), etoposide phosphate
100 (Etopophos@), and teniposide 101 (Vumon@) (Figure 4-5). Podophyllotoxin 98 is
produced by the Podophyllum species, which is also known as the American
138
Mayapple
o OH
R,, H cinnamyl alcohol R2  N.,'
+ NADPH dehydrogenase R + NADP+
R3  R3
p-hydroxy- cinnamyl alcohol
cinnamyl aldehyde analogs 95
analogs 94
0 HH
N. H sinapyl alcohol HO + NADP+
HO + NADPH dehydrogenase HO
sinapaldehyde 96 sinapyl alcohol 97
Figure 4-4: Cinnamyl alcohol dehydrogenases are NADPH-dependent enzymes that
catalyze the reductions of p-hydroxycinnamyl aldehyde (RI OH; R2 = R= H) and p-
hydroxycinnamyl aldehyde analogs 94 into the corresponding cinnamyl alcohol analogs
97120 Sinapyl alcohol dehydrogenases are NADPH-dependent enzymes that catalyze the
reduction of sinapaldehyde 96 to sinapyl alcohol 97.
213
OH
o
o
0 0
podophyllotoxin
O O
KI l .0
00
- 0
0 0
OH
98 etoposide 99
HO HO 
SHO~~O0 N 
HO 0
00
0 0
H-0 09 0.
OH
etoposide teniposide 101
phosphate 100
Figure 4-5: Structures of podophyllotoxin 98, etoposide 99, etoposide phosphate 100, and
teniposide 101120.
Other lignans include matairesinol 102 and secoisolariciresinol 103, which serve
as precursors to enterolactone 104 and enterodiol 105 (Figure 4-6)20. Intestinal bacteria
form enterolactone 104 and enterodiol 105 in the gut from matairesinol 102 and
secoisolariciresinol 103 following ingestion of food high in fiber 37,139. Enterolactone
104 and enterodiol 105 are believed to help protect against colon, prostate, and breast
cancers.
matairesinol secoisolariciresinol enterolactone enterodiol
102 103 104 105
Figure 4-6: Structures of matairesinol 102, secoisolariciresinol 103, enterolactone 104,
and enterodiol 10512.
Many cinnamyl alcohol dehydrogenases are reported to be zinc-dependent 2 . For
example, in a cinnamyl alcohol dehydrogenase from Arabidopsis thaliana shown below
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in Figure 4-7, the catalytic Zn 2 ion (shown in red) is coordinated to the carbonyl oxygen
of the cinnamyl aldehyde analog substrate (shown in black) and facilitates the reduction
of the aldehyde to an alcohol 2 0.
H
H'O0
H
- Thr49
H Zn 2H - - H 
O"'
H I Asp57
HRN , N 
- is52
HO - K H'
R, NADPHSubstrate 0 NH:
Figure 4-7: Cinnamyl alcohol dehydrogenases are zinc-dependent. This figure is taken
from Youn et al.
Five of the most frequently observed cinnamyl aldehyde analogs 94 utilized in
lignin and lignan biosynthesis are p-coumaryl aldehyde 106, caffeyl aldehyde 107,
coniferyl aldehyde 108, 5-hydroxy coniferyl aldehyde 109, and sinapaldehyde 96 (Figure
4-8)14o'141. Cinnamyl alcohol dehydrogenases typically do not display absolute specificity
for a given cinnamyl aldehyde analog 94140. For example, in a study of six cinnamyl
alcohol dehydrogenases from A. thaliana, all six cinnamyl alcohol dehydrogenases were
able to reduce each of the five aldehydes shown in Figure 4-8.
. ...... ..
... . .........
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p-coumaryl caffeyl coniferyl 5-hydroxy sinapaldehyde
aldehyde aldehyde aldehyde coniferyl 96
106 107 108 aldehyde
109
Figure 4-8: Structures of common lignin and lignan precursors p-coumaryl aldehyde 106,
caffeyl aldehyde 107, coniferyl aldehyde 108, 5-hydroxy coniferyl aldehyde 109, and
sinapaldehyde 96140'141.
Malate dehydrogenase and mannitol dehydrogenase
Malate dehydrogenase, an enzyme in the citric acid cycle, catalyzes the reversible
NADP*-dependent conversion of malate 110 to oxaloacetate 111 (Figure 4-9)142
Additionally, in gluconeogenesis, malate dehydrogenase facilitates the transport of
oxaloacetate 111 out of the mitochondria by reducing oxaloacetate 111 to malate 110.
Once malate 110 has reached the cytosol, it is oxidized back to oxaloacetate 111 by
142
malate dehydrogenase142
0 ~ malate0
HO OH + NADP+ dehydrogenase H0 OH + NADPH0 OH o O
malate 110 oxaloacetate 111
Figure 4-9: Malate dehydrogenase catalyzes the reversible NADP*-dependent conversion
of malate 110 to oxaloacetate 111142.
Mannitol dehydrogenase catalyzes the reversible NADP*-dependent conversion
of D-mannitol 112 to D-mannose 113 (Figure 4-10), the first step in the catabolism of D-
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mannitol 112143. Mannitol 112 is a six-carbon acyclic alcohol present in more than 70
higher plant families 43
OH OH OH mannitol
HOOH + NADP+ dehydrogenase
OH OH
D-mannitol 112
Figure 4-10: Mannitol dehydrogenase catalyzes
conversion of D-mannitol 112 to D-mannose 113143.
OH OH 0
HOI
HO- + NADPHOH OH
D-mannose 113
the reversible NADP*-dependent
10-hydroxy geraniol oxidoreductase
10-hydroxy geraniol oxidoreductase catalyzes the conversion of 10-hydroxy
geraniol 23 to 1O-oxo geraniol 72 (Figure 4-11). A protein that catalyzes this reaction has
been isolated and characterized from C. roseus, though because this enzyme reduces a
variety of unsaturated aldehydes, it is not certain whether this is the physiological
function (personal communication, Professor Thomas McKnight, Texas A&M
University). This protein is 360 amino acids, is 38,937 Da144'145, and has 79% identity
with a cinnamyl alcohol dehydrogenase from Nicotiana tabacum (common
tobacco) 35 ,146
\ OH
OH
10-hydroxy
geraniol 23
10-hydroxy geraniol z 0
+ NADP+ oxidoreductase I11
1O-oxo
geraniol 72
+ NADPH
Figure 4-11: 1 0-hydroxy geraniol oxidoreductase catalyzes the NADP*-dependent
conversion of 10-hydroxy geraniol 23 to 1O-oxo geraniol 72144'145'147-149.
217
In the biosynthesis of loganic acid 42, a precursor to secologanin 17, from
geraniol 22 (Figure 4-12), geraniol-10-hydroxylase and 10-hydroxy geraniol
oxidoreductase are the only two enzymes that have been isolated. The enzymes
converting 10-oxo geraniol 72 to loganic acid 42 remain to be identified' 922
geraniol- 10- 10-hydroxy
OH hydroxylase OH geraniol
(G1OH) oxidoreductaseOH 0
geraniol 22 10-hydroxy 10-oxo
geraniol 23 geraniol 72
H 0 0
"OH H /
H ,OH___H"H 
- '
SH OH
iridotrial 24
glycosylation,
oxidation
HQ
H" OH hydroxylation H' OHHO HO I OH W. HO ~
H0 O HO OH
0 OH 0 OH
7-deoxyloganic acid loganic acid 42
Figure 4-12: In the biosynthesis of loganic acid 42, geraniol 22 is hydroxylated by
geraniol-10-hydroxylase to form 10-hydroxy geraniol 23, which is then oxidized by 10-
hydroxy geraniol oxidoreductase to form 10-oxo geraniol 72. The conversion of 10-oxo
geraniol 72 to loganic acid 42 involves a number of enzymes that have not been
isolated19 22.
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11. Results
A. Crosslinking experiments
Ajmalicine synthase and isositsirikine synthase have proven difficult to purify to
homogeneity using traditional protein purification methods, as described in Chapter 3. As
an alternative approach, in collaboration with Dr. Elizabeth McCoy and Dr. Aimee Usera,
I performed a crosslinking experiment in an attempt to isolate ajmalicine synthase. Initial
crosslinking experiments were performed by Dr. Elizabeth McCoy3 6, and these efforts
were continued by Dr. Aimee Usera and me. In the crosslinking experiments, I used a
bifunctional probe, 1 1-azido-pentynyl-ester strictosidine 114 (Figure 4-13)150; Dr. Aimee
Usera concurrently performed an identical experiment using 12-azido-pentynyl-ester
strictosidine 115. The indole azide moiety served as the photoaffinity label. Indole azides
have been reported to label a wide variety of proteins after irradiation at 280-300 nm to
generate the reactive nitrene species. For example, tryptophan synthase has been labeled
by 6-azidotryptophan151, and 5-azido-indole-3-acetic acid, an analog of the plant auxin
152indole-3-acetic acid, was shown to covalently modify its auxin receptor . An indole
azide was also chosen because 4-, 5-, 6-, and 7-azidotryptamines had been previously
synthesized and shown through precursor directed biosynthesis studies to be accepted by
downstream enzymes in C. roseus15 0. Therefore, it seemed reasonable that downstream
enzymes would bind the azido-derivatized substrate analogs. Similarly, a pentynyl ester
was used because a previous study showed that C. roseus hairy root cultures co-cultured
with pentynyl-ester strictosidine 1-t produced ajmalicine 4, serpentine 5, and
isositsirikine 7 analogs containing pentynyl esters, thus indicating that downstream
enzymes can accept substrates containing a pentynyl ester87'105'150.
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In the crosslinking experiment that I performed (Figure 4-13), 11-azido-pentynyl-
ester strictosidine 114 served as a bifunctional substrate designed to covalently modify
and label ajmalicine synthase. In this experiment, 1 I-azido-pentynyl-ester strictosidine
114 was first incubated with SGD to form deglycosylated 11 -azido-pentynyl-ester
strictosidine 116. Upon deglycosylation, I added NADPH and a partially purified C.
roseus cell culture lysate containing ajmalicine synthase activity. The reaction mixture
was then irradiated with 302 nm light to generate the reactive nitrene moiety from the
indole azide (Figure 4-13). The alkyne was then modified with rhodamine azide 92 via
Huisgen 1,3-dipolar cycloaddition, or "click chemistry" (Figure 4-13), and the labeled
proteins were separated by 2D SDS-PAGE and identified by fluorescence. Since 12-
azido-pentynyl-ester strictosidine 115 appeared to label fewer proteins than 1 1-azido-
pentynyl-ester strictosidine 114, proteins labeled by 12-azido-pentynyl-ester strictosidine
115 were subjected to sequencing (Figure 4-14). The genome of C. roseus has not been
sequenced, and so the peptides identified via mass spectrometry were used to probe the
EST database of C. roseus. Potential candidates for ajmalicine synthase and isositsirikine
synthase were thus identified. The results from a BLAST (Basic Local Alignment Search
Tool) search of the amino acid sequences obtained from each spot are shown in Table
-135
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Figure 4-13: In the crosslinking experiments of C. roseus enzymes, the probe 1 l-azido-
pentynyl-ester strictosidine 114 was incubated with SGD, followed by NADPH and a
partially purified enzyme fraction containing ajmalicine synthase activity. The reaction
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mixture was then irradiated with 302 nm light to generate the reactive nitrene moiety, and
the alkyne was then derivatized with rhodamine azide 92.
sizeT
pI-+
Figure 4-14: A 2D SDS-PAGE of crosslinked enzymes using 11 -azido-pentynyl-ester
strictosidine 114. The 2D SDS-PAGE was observed with a UV transilluminator at 254
nm (Bio-Rad).
sizet
pL-
Figure 4-15: A 2D SDS-PAGE of crosslinked enzymes using 12-azido-pentynyl-ester
strictosidine 115, with the enzymes that were excised and sent for sequencing labeled in
green. The 2D SDS-PAGE was observed with a UV transilluminator at 254 nm.
. .. . ..... . ....
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Spot EST accession number Enzyme type
CR02026D12 malate dehydrogenase
CR02028A05 malate dehydrogenase
1 RT00013RT3_013_B06_27_MAY2004_046_abI fructose-bisphosphate aldolaseCR03023A01 sinapyl alcohol dehydrogenase
SM-JB R14-G08 T3 G08 3100401 14 abI fructose-bisphosphate aldolase
CROLFINGEX2 165_GOl_25AUG2006_003 10-hydroxy geraniol oxidoreductase
CR02028A05 malate dehydrogenase
CR02026D312 malate dehydrogenase
LB00003RT3003_A03_04JUN2004_-031_-ab I malate dehydrogenase
2 G08-T3__G08_-3100401 -14_-ablI fructose-bisphosphate aldolase
CR0 1002H09 fructose-bisphosphate aldolase
CROLFINGEX2 110iC06 n23AUG2004y04 malate dehydrogenase
CR010 12B09 fructose-bisphosphate aldolase
CR02028A05 malate dehydrogenase
RT00013R T3 013 B06 27MAY2004 046 abl fructose-bisphosphate aldolase
SM-JB_ R14-G08-T3_G08_ 3100401 14 abi fructose-bisphosphate aldolase
LBO 3TT3003_A0304JUN20042031Hab9 malate dehydrogenase
3 CR03023A U 0 sinapyl alcohol dehydrogenase
CR04012B03 u-hydroxy geraniol oxidoreductase
CR02024C06 4-diphosphocytidyl-2-C-methyl-D-
erythritol kinase
CROLFING EX2 101 B09 17AUG2006 077 caffeic acid 0-methyltransferase
CR02028A05 malate dehydrogenase
CR0 1002H09 fructose-bisphosphate aldolase
4 CR0101 5D08 malate dehydrogenase
CROLFINGEX2 f110coC06 s-23AUG2006b04 malate dehydrogenase
CR0101 iBOl malate dehydrogenase
CR02023A0 1 sinapyl alcohol dehydrogenase
LBOOO3RT3003_A03_-04JUN2004_031 ab 1 malate dehydrogenase
5 CR020 12A04 10-hydroxy geraniol oxidoreductase
RTOOO 14RT3014 -Fl 28MAY2004_085 abe 3-phosphoglycerate kinase
CR04016D0 alcohol dehydrogenase
RTOOO1I5R -T3 -015_-C09_F28MAY2004 075_ab I fructose-bisphosphate aldolase
LBOO35RT3R035_B 1_21JUN2004093ab fructose-bisphosphate aldolase
CR02028A 5 malate dehydrogenase
6 CROLFINGEX2_110_C06_23AUG2006_044 malate dehydrogenase
CR0202612 malate dehydrogenase
LB00003R T3 003 A03 04JUN2004 031 abl malate dehydrogenase
CRS1008B12 formate dehydrogenase
RT00015R T3 015 C09 28MAY2004_075 abI fructose-bisphosphate aldolase
G08T3G08 3100401_14 _ abi fructose-bisphosphate aldolase
CR01031DII1 fructose-bisphosphate aldolase
7 CR02028A05 malate dehydrogenase
LB00003R_-T3_-003 -A03_-04JUN2004 -031_-ab 1 malate dehydrogenase
CROLFINGEX2 110 C06 23AUG2006 04 malate dehydrogenase
CRS1008B12 formate dehydrogenase
CR03023H0 1 serine protease
RTOOO15R T3 015 C09 28MAY2004 075 abI fructose-bisphosphate aldolase
_ GSM-JRR4-G08 T3_G08_3100401 14_abi fructose-bisphosphate aldolase
LB 35RT3R035H03 21JUN2004017ab fructose-bisphosphate aldolase
CR03022C07 mitochondrial chaperonin
CR04015E12 mitochondrial chaperonin
9 CR04015EI2 mitochondrial chaperonin
LB00007R T3 007 B05 15JUN2004 045 abI mitochondrial chaperonin
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CR02019F1 1 mitochondrial F 1 -ATPase beta subunit
CR03023H01 serine protease
CR03022C07 serine protease
CR0 1020A03 alanine aminotransferase
CR02028B05 alanine aminotransferase
1 SM-JB S4-BO1 T3 BO 3100192 03 abl alanine aminotransferase
CR01020E07 aldehyde dehydrogenases
LB00007R T3 007 B05 15JUN2004 045 abI mitochondrial chaperonin
10 RT00038RT3_038_DO5_01JJUN2004_-41_abI pyruvate dehydrogenase
RTOOO19R T3_019 G12 31MAY2004_084_abl alcohol dehydrogenase, class V
CR0101OC 11 succinyl CoA-ligase
1 SM-JB R6-E09 T3 E09 3100310 09 abl aspartyl protease
1RT00028R T3 028 B09 01JUN2004 077 abI alcohol dehydrogenase, class V
1 SM-JB S4-BO1 T3 BOl 3100192_03_abl alanine aminotransferase
LB00002R T3 002 D07 04JUN2004_057_abl enolase
RT00038R T3_038 D05 OO1JUN2004_041_abl pyruvate dehydrogenase
CR03023A01 sinapyl alcohol dehydrogenase
11 CRO1OOCIl succinyl-CoA-ligase
CR02023D04 enolase
CR02028B05 alanine aminotransferase
CR03023H01 serine protease
LB00007R T3 007 B05 15JUN2004 045 abl mitochondrial chaperonin
1 SM-JB R6-E09 T3 E09 3100310 09 abI aspartyl protease
RT00028R T3 028 B09 01JUN2004 077 abI alcohol dehydrogenase, class V
1 SM-JB S4-BO1 T3 BO 3100192_03_abI alanine aminotransferase
CR03023A01 sinapyl alcohol dehydrogenase
RT00014RT3 014_ F11 28MAY2004_085 abl 3-phosphoglycerate kinase
CR02028B05 alanine aminotransferase
12 CR0101OC11 succinyl-CoA-ligase
LB00002R T3_002 D07 04JUN2004 057_abl enolase
CR03023H01 serine protease
Cr0203 IB05 alanine aminotransferase
CR01012B04 enolase
RT00027R T3 027 F12 01JUN2004 086 abl enolase
1_SM-JBS4-B01 t3_BO1_3100192_03_abI alanine aminotransferase
CRO1012BO4 enolase
13 CR020 10G03 enolase
CR02028B05 alanine aminotransferase
RT0028RT3_028 B09 O1JUN2004 077 abl alcohol dehydrogenase, class V
CR03023A01 sinapyl alcohol dehydrogenase
14 RT00038R T3 038 DO5 O1JUN2004 041 abl pyruvate dehydrogenase
CR02028A05 malate dehydrogenase
RTOOO13RT3-13 B06 27MAY2004_046_abl fructose-bisphosphate aldolase
CR02026D12 malate dehydrogenase
15 RT00003R T3 003 DlI 18MAY2004 089 abl enoyl-[acyl-carrier-protein]
1_SM-JBR14-G08_T3_G08_3100401_14_abi fructose-bisphosphate aldolase
CROLFING EX2 165 GO1 25AUG2006 003 10-hydroxy geraniol oxidoreductase
RT00038R T3_038 DOSO1JUN2004 041_abi pyruvate dehydrogenase
RT00028R_-T3_-028 -B09_O 1 JUN2004 -077_-abi alcohol dehydrogenase, class V
1_SM-lBR14-G08_T3__G08_3100401_14_abi fructose-bisphosphate aldolase
16 CRO1fc2BO4 enolase
CR0 1004C04 sinapyl alcohol dehydrogenase
CROLFING EX2 110 C06 23AUG2006 044 malate dehydrogenase
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Table 4-1: Protein candidates 1-16 sequenced from the 2D SDS-PAGE shown in Figure
4-15. The identities of the proteins, as determined by a BLAST search of the mass
spectrometry data against the C. roseus EST database, are shown135. When the peptide
sequence matched to more than one EST sequence, all matching EST sequences are
shown. The ESTs are listed in order of likely match.
From the crosslinking study described above and from a preliminary crosslinking
study previously performed by Dr. Elizabeth McCoy 36, four enzymes - Cr-2141, Cr-12,
Cr-318, and Cr-611 - have been successfully cloned by Dr. David Liscombe and Dr.
Nathan Ezekiel Nims. Dr. Liscombe, Dr. Nims, and I heterologously expressed and
purified to homogeneity each gene in E. coli. The four enzymes were chosen for further
analysis because all have high sequence identity to NADP-dependent dehydrogenases,
and thus could potentially display the desired reductase activity. Cr-2141 and Cr- 12 were
each identified from protein 1 (Table 4-1) in this study, Cr-611 was identified from
protein 5 (Table 4-1) in this study, and Cr-318 was identified in a preliminary
crosslinking study performed by Dr. McCoy 36. Descriptions of the cloning, expression,
and purification procedures are provided in the Materials and Methods section, and were
performed with Dr. Liscombe and Dr. Nims. Additional enzymes identified in the
crosslinking study will continue to be cloned and functionally characterized.
All four enzymes were assayed for ajmalicine synthase and isositsirikine synthase
activity as described in Chapter 3. Unfortunately, no ajmalicine synthase and
isositsirikine synthase activity was observed for any of the four enzymes. Nonetheless,
efforts were made to determine the function of these novel C. roseus enzymes, and we
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uncovered an enzyme that displays sinapyl alcohol dehydrogenase activity and is
presumably involved in lignin biosynthesis.
B. Characterization of enzymes isolated via crosslinking experiments
Cr-2141 characterization
Based on the amino acid sequence, the calculated pI and molecular weight of Cr-
2141 are 6.86 and 38,411 Da, respectively 146. A BLAST search of the Cr-2141 amino
acid sequence shows that Cr-2141 has the highest sequence identity to cinnamyl / sinapyl
alcohol dehydrogenases and 1 0-hydroxy geraniol oxidoreductase3 5. The top ten results in
the BLAST search of Cr-2141 against the protein database are shown below (Table
4-2)135. Table 4-2 below shows the score, protein ID probability, accession number, entry
name, and species for each cinnamyl alcohol dehydrogenase or 10-hydroxy geraniol
oxidoreductase. The score is calculated based on the substitutions and gaps associated
with the aligned sequences. A higher score indicates a better alignment, with a score of
600 indicating a perfect alignment. The protein ID probability indicates the percentage of
identical amino acids between Cr-2141 and the given enzyme in the table.
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Score Protein ID Accession Entry name Species
probability number
501 79% B91IT8 Sinapyl alcohol Populus trichocarpadehydrogenase (Western balsam poplar)
Cinnamyl Populus trichocarpa
501 79% B2Z6P7 alcohol Western balsam poplar)dehydrogenase
Sinapyl alcohol Populus tremula x
499 79% 0516D6 dehydrogenase- Populus tremuloides
like protein
498 78% Q94G59 Sinapyl alcohol Populus tremuloidesdehydrogenase (Quaking aspen)
Cinnamyl
491 77% B9H9N8 alcohol Populus trichocarpadehydrogenase- (Western balsam poplar)
like protein
10-hydroxy Camptotheca acuminata
490 80% Q7XAB2 geraniol Ca ptote m
oxidoreductase (Happy tree)
10-hydroxy Catharanthus roseus
486 78% Q6V4HO geraniol (Madagascar periwinkle)
oxidoreductase (Vinca rosea)
Alcohol Ricinus communis
485 78% B9T7R7 dehydrogenase, (Castor bean)
putative
Cinnamyl
485 76% B91IG5 alcohol Populus trichocarpadehydrogenase- (Western balsam poplar)
like protein
Cinnamyl
484 78% B9P5A5 alcohol Populus trichocarpadehydrogenase- (Western balsam poplar)
like protein
Table 4-2: BLAST results of Cr-2141. The 10 enzymes with the highest sequence identity
135to Cr-2141 are shown
Because of the high sequence identity of Cr-2141 to cinnamyl alcohol
dehydrogenases, I assayed cinnamyl aldehyde analogs with this enzyme. In the assays,
the cinnamyl aldehyde analogs were incubated with Cr-2141 and NADPH, and product
formation was monitored via LCMS. The commercially available cinnamyl aldehyde
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analogs sinapaldehyde 96 and coniferyl aldehyde 108 were reduced by Cr-2141 and
NADPH to form sinapyl alcohol 97 and coniferyl alcohol 118, respectively (Figure 4-16).
Sinapaldehyde 96 and coniferyl aldehyde 108 are known to be turned over by cinnamyl
alcohol dehydrogenases from Arabidopsis, and are known substrates in lignan and lignin
biosynthesis (Figure 4-8)140. Although p-coumaryl aldehyde 106, caffeyl aldehyde 107,
and 5-hydroxy coniferyl aldehyde 109 are also natural substrates for cinnamyl aldehyde
dehydrogenases (Figure 4-8) 40, they are not commercially available, and so they were
not assayed in this screen. Authentic sinapyl alcohol 97 and coniferyl alcohol 118
standards were used to confirm the identities of the products.
0 OH
0 r-- H Cr-2141 0
HO . NADPHIN 0HO H HO
sinapaldehyde 96 sinapyl alcohol 97
0 OH
Oj ~H Cr-2 141H NADPH 0-HIHO H HO
coniferyl aldehyde 108 coniferyl alcohol 118
Figure 4-16: Sinapaldehyde 96 and coniferyl aldehyde 108 were reduced by Cr-2141 and
NADPH to form sinapyl alcohol 97 and coniferyl alcohol 118, respectively.
Cr-2141 was also tested with nonnatural cinnamyl aldehyde derivatives. None of
these substrates, which included a-methyl-trans-cinnamaldehyde 119, 6-hydroxychrome-
3-carboxaldehyde 120, sinapic acid 121, 3,4,5-trimethoxy sinapic acid 122, and
cinnamide 123 (Figure 4-17) was accepted by Cr-2141.
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Figure 4-17: Cinnamyl aldehyde derivatives not reduced by Cr-2141 and NADPH
include a-methyl-trans-cinnamaldehyde 119, 6-hydroxychrome-3-carboxaldehyde 120,
sinapic acid 121, 3,4,5-trimethoxy acid 122, and cinnamide 123.
Steady state kinetic analysis of Cr-2141 was performed to determine if Cr-2141
has kinetic parameters similar to those of other reported cinnamyl alcohol
dehydrogenases. Kim et al.140 have reported the kinetic parameters for five cinnamyl
alcohol dehydrogenases from A. thaliana with the substrates shown in Figure 4-8. Km
values ranging from 13 to 3,685 gM and kcat values ranging from 3 to 871 min' were
observed 140. In the steady state kinetic analysis of Cr-2141, I chose sinapaldehyde 96 as
the substrate instead of coniferyl aldehyde 108 (Table 4-3) because Kim et al.140 had
reported that sinapaldehyde 96 had higher kcat values on average than coniferyl aldehyde
108. Qualitative analysis with Cr-2141 also revealed this preference for sinapaldehyde
96. Though sinapaldehyde 96 showed Km values consistent with those reported by Kim et
al. 140, I observed lower kcat values. Nevertheless, the kinetic parameters are consistent
with Cr-2141 playing a role in lignin biosynthesis in C. roseus.
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Substrate Km Vmax kcat kcat/KmSubtrae4M) (pM min-l (min-) (ptM-' min-1
Sinapaldehyde 96 335.66 + 87.35 0.13 + 0.01 0.092 +0.01 2.74 x 1~
Table 4-3: Steady state kinetic values for sinapaldehyde 96 NADPH-dependent reduction
by Cr-2141.
Cr-2141 was assayed for sinapaldehyde dehydrogenase activity based on the
sequence identity of this enzyme to known enzymes in lignin biosynthesis. However,
although Cr-2141 turns over the appropriate substrates in vitro, this does not prove that
Cr-2141 plays a role in lignin biosynthesis in C. roseus. Additional experiments,
described in the Discussion section of this chapter, are required to validate the function of
this gene inplanta.
Cr-12 characterization
Based on the amino acid sequence, the calculated pI and molecular weight of Cr-
12 are 6.21 and 38,870 Da, respectively 146. Cr-12 has the highest sequence identity to
cinnamyl / sinapyl alcohol dehydrogenases, and has high sequence identity to 1 0-hydroxy
geraniol 23 from Camptotheca acuminata, as well as to mannitol dehydrogenase from
Apium graveolens (celery) (Table 4-4). The first ten results from a BLAST search are
shown below (Table 4-4)13.
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Score Protein ID Accession Entry name Speciesprobability number
Cinnamyl Populus trichocarpa
435 73% B2Z6P7 alcohol (Western balsam
dehydrogenase poplar)
Sinapyl alcohol Populus tremula x
434 73% 0516D6 dehydrogenase- Populus tremuloides
like protein
432 72% 094G59 Sinapyl alcohol Populus tremuloidesdehydrogenase (Quaking aspen)
Sinapyl alcohol Populus trichocarpa432 73% B91IT8 dehydrogenase (Western balsam
poplar)
10-hydroxy Camptotheca
432 73% Q7XAB2 geraniol acuminata (Happy tree)
oxidoreductase
Cinnamyl Populus trichocarpa
429 72% B9H9N8 alcohol (Western balsamdehydrogenase- poplar)
like protein
Putative
427 70% A5CA75 uncharacterized Vitis vinifera (Grape)
protein
Cinnamyl Populus trichocarpa
426 72% B91IG5 alcohol (Western balsamdehydrogenase- poplar)
like protein
Cinnamyl Populus trichocarpa
425 72% B9HNN3 alcohol (Western balsamdehydrogenase- poplar)
like protein
425 73% 038707 Mannitol Apium graveolens4 dehydrogenase (Celery)
Table 4-4: BLAST results of Cr-12. The 10 proteins with the highest sequence identity to
135Cr-12 are shown13s
Cr-12 failed to show dehydrogenase activity when incubated with sinapaldehyde
96 and NADPH. Given that Cr-12 also displayed sequence similarity to 10-hydroxy
geraniol oxidoreductase, Cr-12 could potentially be an enzyme involved in secologanin
17 biosynthesis, such as one of the enzymes converting 10-oxo geraniol 72 to loganic
acid 42 (Figure 4-12)19-22. Future efforts could involve synthesizing or isolating the
intermediates between 10-oxo geraniol 72 and loganic acid 42 for use in activity assays to
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determine the function of Cr-12. Additionally, disrupting the function of the gene in vivo
could also provide clues to its function.
Cr-318 characterization
The calculated pI and molecular weight of Cr-318 are 6.09 and 38,770 Da,
respectively, based on the predicted amino acid sequence1 46. Cr-318 has the highest
sequence identity to cinnamyl / sinapyl alcohol dehydrogenases (Table 4-5). The first ten
results from a BLAST search are shown below (Table 4-5)135. However, as with Cr-12,
assays performed with sinapaldehyde 96 did not show sinapyl alcohol dehydrogenase
activity. The function of Cr-318 remains to be determined.
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Score Protein ID Accession Entry name Speciesprobability number
Cinnamyl Populus trichocarpa
392 67% B2Z6P7 alcohol (Western balsam
dehydrogenase poplar)
Sinapyl alcohol Populus tremula x
392 67% 0516D6 dehydrogenase- Populus tremuloides
like protein
390 67% 094G59 Sinapyl alcohol Populus tremuloidesdehydrogenase (Quaking aspen)
Sinapyl alcohol Populus trichocarpa390 67% B911T8 S dna se (Western balsam
dehydrogenase poplar)
Cinnamyl Populus trichocarpa
385 66% B91IG5 alcohol (Western balsamdehydrogenase- poplar)
like protein
Putative
385 66% A5CA75 uncharacterized Vitis vinifera (Grape)
protein
Putative ouu rcoapx
383 66% A9PJN2 uncharacterized Populus trichocrpa x
protein
Cinnamyl Populus trichocarpa
381 66% B9P5A5 alcohol (Western balsamdehydrogenase- poplar)
like protein
Cinnamyl Populus trichocarpa
381 66% B9HNN3 alcohol (Western balsamdehydrogenase- poplar)
like protein poplar)
Cinnamyl Populus trichocarpa
380 66% B9HNNO alcohol (Western balsamdehydrogenase- poplar)
like protein
Table 4-5: BLAST results of Cr-318; the 10 enzymes with the highest sequence identity
135
to Cr-318 are shown
Cr-611 characterization
The calculated pI and molecular weight of Cr-611 are 6.02 and 35,593 Da,
respectively 46. Cr-611 has the highest sequence identity to malate dehydrogenases
(Table 4-6). The first ten results from a BLAST search are shown below (Table 4-6)' .
The high score (588-596) and protein ID probabilities (91-93%) shown in Table 4-6
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indicate that Cr-61 1 is most likely a malate dehydrogenase. After validating that this
enzyme did not exhibit ajmalicine synthase or isositsirikine synthase activity, functional
characterization of this enzyme was not pursued further.
Score Protein ID Accession Entry name Species
probability number
596 93% Q9FSFO Malate Nicotiana tabacum
dehydrogenase (Common tobacco)
595 92% D23318 Malate Gossypium hirsutumdehydrogenase (Upland cotton)
Malate Arabidopsis thaliana
593 93% P57106 dehydrogenase, (Mouse-ear cress)
cytoplasmic 2
Malate Populus trichocarpa
593 91% B9NBW3 dehydrogenase (Western balsam
poplar)
592 93% 08LA78 Malate Arabidopsis thalianadehydrogenase (Mouse-ear cress)
Malate
592 92% 008062 dehydrogenase, Zea mays (Maize)
cytoplasmic
592 92% C4IZW9 dehydrogenase Zea mays (Maize)
591 93% B6SLL8 dehydrogenase Zea mays (Maize)
590 92% Q2PYY8 Malate Solanum tuberosumdehydrogenase (Potato)
588 92% C5WYF2 Malate Sorghum bicolordehydrogenase (Sorghum)
Table 4-6: BLAST results of Cr-61 1; the 10 enzymes with the highest sequence identity
135to Cr-61 1 are shown.
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III. Discussion
Although Cr-2141, Cr-12, Cr-318, and Cr-611 do not exhibit the desired
ajmalicine synthase or isositsirikine synthase activity, these proteins undoubtedly perform
other metabolic functions in C. roseus. I discovered that Cr-2141 exhibits sinapyl
dehydrogenase activity, reducing sinapaldehyde 96 to sinapyl alcohol 97 with a kcat/Km
value of 2.74 x 10-4 RM_' min-. (Table 4-3). Cr-2141 may also exhibit dehydrogenase
activity with other substrates. Sinapyl alcohol dehydrogenases often have broad substrate
specificities; Kim et al.140 reported that six cinnamyl alcohol dehydrogenases from A.
thaliana reduce five different cinnamyl aldehyde analogs (96 and 106-109) (Figure 4-8)
with similar catalytic efficiency. Intriguingly, the R. serpentina alkaloid biosynthetic
enzyme perakine reductase shows cinnamyl alcohol dehydrogenase activity in addition to
perakine reductase activity; it reduces cinnamaldehyde 126 to cinnamyl alcohol 127 and
121
reduces perakine 124 to raucaffrinoline 125 (Figure 4-18) . Notably, perakine reductase
reduces cinnamaldehyde 126 to cinnamyl alcohol 127 with a 31% higher relative activity
121than when it reduces perakine 124 to raucaffrinoline 125 (Figure 4-18) . Therefore in
vitro enzymatic activity assays do not always provide a definitive answer for the
metabolic function of an enzyme.
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perakine 124 raucaffrinoline 125
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Figure 4-18: NADPH-dependent perakine reductase reduces the TIA perakine 124 to
raucaffrinoline 125; the aldehyde that is reduced is shown in red. Perakine reductase also
121reduces cinnamaldehyde 126 to cinnamyl alcohol 127
The relatively high sequence similarity of Cr-2141 to known cinnamyl / sinapyl
alcohol dehydrogenases led us to test Cr-2141 for this activity. The activity is clear, but
the catalytic efficiency is slightly lower than those reported for cinnamyl / sinapyl alcohol
dehydrogenases identified from A. thaliana. Whereas Cr-2141 has a kcat of 0.092 min 1
for sinapaldehyde 96, six cinnamyl alcohol dehydrogenases from A. thaliana have kcat
values from 3 to 871 min ; this lower kcat value may simply indicate that Cr-2141 is a
less efficient enzyme, or that it is not expressed in a highly functional form under
heterologous expression conditions. It is also possible that Cr-2141 plays some additional
role in C. roseus metabolism, and the sinapyl alcohol dehydrogenase activity is
adventitious. The function of Cr-2141 can be more definitively assessed by examining its
expression in vivo. Future work will examine the expression levels of Cr-2141 by
measuring Cr-2141 mRNA levels by Northern blot or qPCR, and evaluating whether the
expression levels are comparable in level and location to other known lignin biosynthesis
236
genes. Moreover, the function of Cr-2141 can be disrupted in C. roseus using RNAi35.
After disruption of this gene, the resulting phenotype or metabolic profile can be
compared with wild-type tissue to provide more information about the role of this
enzyme in the plant.
We note that Cr-2141 also exhibits 80% sequence identity to 10-hydroxy geraniol
oxidoreductase from Camptotheca acuminata, an enzyme that also catalyzes the inter-
conversion of an aldehyde and an alcohol. It is possible that Cr-2141 may also act on one
of the geraniol 22 derived substrates of the secologanin 17 pathway. The substrates of the
enzymes that convert 10-oxo geraniol 72 to loganic acid 42 (Figure 4-12) could be
synthesized or isolated and then assayed with Cr-2141 in vitro. If Cr-2141 plays a role in
secologanin 17 biosynthesis, disruption of Cr-2141 production through RNAi could
disrupt secologanin 17 biosynthesis in vivo.
The functions of Cr-12, Cr-318, and Cr-611 have not been established. Again,
disruption of these genes in C. roseus using RNAi followed by comparison of the
resulting phenotype or metabolic profile with that of wild-type tissue could facilitate
determination of the functions of these genes.
Crosslinking as a method to identify C. roseus enzymes has proven partially
successful. Unfortunately, no recombinant enzyme exhibiting ajmalicine synthase or
isositsirikine synthase activity was isolated. However, we did isolate one enzyme that
exhibited dehydrogenase activity with a substrate utilized in lignin biosynthesis.
Although the sinapaldehyde 96 substrate is not structurally identical to the deglycosylated
1 I-azido-pentynyl-ester strictosidine 116 probe (Figure 4-19), there are nevertheless
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some similar structural recognition elements, such as the aromatic moiety, that could
perhaps allow the probe to bind to this sinapaldehyde dehydrogenase. These results
highlight the advantages and pitfalls of a crosslinking strategy. Obviously, our data
indicates that crosslinking to non-targeted enzymes occurs, but nevertheless, this strategy
allowed us to identify a new enzyme involved in C. roseus secondary metabolism.
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sinapaldehyde 96 deglycosylated 1 1-azido-
pentynyl-ester strictosidine 116
Figure 4-19: The structures of sinapaldehyde 96 and deglycosylated 1 1-azido-pentynyl-
ester strictosidine 116.
IV. Materials and Methods
A. Crosslinking experiments conditions
The probe 11-azido-pentynyl-ester strictosidine 114 (0.7 mg, 1.6 mmol) was
incubated with SGD (7 jiM) at room temperature for 30 minutes in 50 mM sodium
phosphate buffer, pH 7.5. NADPH (3 mM) was then added, followed by ajmalicine
synthase partially purified by acetone precipitation (1 mg total protein). The reaction
mixture was wrapped in aluminum foil to prevent photolysis of the azide and was
incubated at 25'C for 30 minutes. After 30 minutes, the aluminum foil was removed, and
the reaction mixture was irradiated at 302 nm for 5 minutes, followed by the addition of 1
mM TCEP, CuSO 4, rhodamine azide, and tBuOH. After an incubation period of 75
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minutes, the sample was prepared for 2D SDS-PAGE using the Perfect-FOCUS (G-
Biosciences) protocol.
For 2D SDS-PAGE analysis, 200 tL rehydration/sample buffer (BioRad) was
added to the labeled protein pellet obtained using the Perfect-FOCUS kit. The reaction
mixture was vortexed and centrifuged to remove particulates, and the sample was then
put in the 2D gel tray. An 11 cm pH 4-7 IPG strip (Biorad) was laid over the sample. The
sample and IPG strip were incubated for 15 minutes, after which time 2 mL mineral oil
was added. The 2D gel was run for 17 hours, and then incubated for 10 minutes with 1.6
mL of equilibration buffer I (Biorad), followed by another 10 minutes with equilibration
buffer II (Biorad), and then separated in the second dimension on a Criterion Precast Gel
(12.5% Tris HCl, 11 cm, IPG+1, Biorad). The 2D SDS-PAGE was observed with a UV
transilluminator (254 nm).
B. Cloning of crosslinked enzymes
The plant growth and cloning procedures were performed by Dr. David Liscombe
and Dr. Nathan Ezekiel Nims. Briefly, C. roseus seeds were purchased from Horizon
Herbs (Williams, Oregon). Sterile seedlings were cultured and elicited with the plant
hormone methyl jasmonate as described previously by Aerts et al.153 Total RNA was
isolated from mature C. roseus leaves, as well as from unelicited and methyl jasmonate-
elicited seedlings, using the Plant RNeasy kit (QIAGEN). First-strand cDNA was
obtained using M-MuLV Reverse Transcriptase (New England Biolabs) and oligo d(T)
primer. Leaf, unelicited seedling, and methyl jasmonate-elicited seedling cDNA were
combined (1:1:1) and used as a template for PCR.
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The full-length open reading frames of Cr-2141, Cr-12, Cr-318, and Cr-611 were
each amplified by PCR using a sense primer, an antisense primer, and Platinum Taq High
Fidelity (Invitrogen) (Table 4-7). Each amplicon was cloned into pGEM-T Easy shuttle
vector, and the gene products were confirmed by DNA sequencing. The ORF was then
reamplified using primers containing the appropriate restriction sites and cloned into
pET28a (Novagen).
Enzyme Sense primer
Cr-2141 5'-ATGGCCGGAAAATCACCAGAAGAG-3'
Cr-12 5'-AAAGGATCCATGAAAGATCAACACCCCGTGAAGG-3'
Cr-318 5'-ATGGCTGGAAAATCACCAGAAGAGCAAC-3'
Cr-611 5'-ATGGCTGGAAAATCACCAGAAGAGCAAC-3'
Enzyme Antisense primer
Cr-2141 5'-TTAAGGAGCTTTCAAGGTCTTTGCAACG-3'
Cr-12 5'-TTTCTCGAGTAGGCTTAAGACTCCGGTGGAGG-3'
Cr-318 5'- AGACTCCGGTGGAGGAGTTAAAGTGTTCC-3'
Cr-611 5'-AGACTCCGGTGGAGGAGTTAAAGTGTTCC-3'
Table 4-7: Sense and antisense primers used to clone Cr-2141, Cr-12, Cr-318, and Cr-
611.
C. Heterologous expression and purification of crosslinked enzymes
E. coli Rosetta 2 (DE3) pLysS cells harboring the pET28 expression constructs
were grown in 500 mL of Luria-Bertani medium supplemented with antibiotic at 37'C
with shaking (220 rpm) to an absorbance at 600 nm of 0.6, and then induced with 1 mM
IPTG. After 4 hours of growth at 37'C, the cells were collected by centrifugation at
3000g, and stored at -80'C. Pelleted cells were resuspended in buffer A (100 mM Tris-
HCl, pH 7.5, 100 mM KCl, 10% glycerol, 20 mM p-mercaptoethanol) and lysed by
sonication. Cell debris was removed by centrifugation (10,000g) for 30 minutes at 4'C,
and the supernatant was bound to Talon cobalt affinity resin (bed volume of 300 piL;
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Clontech, http://www.clontech.com), which was then washed with buffer A and eluted
with buffer A containing increasing concentrations (10, 50, 100, and 200 mM) of
imidazole. Under these conditions, the largest amount of pure recombinant protein is
typically recovered in the 100 mM imidazole fraction. Figure 4-20 below shows 1 D SDS-
PAGE of purified Cr-2141, Cr-12, Cr-318, and Cr-61 1.
Cr-2141
So
Cr-12 Cr-318 Cr-611
Figure 4-20: A ID SDS-PAGE of purified Cr-2141, Cr-12, Cr-318, and Cr-61 1.
D. DNA and amino acid sequences of crosslinked enzymes
The DNA and amino acid sequences of Cr-2141, Cr-12, Cr-318, and Cr-611 are
listed below.
Cr-2141 DNA sequence:
ATGGCCGGAAAATCACCAGAAGAGGAGCACCCAGTCAAGACCTATGGATTGGCTGCTCATGA
TTCATCTGGGGTTTTATCTCCGTTCAAATTCTCCAGGAGGGCAACTCTTGAGGATGATGTGAG
GTTCAAGGTGCTATATTGTGGGATTTGTCATACTGACCTTCATTTCGCTAAGAATGAGTGGGGT
ATTTCGACCTATCCTCTTGTACCAGGACATGAAATCGTAGGGGAAGTTACAGAGGTCGGCGGC
AAAGTTACAAAGGTCAAGGTTGGAGATAAAGTTGGTGTTGGCTGCTTGGTTGGTTCATGCCGC
ACTTGTGATAATTGTCGTGCAGATCTTGAGAACTATTGTCCCAAAATGGTGCTAACCTATGCA
AGTCCAAACGTTGATGGAACGATTACCTATGGAGGCTATTCCAATGAGATGGTATGCAACGA
ACACTTTATTGTTCGTTTCCCAGAGAACCTACCACTTGATGGTGGGGCACCATTGCTTTGTGCC
GGTATTACTGTGTACAGTCCAATGAAATACTATGGCTTCGCCAAACCCGGGAGCCACATAGCT
GTTAATGGTCTTGGTGGACTTGGCCATGTGGCTGTTAAGTTTGCAAAGGCCATGGGAGCAAAA
GTGACAGTTATAAGTACATCTGAGGGCAAGAAAGACGATGCCCTCAATCGTTTGGGTGCAGA
TGCATTTTTGTTGAGCAGTAATCCAGAAGCACTGCAGGCTGCAACAGGCACATTTGATGGCAT
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ACTTAATACTATTTCTGCTAAGCACGCTATTATCCCATTGCTTGGTCTACTAAAGTCTCATGGC
AAGCTTGTTCTTCTTGGGGCACCCCCGGAACCACTTGATCTTCACTCTGCTCCTTTGCTTATGG
GGAGGAAGATGGTTGCTGGAAGTAGCATTGGAGGATTGAAGGAGACCCAAGAGATGCTTGAT
TTTGCCGGAAAGCATAACATTACTGCAGATATAGAACTCATTTCCGCGGACAATATCAACACA
GCTTTGGAGCGTCTGGCCAAGGGTGATGTTAGATATCGCTTTGTCCTTGACGTTGCAAAGACC
TTGAAAGCTCCTTAA
Cr-2141 amino acid sequence:
MAGKSPEEEHPVKTYGLAAHDSSGVLSPFKFSRRATLEDDVRFKVLYCGICHTDLHFAKNEWGIS
TYPLVPGHEIVGEVTEVGGKVTKVKVGDKVGVGCLVGSCRTCDNCRADLENYCPKMVLTYASPN
VDGTITYGGYSNEMVCNEHIFIVRFPENLPLDGGAPLLCAGITVYSPMKYYGFAKPGSHIAVNGLG
GLGHVAVKFAKAMGAKVTVISTSEGKKDDALNRLGADAFLLSSNPEALQAATGTFDGILNTISAK
HAIIPLLGLLKSHGKLVLLGAPPEPLDLHSAPLLMGRKMVAGSSIGGLKETQEMLDFAGKHNITAD
IELISADNINTALERLAKGDVRYRFVLDVAKTLKAP
Cr-12 DNA sequence:
ATGAAAGATCAACACCCCGTGAAGGCTTATGGATGGGCAGCTAGAGACACATCTGGGATTCT
TTCTCCTTTCAAGTTTTCCAGAAGGGCAACAGGGGATCATGATGTAAGAGTAAAGATTCTCTA
CTGTGGTATTTGCCATTCTGACCATCAAGCTGCCACGAACTTAATGGGCTTTTATACATATCCT
ATTGTGCCCGGGTTCGAGACAGTACGGGTAGCATCTGAAGTTGGAAGCAAGGTCACAAAAGT
GAAAGTTGGTGATAAAGTTGCCACGGGGATCATTGTGGGATCATGTGGCGAATGTAATGAGT
GTATCAATGACCGTGATTGTTATTGCCCTAAGATGACCGCAGCTTATGGTTCGGTAGACCGTG
ATGGAACTCCCAATTATGGAGGTTTCTCCAATGAGACAGTAGTAAATGAGAATTTTGTCTTTC
GTTTTCCTGAAAACCTTTCTCTTCCTGGTGGTGCTCCACTGCTCAATGCTGGAATAACTGTGTA
CAGTCCCATGAGATTTTATGGCCTGGACAAACCAGGAATGCACTTGGGAGTTGTTGGCCTAGG
TGGACTTGGTCATTTAGCTGTGAAGTTTGGCAAGGCTTTTGGGGCCAAAGTCACTGTGATTAG
TACCTCTCCAAGCAAGAAAGACGAAGCTGTCAATTTTCTTGGTGCGGATGGCTTCTTGGTCAG
CAGTGATGCTGAACAAATGAAGGCTGCTGCTGGAACCTTGGATGGGATTATTGATACCGTGCC
TGTTGTCCATCCTATTGAGCCCTTGCTATGGCTTCTGAAGAATCATTCAAAGCTTGTTTTGGTT
GGAGCTACAGGTGGTTCATTTGATTTGCCAATTCTTCCTTTAGCATTGGGCAGGAGAACTGTG
GCTTCAAGCATTGGTGGAAGTACAAAGGAGGCTCAAGAGATGCTCGATTTTGCAGCTGAGCA
CAATATCACTGCAAACGTTGAGATTATTCCAATGGACTATGCGAATACAGCAATGGAACGCAT
TGACAAGAGTGATGTTCGATACCGATTTGTGATTGATATTTGGGAACACTTTAACTCCTCCACC
GGAGTCTTAAGCCTATAG
Cr-12 amino acid sequence:
MKDQHPVKAYGWAARDTSGILSPFKFSRRATGDHDVRVKILYCGICHSDHQAATNLMGFYTYPIV
PGFETVRVASEVGSKVTKVKVGDKVATGIIVGSCGECNECINDRDCYCPKMTAAYGSVDRDGTPN
YGGFSNETVVNENFVFRFPENLSLPGGAPLLNAGITVYSPMRFYGLDKPGMHLGVVGLGGLGHLA
VKFGKAFGAKVTVISTSPSKKDEAVNFLGADGFLVSSDAEQMKAAAGTLDGIIDTVPVVHPIEPLL
WLLKNHSKLVLVGATGGSFDLPILPLALGRRTVASSIGGSTKEAQEMLDFAAEHNITANVEIIPMD
YANTAMERIDKSDVRYRFVIDIWEHFNSSTGVLSL
Cr-318 DNA sequence:
ATGGCTGGAAAATCACCAGAAGAGCAACACCCAGTGAAGGCCTATGGATGGGCAGCAAGAG
ATTCTTCTGGGATTCTTTCTCCCTTCAAGTTTTCTAGAAGGGTTACAGGTGATTATGATGTCAG
AGTTAAAATTCTTTACTGTGGTATTTGTCATTCTGACCTTCAAATTGCCAAGAATGAAATGGGC
TTTTCCACATATCCTCTTGTCCCTGGGTTTGAGACGGTAGGGATAGCAACTGAAGTTGGAAGC
AAGGTCACAAAAGTGAAAGTTGGTGACAAAGTTGCAGTGGGAGCCATTGTGGGATCATGCGG
TAAATGTGATGAGTGTGTGAATGACCGTGATTGTTATTGCCCTAGGCTTATCACGGCTTATGG
CGGAATAGACCATGATGGAACTCCCACTTATGGAGGGTTTTCCAATGAGACAGTAGCAAATG
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AGAATTATGTTTTTCGTTTCCCTGAAAATCTTCCGCTTGCTGCTGGTGCTCCACTACTCAATGC
TGGACTCACGGTATACAGTCCAATGAGATTTTATGGTCTAGATAAACCAGGCACGAGGATGCA
CTTGGGAGTTGTTGGTCTAGGTGGACTTGGTCATTTAGCTGTGAAGTTTGGCAAGGCTTTTGGG
GCCAAAGTCACTGTGATTAGTACCTCTCCAAGCAAGAAAGACGAAGCTGTCAATTTTCTTGGT
GCGGATGGCTTCTTGGTCAGCAGTGATGCTGAACAAATGAAGGCTGCTGCTGGAACCTTGGAT
GGGATTATTGATACCGTGCCTGTTGTCCATCCTATTGAGCCCTTGCTATGGCTTCTGAAGAATC
ATTCAAAGCTTGTTTTGGTTGGAGCTACAGGTGGTTCATTTGATTTGCCAATTCTTCCTTTAGC
ATTGGGCAGGAGAACTGTGGCTTCAAGCATTGGTGGAAGTACAAAGGAGGCTCAAGAGATGC
TCGATTTTGCAGCTGAGCACAATATCACTGCAAACGTTGAGATTATTCCAATGGACTATGTGA
ATACAGCAATGGAACGCATTGACAAGAGTGATGTTCGATACCGATTTGTGATTGATATTGGGA
ACACTTTAACTCCTCCACCGGAGTCTTAA
Cr-318 amino acid sequence:
MAGKSPEEQHPVKAYGWAARDSSGILSPFKFSRRVTGDYDVRVKILYCGICHSDLQIAKNEMGFS
TYPLVPGFETVGIATEVGSKVTKVKVGDKVAVGAIVGSCGKCDECVNDRDCYCPRLITAYGGIDH
DGTPTYGGFSNETVANENYVFRFPENLPLAAGAPLLNAGLTVYSPMRFYGLDKPGTRMHLGVVG
LGGLGHLAVKFGKAFGAKVTVISTSPSKKDEAVNFLGADGLVSSDAEQMKAAAGTLDGIIDTVPV
VHPIEPLLWLLKNHSKLVLVGATGGSFDLPILPLALGRRTVASSIGGSTKEAQEMLDFAAEHNITAN
VEIIPMDYVNTAMERIDKSDVRYRFVI IGNTLTPPPES
Cr-611 DNA sequence:
ATGGCAAAAGAGCCCGTTCGTGTTCTCGTCACCGGTGCCGCAGGGCAAATCGGTTATGCTCTC
GTTCCCATGATTGCCAGGGGAGTTATGTTGGGTGCTGATCAACCTGTTATCCTCCACATGCTAG
ATATTCCTCCTGCTGCAGAGGCATTGAATGGGGTTAAGATGGAATTGGTTGATGCTGCTTTTCC
TCTACTTAAAGGTGTTGTCGCTACAACTGATGTTGCTGAGGCTTGTGCTGGTGTTAACATTGCT
GTGATGGTTGGTGGGTTCCCAAGGAAAGAGGGAATGGAGCGGAAAGATGTAATGTCAAAGAA
TGTATCTATTTACAAGTCCCAAGCTTCTGCACTTGAGCAATATGCTGCCCCTAACTGCAAGGTT
TTGTTTGTTGCTAACCCAGCCAACACCAATGCATTGATTCTGAAGGAATTTGCACCATCTATTC
CTGCAAAAAATGTTACTTGTTTGACAAGATTGGACCACAACAGGGCCCTTGGTCAAATCTCAG
AGAGATTGAACGTTCCAGTTTCTGAGGTTAAAAATGTCATAATTTGGGGAAATCACTCCTCAA
CACAATATCCTGATGTCAACCATGCCACTGTTAAAACATCAGCTGGAGAAAAGCCTGTGCGGG
AGCTAGTTAAAGATGATGAATGGTTGAATGGGGAGTTCATAACTACTGTCCAGCAACGTGGTG
CTGCAATTATTAAAGCCAGGAAGCTTTCTAGTGCACTTTCTGCTGCTAGTGCTGCATGTGACCA
CATTCGTGACTGGGTCCTTGGAACTCCTGAGGGCACTTGGGTCTCCATGGGTGTATACTCAGA
TGGCTCCTACAATGTCCCTGCTGGTCTTATTTACTCCTTCCCAGTTACATGTAAAAATGGAGAA
TGGACTGTTGTTCAAGGACTTCCAATTGACGAGTTATCAAGAAAGAAGATGGACTCAACAGCT
GAAGAACTCTCTGAGGAAAAGGCTTTGGCATACTCATGTCTTACTTAA
Cr-611 amino acid sequence:
MAKEPVRVLVTGAAGQIGYALVPMIARGVMLGADQPVILHMLDIPPAAEALNGVKMELVDAAFP
LLKGVVATTDVAEACAGVNIAVMVGGFPRKEGMERKDVMSKNVSIYKSQASALEQYAAPNCKV
LFVANPANTNALILKEFAPSIPAKNVTCLTRLDHNRALGQISERLNVPVSEVKNVIIWGNHSSTQYP
DVNHATVKTSAGEKPVRELVKDDEWLNGEFITTVQQRGAAIIKARKLSSALSAASAACDHIRDWV
LGTPEGTWVSMGVYSDGSYNVPAGLIYSFPVTCKNGEWTVVQGLPIDELSRKKMDSTAEELSEEK
ALAYSCLT
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E. Assay conditions
In sinapaldehyde dehydrogenase assays of Cr-2141, I incubated Cr-2141 (30 pM)
with 2.3 mM substrate and 7.8 mM NADPH in a 128 pL reaction volume. All substrates
were purchased from Sigma Aldrich, and product formation was monitored by LCMS.
Sinapyl alcohol 97 and coniferyl alcohol 118 produced in assays with Cr-2141 and
NADPH had the same LCMS retention time and mass as sinapyl alcohol 97 and coniferyl
alcohol 118 standards (Sigma Aldrich) (Figure 4-21). In the LCMS analysis of the assays,
the starting material and products were separated using a 5-minute method with a
gradient of 10-90% acetonitrile in 0.1% formic acid.
sinapyl alcohol 97
(standard) m/: 193
sinapyl alcohol 97
2 (assay) mlz 193
coniferyl alcohol 118
(standard) i/: 163
4 coniferyl alcohol 118(assay) im/z 163
2 92 22bc I 1 ' 277 , 9 797 ,272"7 7
Figure 4-21: A sinapyl alcohol 97 standard (chromatogram 1) has the same LCMS
retention time and mass as sinapyl alcohol 97 produced in an assay with Cr-2141,
sinapaldehyde 96, and NADPH (chromatogram 2). A coniferyl alcohol 118 standard
(chromatogram 3) has the same LCMS retention time and mass as coniferyl alcohol 118
produced in an assay with Cr-2141, coniferyl aldehyde 108, and NADPH (chromatogram
4). Sinapyl alcohol 97 and coniferyl alcohol 118 both lost one unit of H20 under the mass
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spectrometry ionization conditions. The x-axis is time in minutes, and the y-axis is
intensity.
Assays to determine whether Cr-2141, Cr-12, Cr-318, or Cr-611 contained
ajmalicine synthase or isositsirikine synthase activity were performed as described in the
Materials and Methods section of Chapter 3; Cr-2141, Cr-12, Cr-318, or Cr-611 was used
in place of a partially purified enzyme fraction.
F. Steady state kinetic analysis conditions
I performed steady state kinetic analysis assays for Cr-2141 with sinapaldehyde
96 in 50 mM sodium phosphate buffer, pH 7.5, at 30'C. Six substrate concentrations
were used, and three time points were measured for each substrate concentration. A 135
pL reaction volume was used, and 5 gL aliquots were taken at minute intervals. Aliquots
were quenched with 950 ptL MeOH containing 500 nM yohimbine 6 as an internal
standard, and centrifuged (1 3,000g, 1 min) to remove particulates. Sinapaldehyde 96 (67-
1481 pM) was incubated with Cr-2141 (1.41 pM) and NADPH (11.1 mM)1 40.
Sinapaldehyde 96 disappearance was measured. A logistic curve using OriginPro 7
(OriginLab, Northampton, MA) was used to fit the data, and R2 value of 0.94 was
obtained for the sinapaldehyde 96 data fit (Figure 4-22).
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sinapaldehyde 96
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Figure 4-22: Data fit for steady state kinetics of Cr-2141 with sinapaldehyde 96. The unit
for the x-axis is gM sinapaldehyde 96, and the unit for the y-axis is gM sinapaldehyde 96
reduced per minute.
G. LCMS conditions
Ultra-performance LC analysis was performed on an Acquity Ultra Performance
BEH C18 column with a 1.7 gm particle size, a 2.1 x 100 mm dimension, and a flow rate
of 0.5 mL min-' in tandem with a Micromass LCT Premier TOF Mass Spectrometer with
an ESI Source (Waters Corporation). The capillary and sample cone voltages were
3000V and 30V, respectively. The desolvation and source temperatures were 300*C and
1004C, respectively. The cone and desolvation gas-flow rates were 60 1 hr-' and 8000 1
hr1. Analysis was performed with MassLynx 4.1.
H. High-resolution mass spectrometry data
High-resolution mass spectrometry data were obtained using the MIT DCIF mass
spectrometry equipment. Samples were diluted in methanol and then ionized by ESI/FT-
MS in the positive ion mode.
sinapyl alcohol 97: [M+H]* expected 211.0965, observed 211.0961
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coniferyl alcohol 118: [M+H]* expected 181.0859, observed 181.0851
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Chapter 5: Conclusions and Future Directions
I. Conclusions
Terpene indole alkaloids (TIAs) are a large class of natural products produced in plants.
Many TIAs have medicinal uses; for example, vinblastine 2 and vincristine 3 have anti-cancer
activity, ajmalicine 4 has anti-hypertensive activity, and ajmaline 9 has anti-arrhythmic activity'.
Many TIAs most likely did not evolve to treat human diseases, however, and thus perhaps do not
have optimal pharmacological properties 2. There are many examples of modified natural
products that have improved bioactivities when compared with the unmodified natural product;
for example, camptothecin 10 is too toxic and hydrophobic to be used clinically, yet the
camptothecin analogs irinotecan 16 and topotecan 15 are used clinically3 . In drug design, many
modifications can be made to a compound to alter its pharmacological properties. For example,
halogenation can improve lipophilicity4,5, hydroxylation and methylation can improve water
solubility , and alteration of the stereochemistry at a chiral center can change the bioactivity of a
drug candidate6,7
Unfortunately, the immense structural complexity of TIAs makes cost-effective
industrial-scale synthesis of the majority of TIAs and TIA analogs unfeasible. The current
method of isolation of medicinal TIAs is via purification from the plant; purification is no simple
task, however, because numerous compounds are present. Industrial scale production of TIAs
would be improved if TIAs could be produced via heterologous reconstitution of the enzymatic
pathways in a heterologous organism such as yeast 2. However, many of the enzymes involved in
TIA biosynthesis are unknown, thereby precluding these efforts. If more TIA biosynthetic
enzymes were isolated and cloned, and the substrate specificity of the enzymes were known,
both natural and novel TIA analogs could be more readily produced on an industrial scale.
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In this thesis I developed strategies to make novel ajmalicine 4 and isositsirikine 7
analogs in vitro. The NADPH-dependent reductase enzymes that produce the anti-hypertensive
agent ajmalicine 4 and the anti-neoplastic agent isositsirikine 7 have not been isolated. To
produce ajmalicine 4 and isositsirikine 7 analogs in vitro, two aims must be accomplished: first,
the reductases forming ajmalicine 4 and isositsirikine 7 must be partially purified, and second,
the substrate specificity of the reductase enzymes ajmalicine synthase and isositsirikine synthase
must be determined.
To satisfy the first of these aims, I developed a partial purification procedure for
ajmalicine synthase and isositsirikine synthase from C. roseus hairy root and cell suspension
cultures using protein precipitation, ion exchange, and gel filtration chromatography. Ajmalicine
synthase and isositsirikine synthase retain activity in all steps of the purification procedure.
Analysis by 2D SDS-PAGE shows that the proteins have been significantly purified. Enzymes
from the 2D SDS-PAGE of an active size 200 gel filtration column fraction were sequenced, and
one enzyme was found to have high sequence identity to a cinnamyl alcohol dehydrogenase.
Future efforts will involve cloning and characterizing the full length gene.
In collaboration with Dr. Aimee Usera and Dr. Elizabeth McCoy, I also performed
crosslinking experiments with a substrate probe in attempts to isolate ajmalicine synthase and
isositsirikine synthase. In the crosslinking studies, four enzymes - Cr-2141, Cr-12, Cr-318, and
Cr-6 11 - were isolated and cloned. Though the functions of Cr- 12, Cr-318, and Cr-6 11 have yet
to be determined, Cr-2141 was shown to have sinapyl alcohol dehydrogenase activity, reducing
sinapaldehyde 96 to sinapyl alcohol 97 with a measured kcat of 0.092 min-.
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I determined the substrate specificities of SGD, ajmalicine synthase, and isositsirikine
synthase. SGD, which deglycosylates strictosidine 1, the central intermediate in TIA
biosynthesis, does not act as a gatekeeper in TIA biosynthesis: in fact, SGD deglycosylates all
indole substituted strictosidine analogs 1-c through 1-s tested, as well as strictosidine 1 analogs
substituted at the C-5 position 1-u and 1-v and the methyl ester position 1-t. An indole moiety
does not appear to be required for turnover by SGD, because deglycosylation of
deacetylipecosides 45-1 was observed. Additionally, strictosidine analogs containing alternate
heterocycles 1-a, 1-b, 1-w, and 1-x were also deglycosylated. SGD recognizes a different
stereoisomer, deglycosylating the C-3 R diastereomer of strictosidine 1, vincoside 43. Steady
state kinetic analysis of indole substituted strictosidine analogs 1-d, 1-e, 1-g, 1-h, 1-j, 1-j, 1-r,
and 1-s showed that the catalytic efficiencies (Vmax/Km values) did not differ by more than an
order of magnitude, indicating that all indole substituted strictosidine analogs assayed were
accepted at similar efficiencies. Additional steady state kinetic analysis studies showed that SGD
has a sixfold catalytic preference of strictosidine 1 over vincoside 43.
Ajmalicine synthase and isositsirikine synthase also have broad substrate specificity,
which is promising for the development of novel ajmalicine 4 and isositsirikine 7 analogs with
potentially improved therapeutic activities. Partially purified ajmalicine synthase and
isositsirikine synthase could reduce indole substituted deglycosylated strictosidine analogs 49-c
through 49-s, as well as deglycosylated benzo strictosidine 49-a, deglycosylated thio
strictosidine 49-b, deglycosylated pentynyl-ester strictosidine 49-t, and deglycosylated d4
vincoside 84. To determine the effects of substrate specificity, I also performed steady state
kinetic analysis studies. Partially purified ajmalicine synthase was found to reduce
deglycosylated vincoside 84 to C-3 R ajmalicine 85 with a catalytic efficiency of 1.13 x 10-4 min-
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1. Deglycosylated methyl strictosidine analogs 49-g, 49-h, 49-i, and 49-j were also reduced by
partially purified ajmalicine synthase, with catalytic efficiencies of 7.08 x I0- min-, 6.52 x 10-3
min-', 11.7 x 10-3 mn-', and 7.01 x 10-3 min-, respectively. Partially purified isositsirikine
synthase reduced deglycosylated d4 strictosidine 49-1, deglycosylated benzo strictosidine 49-a,
and deglycosylated thio strictosidine 49-b with catalytic efficiencies of 1.63 x 10-3 min-', 3.36 x
102 min- , and 6.03 x 10-2 min-, respectively.
II. Future directions
Additional efforts will be made to clone, express, and functionally characterize the
enzymes isolated via the native purification and crosslinking studies described in Chapters 3 and
4. The gene candidate identified by native purification that had sequence identity to a cinnamyl
alcohol dehydrogenase will be cloned and heterologously expressed. A large-scale sequencing
project scheduled to be completed in July 2010 will provide the full length sequence of this gene,
after which this candidate will be amplified from C. roseus cDNA, placed in an expression
vector, heterologously expressed in E. coli or yeast, and functionally characterized for ajmalicine
synthase and isositsirikine synthase activity. Additionally, the function of enzymes that have
already been expressed, Cr-2141, Cr-12, Cr-318, and Cr-6 11, will be further probed to determine
their function in the plant. The functions of Cr-2141, Cr-12, Cr-318, and Cr-611 can be disrupted
in the plant by using RNAi8 or virus-induced gene silencing (VIGS) 9 (Liscombe, O'Connor,
unpublished). After disruption of each gene, the resulting phenotype or metabolic profile can be
compared with wild-type tissue to provide more information about the role of these enzymes in
the plant.
Other efforts can be made to clone similar enzymes in TIA biosynthesis; for example,
there are no reports in the literature of reductase(s) forming yohimbine 6. To isolate the
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reductase(s) forming yohimbine 6, a different type of cell culture that produces large amounts of
yohimbine 6 should be utilized. The PC5 10 C. roseus cell suspension culture line from DSMZ
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) was used for all research
performed in this thesis; this line produces negligible amounts of yohimbine 6. If a cell
suspension culture line that produced more yohimbine 6, such as Pausinystalia yohimbe, was
used'0 , perhaps the reductase(s) catalyzing yohimbine 6 formation from deglycosylated
strictosidine 49 could be isolated.
Additionally, numerous enzymes in TIA biosynthesis are not soluble, and we suspect that
at least one membrane-bound enzyme utilizes deglycosylated strictosidine 49 as a substrate. To
initiate biochemical studies of these membrane-bound enzymes, microsomes were used to
develop in vitro enzyme assays. To obtain the microsomes, 16 g of cell suspension culture were
blended in 60 mL 0.iM borate buffer, pH 7.5, containing 20 mM p-mercaptoethanol, 1 mM
EDTA, 0.1% PVP, and 10% glycerol. The mixture was then ultracentrifuged at 140,000g for 1
hour. The pellet was then resuspended in 1.5 mL borate buffer, and 200 uiL 60% glycerol was
added. In assays with resuspended pellet, strictosidine 1, SGD, and NADPH, a peak with m/z 325
was observed by LCMS (Figure 5-1). This peak was not seen in LCMS traces in assays lacking
strictosidine 1. In assays using numerous other strictosidine 1 analogs (Figure 5-1), including 9-
methyl strictosidine 1-g, 11-methyl strictosidine 1-i, and 11-methoxy strictosidine 1-s, the
corresponding analog of the parent m/z 325 compound was observed.
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Figure 5-1: In an assay with microsomes, SGD, and NADPH, various strictosidine 1 analogs,
including strictosidine 1, 9-methyl strictosidine 1-g, 1 1-methyl strictosidine 1-i, and 11 -methoxy
strictosidine 1-s, were converted to a product with m/z 325, 339 (325 + 14), 339 (325 + 14), and
355 (325 + 30), respectively. The x-axis is time in minutes and the y-axis is intensity.
Four potential known TIAs that the product with m/z 325 may correspond to are
lochnerine 12811, rosicine 1291, tubotaiwin 1301, and dihydroakuammicine 1314.
Unfortunately, repeated efforts to reproducibly obtain this novel activity failed. This failure may
be because the cell suspension cultures lost the ability to produce the m/z 325 product; after years
of subculturing, cell suspension cultures frequently lose the ability to produce natural products".
Future efforts could involve isolating microsomes from new stocks of cell suspension cultures.
.. . ..................... ...... .1
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Figure 5-2: Four potential TIAs that the product with m/z 325 may correspond to are lochnerine
128", rosicine 1292, tubotaiwin 13013, and dihydroakuammicine 1314.
The deglycosylated strictosidine 49 intermediate produced by SGD is reported to be
extremely reactive and have low solubility in water 16, and thus it can be hypothesized that
ajmalicine synthase and isositsirikine synthase interact with SGD, forming a metabolon that will
facilitate the shuttling of this reactive, hydrophobic intermediate. Metabolon formation has been
17-19 20
reported in A. thaliana7- in phenylpropanoid and flavonoid metabolism . A co-
immunoprecipitation experiment2 ' with SGD could potentially be performed to isolate ajmalicine
synthase and isositsirikine synthase. SGD can be expressed as a fusion protein with glutathione-
S-transferase (GST), and transformed into C. roseus. The transformed cells will be lysed, GST
antibody will be added, and then the lysate will be passed over an IgG column. The column will
be stripped, and the eluted proteins will be assayed for ajmalicine synthase and isositsirikine
synthase activity. Additional methods for detecting protein-protein interactions, such as yeast
two-hybrid assays, could also be performed.
Finally, the pharmaceutical activity of novel ajmalicine 4 and isositsirikine 7 analogs will
be assessed. Cytotoxicity screens are already underway for various TIA analogs at Vanderbilt
and the University of Illinois (Usera, Lee, O'Connor, unpublished). Additionally, crude extracts
of these lysates will be sent to a natural product lysate collection at the University of Michigan.
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